


Communicable Diseases in Toronto 2005



Annual Report

Dr. David McKeown
Medical Officer of Health

 **TORONTO**
Public Health

Communicable Diseases in Toronto 2005

Dr. David McKeown
Medical Officer of Health

March 2007



Reference:

Toronto Public Health. *Communicable Diseases in Toronto 2005*. City of Toronto: Toronto, Canada. March 2007.

Acknowledgements:

We wish to extend a general message of appreciation to all Toronto Public Health Communicable Disease Control program staff for their ongoing work in collecting the data contained in this report. Specific acknowledgement for contributing to the production of this report is extended to:

- **Communicable Disease Control program staff:** Jo-Ann Ackery, Dr. Irene Armstrong, Mark Bartlett, Dr. Vinita Dubey, Rise Kogon, Dr. Michael Finkelstein, Abimbola Forde, Jann Houston, Manisa Jiaravuthisan, Anna Miranda, Marg Mulholland, Dr. Elizabeth Rea, Dr. Rachel Rodin, Dr. Herveen Sachdeva and Dr. Rita Shahin.
- **Policy and Planning staff:** Gene Long, Mary Margaret Crapper, Rick Travaglini and Heidi Weninger.

We also acknowledge the Public Health Agency of Canada and the Ontario Ministry of Health and Long-Term Care for making their data available.

Lead Authors:

Communicable Diseases in Toronto 2005 was written by the Communicable Disease Surveillance Unit's epidemiology team that includes the following members:

Manager: Effie Gournis

Epidemiologists: Camille Achonu, Anne Arthur, Olayemi Kadri, Leslie Shulman, Rebecca Stuart

Health Information Analysts: Jay DeSilva, Eleni Kefalas, Nicole Whittingham

Health Promotion Consultant: Sophia Hussain

Director, Communicable Disease Control:

Dr. Barbara Yaffe

Medical Officer of Health:

Dr. David McKeown

Distribution:

Copies of this document can be downloaded at http://www.toronto.ca/health/cdc/communicable_disease_surveillance/statistics_and_reports/annual_reports/

Limited copies of CD-ROMs can be acquired by reaching:

Communicable Disease Surveillance Unit
Toronto Public Health
277 Victoria St., 10th Floor
Toronto, ON M5B 1W2

Tel: 416-392-7411

Fax: 416-392-0047

E-mail: CDSU@toronto.ca

Cover photos:

Infant photo: US Centers for Disease Control, Public Health Image Library. By internet: URL: <http://phil.cdc.gov/phil/home.asp>

Kitchen and lab photos: comstock.com

Fowl photo © 2007 JupiterImages Corporation

Table of Contents

| | | | |
|---|------------|---|------------|
| Executive Summary | iii | Diseases Transmitted by Direct Contact and Respiratory Routes | 109 |
| List of Figures | v | Chickenpox (Varicella Zoster virus) | 113 |
| List of Tables | ix | Legionellosis | 117 |
| Overview | | Meningococcal disease, invasive | 121 |
| Introduction to report | 1 | Streptococcal infections, Group A invasive | 125 |
| Standard report format | 2 | Streptococcal infections, Group B neonatal | 129 |
| Overall ranking table | 4 | <i>Streptococcus pneumoniae</i> , invasive | 131 |
| | | Tuberculosis | 133 |
| Sexually Transmitted and Bloodborne Diseases | 5 | Vectorborne and Zoonotic Diseases | 141 |
| Chlamydia | 9 | Lyme disease | 145 |
| Gonorrhea | 13 | Malaria | 147 |
| Hepatitis B | 17 | West Nile Virus (WNV) | 151 |
| Hepatitis C | 21 | Encephalitis/Meningitis | 155 |
| HIV | 25 | Rare Diseases | 163 |
| Syphilis, infectious | 29 | Outbreaks | 167 |
| Syphilis, late latent | 33 | References | 177 |
| Enteric, Food and Waterborne Diseases | 37 | Appendices | 181 |
| Amebiasis | 41 | Data sources and technical notes | 183 |
| <i>Campylobacter</i> enteritis | 45 | List of reportable diseases in Ontario | 189 |
| Cryptosporidiosis | 49 | Glossary of Terms | 191 |
| Cyclosporiasis | 53 | Data tables (Case numbers and rates) | |
| Giardiasis | 57 | Appendix table 1: Number of cases and incidence rates by disease. Toronto, 1995-2005. | 195 |
| Hepatitis A | 61 | Appendix table 2: Number of cases and incidence rates by disease and sex. Toronto, 1995-2005. | 197 |
| Listeriosis | 65 | Appendix table 3: Number of cases by disease, sex and age group. Toronto, 2005. | 202 |
| Paratyphoid fever | 67 | Appendix table 4: 5-year and 10-year means and incidence rates by disease and by sex. Toronto, 1995-2004. | 207 |
| Salmonellosis (non-typhoidal <i>Salmonella</i>) | 69 | | |
| Shigellosis | 73 | | |
| Typhoid fever | 79 | | |
| Verotoxin-producing <i>E. coli</i> infection (VTEC) | 83 | | |
| Yersiniosis | 87 | | |
| Diseases Preventable by Routine Vaccination | 91 | | |
| Influenza | 95 | | |
| Measles | 99 | | |
| Mumps | 101 | | |
| Pertussis | 103 | | |
| Rubella | 107 | | |

Executive Summary

This summary of reportable communicable diseases in the City of Toronto for 2005 is the fourth in a series of annual reports describing trends in our city. The data in *Communicable Diseases in Toronto 2005* provide updates to previous trends and highlight significant considerations for the practice of communicable disease control in a local public health setting. As in the past, factors related to Toronto's status as Canada's most populated and ethnically diverse urban setting significantly influence the range of communicable disease events faced by the city. While the media focused much attention in 2005 on the threat of avian influenza in parts of Asia, Toronto Public Health dealt with several local communicable disease events.

The most notable communicable disease story in 2005 involved an outbreak of legionellosis in a long term care facility. This presented as a respiratory outbreak with escalating morbidity and mortality. Toronto Public Health worked with the long term care home, acute care leaders as well as provincial and federal health authorities from Canada and the U.S. to investigate and manage the outbreak. Collaboration with the Coroner's Office, laboratories and environmental health leaders led to the detection of *Legionella pneumophila* bacteria from the facility's cooling tower which matched the strain of bacteria isolated from victims of the disease. With a total of 134 cases (including 23 deaths) of legionellosis, Toronto experienced one of the largest known *Legionella* outbreaks in a long term care facility. When commenting on the progress made since SARS, *The Report of the Expert Panel on the Legionnaires' Disease Outbreak in the City of Toronto* stated: "...The system's response to the Legionnaires' outbreak was more organized, efficient and effective...".

There were several other key events and trends in disease reports. These include:

- An outbreak of *Salmonella enteritidis* PT 13 was linked to the consumption of mung bean sprouts from a local producer and distributor. Toronto and 31 other health units in Ontario were affected, with a total of 522 confirmed cases of salmonellosis associated with this outbreak across the province. This was the

largest documented *Salmonella* outbreak related to mung bean sprouts.

- A cluster of cyclosporiasis was detected among a Toronto group who attended a high school retreat in April 2005. Illness was linked with the consumption of a pasta salad containing fresh basil, which was believed to be the source of the parasite. The basil originated in a Central American country, underscoring the concerns associated with the globalization of our food supply.
- Increased reports of pertussis were recorded, reaching the highest level since current electronic records were maintained (1991). This increase was related to an outbreak that began in November 2005. There were 177 cases reported in 2005, most of whom were previously vaccinated. The median age of cases was 3 years, lower than in previous years. Increased testing and the concurrent use of a more sensitive PCR test may explain some of the increase.
- As observed in other cities, the number of West Nile virus cases fluctuates from year to year. The number of cases increased to 38 cases in 2005, after only 6 cases reported in 2004.
- While the overall reported HIV incidence rate for Toronto fell for the third consecutive year, specific groups (e.g. males 20 to 24 years) recorded large increases in their rates, underscoring the need for continued vigilance and targeted programs.
- Female rates of chlamydia remained steady, while rates for males continued to creep up for the 9th consecutive year and increased another 7.3% from 2004.
- The infectious syphilis outbreak primarily affecting men who have sex with men (MSM) that began in 2002 showed signs of abating. Case numbers decreased 35% from the previous year.
- 2005 was the first full year of publicly-funded vaccine for chickenpox in Ontario. The number of chickenpox cases reported declined in 2005 to levels similar to those before 2004.

-
- There were no cases of invasive meningococcal disease due to serogroup C reported in Toronto in 2005 for the first time since 1995. This coincides with the first year of the publicly-funded vaccine campaign for this disease in Ontario which targeted 15 to 20 year olds.

Other communicable disease events that marked 2005 include the implementation of the long-awaited new provincial information system, the integrated Public Health Information System (iPHIS). This replaced the aging Reportable Disease Information System (RDIS). Lack of access to real-time data stored in a province-wide database was seen as a significant hindrance to the investigation and control of the SARS outbreak in 2003. The introduction of iPHIS as the provincially mandated case management and reporting system was an important step in improving the prevention and control of communicable diseases. However, much work remains to be done before we realize a communicable disease information system with both strong case management and surveillance capabilities. It is with great hope that we work with the Province of Ontario to prepare for transition from iPHIS to a Pan-Canadian communicable disease surveillance and management system over the next few years. □

List of Figures

Sexually Transmitted and Bloodborne Diseases

Page

| | |
|--|----|
| Figure 1.1: Incidence of chlamydia by year. Toronto, the rest of Ontario and Canada, 1995 – 2005 | 10 |
| Figure 1.2: Incidence of chlamydia by age group and sex. Toronto, 2005 | 10 |
| Figure 1.3: Incidence rates of chlamydia by sex and year. Toronto, 1995 – 2005 | 11 |
| Figure 1.4: Incidence of gonorrhoea by year. Toronto, the rest of Ontario and Canada, 1995 – 2005 | 14 |
| Figure 1.5: Incidence of gonorrhoea by age group and sex. Toronto, 2005 | 14 |
| Figure 1.6: Incidence rates of gonorrhoea by sex and year. Toronto, 1995 – 2005 | 15 |
| Figure 1.7: Incidence of acute hepatitis B by year. Toronto, the rest of Ontario and Canada, 1995 – 2005 | 18 |
| Figure 1.8: Incidence of acute hepatitis B by age group and sex. Toronto, 1995 – 2005 combined | 18 |
| Figure 1.9: Number of hepatitis B cases, carriers, and unclassified reports by year. Toronto, 1995 – 2005 | 19 |
| Figure 1.10: Incidence of hepatitis C by year. Toronto, the rest of Ontario and Canada, 1995 – 2005 | 22 |
| Figure 1.11: Incidence of hepatitis C by age group and sex. Toronto, 2005 | 22 |
| Figure 1.12: Incidence rates of hepatitis C by sex and year. Toronto, 1995 – 2005 | 23 |
| Figure 1.13: Incidence of HIV infection by year. Toronto, the rest of Ontario and Canada, 1995 – 2005 | 26 |
| Figure 1.14: Incidence rates of HIV infection by age group and sex. Toronto, 2005 | 26 |
| Figure 1.15: Incidence rates of HIV infection by sex and year. Toronto, 1995 – 2005 | 27 |
| Figure 1.16: Incidence of infectious syphilis by year. Toronto, the rest of Ontario and Canada, 1995 – 2005 | 30 |
| Figure 1.17: Incidence of infectious syphilis by age group and sex. Toronto, 2005 | 30 |
| Figure 1.18: Incidence rates of infectious syphilis by sex and year. Toronto, 1995 – 2005 | 31 |
| Figure 1.19: Incidence of infectious syphilis by staging and year. Toronto, 1995 – 2005 | 31 |
| Figure 1.20: Incidence of HIV and infectious syphilis co-infections by year. Toronto, 1995 – 2005 | 32 |
| Figure 1.21: Incidence of late latent syphilis by year. Toronto, the rest of Ontario and Canada, 1995 – 2005 | 34 |
| Figure 1.22: Incidence of late latent syphilis by age group and sex. Toronto, 2005 | 34 |
| Figure 1.23: Incidence rates of late latent syphilis by sex and year. Toronto, 1995 – 2005 | 35 |
| Figure 1.24: Incidence of HIV and late latent syphilis co-infections by year. Toronto, 1995 – 2005 | 35 |

Enteric, Food and Waterborne Diseases

| | |
|---|----|
| Figure 2.1: Incidence of amebiasis by year. Toronto, the rest of Ontario and Canada, 1995 – 2005 | 42 |
| Figure 2.2: Incidence of amebiasis by age group and sex. Toronto, 2005 | 42 |
| Figure 2.3: Incidence rates of amebiasis by sex and year. Toronto, 1995 – 2005 | 43 |
| Figure 2.4: Number of reported cases of amebiasis by month. Toronto, 2005 compared to 1995 – 2004 mean | 43 |
| Figure 2.5: Proportion of reported cases of amebiasis by suspected source of infection. Toronto, 2005 | 44 |
| Figure 2.6: Proportion of reported cases of amebiasis by suspected risk setting. Toronto, 2005 | 44 |
| Figure 2.7: Incidence of <i>Campylobacter</i> enteritis by year. Toronto, the rest of Ontario and Canada, 1995 – 2005 | 46 |
| Figure 2.8: Incidence of <i>Campylobacter</i> enteritis by age group and sex. Toronto, 2005 | 46 |
| Figure 2.9: Number of reported cases of <i>Campylobacter</i> enteritis by month. Toronto, 2005 compared to 1995 – 2004 mean | 47 |
| Figure 2.10: Proportion of reported cases of <i>Campylobacter</i> enteritis by suspected source of infection. Toronto, 2005 | 47 |
| Figure 2.11: Proportion of reported cases of <i>Campylobacter</i> enteritis by suspected risk setting. Toronto, 2005 | 48 |
| Figure 2.12: Incidence of cryptosporidiosis by year. Toronto, the rest of Ontario and Canada, 1996 – 2005 | 50 |
| Figure 2.13: Incidence of cryptosporidiosis by age group and sex. Toronto, 1996 – 2005 combined | 50 |
| Figure 2.14: Number of reported cases of cryptosporidiosis by month. Toronto, 2005 compared to 1996 – 2004 mean | 51 |
| Figure 2.15: Proportion of reported cases of cryptosporidiosis by suspected source of infection. Toronto, 2005 | 51 |
| Figure 2.16: Proportion of reported cases of cryptosporidiosis by suspected risk setting. Toronto, 2005 | 52 |
| Figure 2.17: Incidence of cyclosporiasis by age group and sex. Toronto, 2002 – 2005 combined | 54 |
| Figure 2.18: Number of reported cases of cyclosporiasis by month. Toronto, 2005 compared to 2002 – 2004 mean | 54 |
| Figure 2.19: Proportion of reported cases of cyclosporiasis by suspected source of infection. Toronto, 2005 | 55 |
| Figure 2.20: Proportion of cases of cyclosporiasis by suspected risk setting. Toronto, 2005 | 55 |
| Figure 2.21: Incidence of giardiasis by year. Toronto, the rest of Ontario and Canada, 1995 – 2005 | 58 |
| Figure 2.22: Incidence of giardiasis by age group and sex. Toronto, 2005 | 58 |

| | |
|--|----|
| Figure 2.23: Number of reported cases of giardiasis by month. Toronto, 2005 compared to 1995 – 2004 mean | 59 |
| Figure 2.24: Proportion of reported cases of giardiasis by suspected source of infection. Toronto, 2005 | 59 |
| Figure 2.25: Proportion of reported cases of giardiasis by suspected risk setting. Toronto, 2005 | 60 |
| Figure 2.26: Incidence of hepatitis A by year. Toronto, the rest of Ontario and Canada, 1995 – 2005 | 62 |
| Figure 2.27: Incidence of hepatitis A by age group and sex. Toronto, 2005 | 62 |
| Figure 2.28: Number of reported cases of hepatitis A by month. Toronto, 2005 compared to 1995 – 2004 mean | 63 |
| Figure 2.29: Proportion of reported cases of hepatitis A by suspected source of infection. Toronto, 2005 | 63 |
| Figure 2.30: Proportion of reported cases of hepatitis A by suspected risk setting. Toronto, 2005 | 64 |
| Figure 2.31: Incidence of listeriosis by year. Toronto, the rest of Ontario and Canada, 1995 – 2005 | 66 |
| Figure 2.32: Incidence of listeriosis by age group and sex. Toronto, 1995 – 2005 combined | 66 |
| Figure 2.33: Incidence of paratyphoid fever by year. Toronto, the rest of Ontario and Canada, 1995 – 2005 | 68 |
| Figure 2.34: Incidence of paratyphoid fever by age group and sex. Toronto, 1995 – 2005 combined | 68 |
| Figure 2.35: Incidence of salmonellosis by year. Toronto, the rest of Ontario and Canada, 1995 – 2005 | 70 |
| Figure 2.36: Incidence of salmonellosis by age group and sex. Toronto, 2005 | 70 |
| Figure 2.37: Number of reported cases of salmonellosis by month. Toronto, 2005 compared to 1995 – 2004 mean | 71 |
| Figure 2.38: Proportion of reported cases of salmonellosis by suspected source of infection. Toronto, 2005 | 72 |
| Figure 2.39: Proportion of reported cases of salmonellosis by suspected risk setting. Toronto, 2005 | 72 |
| Figure 2.40: Incidence of shigellosis by year. Toronto, the rest of Ontario and Canada, 1995 – 2005 | 74 |
| Figure 2.41: Incidence of shigellosis by age group and sex. Toronto, 2005 | 74 |
| Figure 2.42: Incidence rates of shigellosis by sex and year. Toronto, 1995 – 2005 | 75 |
| Figure 2.43: Number of reported cases of shigellosis by month. Toronto 2005 compared to 1995 – 2004 mean | 75 |
| Figure 2.44: Proportion of reported shigellosis cases by agent. Toronto, 2005 | 76 |
| Figure 2.45: Proportion of reported cases of shigellosis by suspected source of infection. Toronto, 2005 | 76 |
| Figure 2.46: Proportion of reported cases of shigellosis by suspected risk setting. Toronto, 2005 | 77 |
| Figure 2.47: Incidence of typhoid fever by year. Toronto, the rest of Ontario and Canada, 1995 – 2005 | 80 |
| Figure 2.48: Incidence of typhoid fever by age group and sex. Toronto, 1995 – 2005 combined | 80 |
| Figure 2.49: Number of reported cases of typhoid fever by month. Toronto, 2005 compared to 1995 – 2004 mean | 81 |
| Figure 2.50: Proportion of reported cases of typhoid fever by suspected source of infection. Toronto, 2005 | 81 |
| Figure 2.51: Proportion of reported cases of typhoid fever by suspected risk setting. Toronto, 2005 | 82 |
| Figure 2.52: Incidence of verotoxin-producing <i>E. coli</i> infection by year. Toronto, the rest of Ontario and Canada, 1995 – 2005 | 84 |
| Figure 2.53: Incidence of verotoxin-producing <i>E. coli</i> infection by age group and sex. Toronto, 1995 – 2005 combined | 84 |
| Figure 2.54: Number of reported cases of verotoxin-producing <i>E. coli</i> infection by month. Toronto, 2005 compared to 1995 – 2004 mean | 85 |
| Figure 2.55: Proportion of reported cases of verotoxin-producing <i>E. coli</i> infection by suspected source of infection. Toronto, 2005 | 85 |
| Figure 2.56: Proportion of reported cases of verotoxin-producing <i>E. coli</i> infection by suspected risk setting. Toronto, 2005 | 86 |
| Figure 2.57: Incidence of yersiniosis by year. Toronto and the rest of Ontario, 1995 – 2005 | 88 |
| Figure 2.58: Incidence of yersiniosis by age group and sex. Toronto, 2005 | 88 |
| Figure 2.59: Number of reported cases of yersiniosis by month. Toronto, 2005 compared to 1995 – 2004 mean | 89 |
| Figure 2.60: Proportion of reported cases of yersiniosis by suspected source of infection. Toronto, 2005 | 89 |
| Figure 2.61: Proportion of reported cases of yersiniosis by suspected risk setting. Toronto, 2005 | 90 |

Diseases Preventable by Routine Vaccination

| | |
|---|----|
| Figure 3.1: Incidence of influenza by seasonal year. Toronto, 1995/96 – 2005/06 | 96 |
| Figure 3.2: Incidence of influenza by seasonal year. Toronto, the rest of Ontario and Canada, 1995/96 – 2005/06 | 96 |
| Figure 3.3: Incidence of influenza by age group and sex. Toronto, 2005/06 | 97 |
| Figure 3.4: Number of reported cases of influenza by month. Toronto, 2005/06 compared to 1995/96 – 2004/05 mean | 97 |

| | |
|---|-----|
| Figure 3.5: Incidence of measles by year. Toronto, the rest of Ontario and Canada, 1995 – 2005 | 100 |
| Figure 3.6: Incidence of measles by age group. Toronto, 1995 – 2005 combined | 100 |
| Figure 3.7: Incidence of mumps by year. Toronto, the rest of Ontario and Canada, 1995 – 2005 | 102 |
| Figure 3.8: Incidence of mumps by age group. Toronto, 1995 – 2005 combined | 102 |
| Figure 3.9: Incidence of pertussis by year. Toronto, the rest of Ontario and Canada, 1995 – 2005 | 104 |
| Figure 3.10: Incidence of pertussis by age group. Toronto, 2005 | 104 |
| Figure 3.11: Number of reported cases of pertussis by month. Toronto, 2005 compared to 1995 – 2004 mean | 105 |
| Figure 3.12: Incidence of rubella by year. Toronto, the rest of Ontario and Canada, 1995 – 2005 | 108 |
| Figure 3.13: Incidence of rubella by age group. Toronto, 1995 – 2005 combined | 108 |

Diseases Transmitted by Direct Contact and Respiratory Routes

| | |
|--|-----|
| Figure 4.1: Incidence of chickenpox by year. Toronto, the rest of Ontario and Canada, 1995 – 2005 | 114 |
| Figure 4.2: Incidence of chickenpox by age group. Toronto, 2005 | 114 |
| Figure 4.3: Number of reported cases of chickenpox by month. Toronto, 2005 compared to 1995 – 2004 mean | 115 |
| Figure 4.4: Incidence of legionellosis by year. Toronto, the rest of Ontario and Canada, 1995 – 2004 | 118 |
| Figure 4.5: Incidence of legionellosis by age group and sex. Toronto, 1995 – 2005 combined | 118 |
| Figure 4.6: Number of reported cases of legionellosis by month. Toronto, 2005 compared to 1995 – 2004 mean | 119 |
| Figure 4.7: Incidence of invasive meningococcal disease by year. Toronto, the rest of Ontario and Canada, 1995 – 2005 | 122 |
| Figure 4.8: Incidence of invasive meningococcal disease by age group and sex. Toronto, 1995 – 2005 combined | 122 |
| Figure 4.9: Number of reported cases of invasive meningococcal disease by serogroup and year. Toronto, 1995 – 2005 | 123 |
| Figure 4.10: Incidence of invasive group A streptococcal infections by year. Toronto, the rest of Ontario and Canada, 1995 – 2005 | 126 |
| Figure 4.11: Incidence of invasive group A streptococcal infections by age group and sex. Toronto, 2005 | 126 |
| Figure 4.12: Incidence of neonatal group B streptococcal infections by year. Toronto, the rest of Ontario and Canada, 1996 – 2005 | 130 |
| Figure 4.13: Incidence of invasive <i>Streptococcus pneumoniae</i> by age group and sex. Toronto, 2005 | 132 |
| Figure 4.14: Number of reported cases of invasive <i>Streptococcus pneumoniae</i> by month. Toronto, 2005 compared to 2002 – 2004 mean | 132 |
| Figure 4.15: Incidence of tuberculosis by year. Toronto, the rest of Ontario and Canada, 1995 – 2005 | 135 |
| Figure 4.16: Incidence of tuberculosis by age group and sex. Toronto, 2005 | 135 |
| Figure 4.17: Incidence rates of tuberculosis by sex and year. Toronto, 1995 – 2005 | 136 |
| Figure 4.18: Reported cases of tuberculosis by origin and year. Toronto, 1995 – 2005 | 137 |
| Figure 4.19: Proportion of foreign-born tuberculosis cases by top 10 countries of birth. Toronto, 2005 | 137 |
| Figure 4.20: Proportion of drug resistant tuberculosis cases by year. Toronto, 1995 – 2005 | 139 |

Vectorborne and Zoonotic Diseases

| | |
|--|-----|
| Figure 5.1: Incidence of lyme disease by year. Toronto, the rest of Ontario and Canada, 1995 – 2005 | 146 |
| Figure 5.2: Incidence of lyme disease by age group and sex. Toronto, 1995 – 2005 combined | 146 |
| Figure 5.3: Incidence of malaria by year. Toronto, the rest of Ontario and Canada, 1995 – 2005 | 148 |
| Figure 5.4: Incidence of malaria by age group and sex. Toronto, 2005 | 148 |
| Figure 5.5: Number of reported cases of malaria by month. Toronto, 2005 compared to 1995 – 2004 mean | 149 |
| Figure 5.6: Incidence of West Nile Virus by age group and sex. Toronto, 2002 – 2005 combined | 152 |
| Figure 5.7: Number of reported cases of West Nile Virus by month. Toronto, 2005 compared to 2002 – 2004 mean | 152 |
| Figure 5.8: Proportion of reported cases of West Nile virus by reported risk setting. Toronto, 2005 | 153 |

Encephalitis/Meningitis

| | |
|---|-----|
| Figure 6.1: Incidence of encephalitis/meningitis, viral and bacterial causes by year. Toronto, 1995 – 2005 | 158 |
| Figure 6.2: Incidence rates of encephalitis/meningitis, viral by year. Toronto compared to the rest of Ontario, 1995 – 2005 | 158 |

| | |
|---|-----|
| Figure 6.3: Incidence of encephalitis/meningitis, viral by age group and sex. Toronto, 1995 – 2005 combined | 159 |
| Figure 6.4: Number of reported cases of encephalitis/meningitis, viral by month. Toronto, 2005 compared to 1995 – 2005 mean | 159 |
| Figure 6.5: Incidence rates of encephalitis/meningitis, bacterial by year. Toronto compared to the rest of Ontario, 1995 – 2005 | 161 |
| Figure 6.6: Incidence of encephalitis/meningitis, bacterial by age group and sex. Toronto, 1995 – 2005 combined | 161 |
| Figure 6.7: Number of reported cases of encephalitis/meningitis, bacterial by month. Toronto, 2005 compared to 1995 – 2004 mean | 162 |

Outbreaks

| | |
|--|-----|
| Figure 8.1: Number of reported enteric outbreaks by month. Toronto, 2005 compared to 2000 – 2004 mean | 172 |
| Figure 8.2: Number of reported respiratory outbreaks by month. Toronto, 2005/06 compared to 2000/01 – 2004/05 mean | 175 |

List of Tables

| | Page |
|---|------|
| Table 1.0: Number and proportion of cases of all reportable diseases by ranking. Toronto, 2005 | 4 |
| Sexually Transmitted and Bloodborne Diseases | |
| Table 1.1: Number and proportion of reported cases of sexually transmitted and bloodborne diseases. Toronto, 2005 | 7 |
| Table 1.2: Chlamydia summary data. Toronto | 9 |
| Table 1.3: Risk factors for reported cases of chlamydia by sex. Toronto, 2005 | 11 |
| Table 1.4: Gonorrhoea summary data. Toronto | 13 |
| Table 1.5: Risk factors for reported cases of gonorrhoea by sex. Toronto, 2005 | 15 |
| Table 1.6: Hepatitis B summary data. Toronto | 17 |
| Table 1.7: Risk factors for reported acute cases of hepatitis B by sex. Toronto, 2005 | 19 |
| Table 1.8: Hepatitis C summary data. Toronto | 21 |
| Table 1.9: Risk factors for reported cases of hepatitis C by sex. Toronto, 2005 | 23 |
| Table 1.10: HIV summary data. Toronto | 25 |
| Table 1.11: Number and proportion of HIV-positive diagnoses by exposure category and sex. Toronto, 2005 | 27 |
| Table 1.12: Infectious syphilis summary data. Toronto | 29 |
| Table 1.13: Risk factors for reported cases of infectious syphilis by sex. Toronto, 2005 | 32 |
| Table 1.14: Late latent syphilis summary data. Toronto | 33 |
| Table 1.15: Risk factors for reported cases of late latent syphilis by sex. Toronto, 2005 | 36 |
| Enteric, Food and Waterborne Diseases | |
| Table 2.1: Number and proportion of reported cases of enteric, food and waterborne diseases. Toronto, 2005 | 39 |
| Table 2.2: Amebiasis summary data. Toronto | 41 |
| Table 2.3: <i>Campylobacter</i> enteritis summary data. Toronto | 45 |
| Table 2.4: Cryptosporidiosis summary data. Toronto | 49 |
| Table 2.5: Cyclosporiasis summary data. Toronto | 53 |
| Table 2.6: Giardiasis summary data. Toronto | 57 |
| Table 2.7: Hepatitis A summary data. Toronto | 61 |
| Table 2.8: Listeriosis summary data. Toronto | 65 |
| Table 2.9: Paratyphoid fever summary data. Toronto | 67 |
| Table 2.10: Salmonellosis (non-typhoidal salmonella) summary data. Toronto | 69 |
| Table 2.11: Ten most prevalent <i>Salmonella</i> species. Toronto, 2005 cases compared to previous 5-year mean | 71 |
| Table 2.12: Shigellosis summary data. Toronto | 73 |
| Table 2.13: Typhoid fever summary data. Toronto | 79 |
| Table 2.14: Verotoxin-producing <i>E. coli</i> infection (VTEC) summary data. Toronto | 83 |
| Table 2.15: Yersiniosis summary data. Toronto | 87 |
| Diseases Preventable by Routine Vaccination | |
| Table 3.1: Number and proportion of reported cases of vaccine preventable diseases. Toronto, 2005 | 93 |
| Table 3.2: Influenza summary data. Toronto | 95 |
| Table 3.3: Measles summary data. Toronto | 99 |
| Table 3.4: Mumps summary data. Toronto | 101 |
| Table 3.5: Pertussis summary data. Toronto | 103 |
| Table 3.6: Rubella summary data. Toronto | 107 |
| Diseases Transmitted by Direct Contact and Respiratory Routes | |
| Table 4.1: Number and proportion of reported cases of direct contact and respiratory diseases. Toronto, 2005 | 111 |
| Table 4.2: Chickenpox summary data. Toronto | 113 |
| Table 4.3: Legionellosis summary data. Toronto | 117 |
| Table 4.4: Invasive meningococcal disease summary data. Toronto | 121 |

| | | |
|-------------|--|-----|
| Table 4.5: | Invasive group A streptococcal infections summary data. Toronto | 125 |
| Table 4.6: | Risk factors for reported cases of invasive group A streptococcal infections. Toronto, 2005 | 127 |
| Table 4.7: | Neonatal group B streptococcal infections summary data. Toronto | 129 |
| Table 4.8: | Invasive <i>Streptococcus pneumoniae</i> summary data. Toronto | 131 |
| Table 4.9: | Tuberculosis summary data. Toronto | 133 |
| Table 4.10: | Risk settings of reported cases of tuberculosis. Toronto, 2005 | 136 |
| Table 4.11: | Number and proportion of reported cases of tuberculosis by anatomic site and country of origin. Toronto, 2005 | 138 |
| Table 4.12: | Reported cases of tuberculosis by treatment status and treatment method. Toronto, 2005 | 138 |

Vectorborne and Zoonotic Diseases

| | | |
|------------|---|-----|
| Table 5.1: | Number and proportion of reported cases of vectorborne and zoonotic diseases. Toronto, 2005 | 143 |
| Table 5.2: | Lyme disease summary data. Toronto | 145 |
| Table 5.3: | Malaria summary data. Toronto | 147 |
| Table 5.4: | West Nile virus summary data. Toronto | 151 |

Encephalitis/Meningitis

| | | |
|------------|--|-----|
| Table 6.1: | Encephalitis/meningitis summary data. Toronto | 157 |
| Table 6.2: | Incidence of viral encephalitis/meningitis by agent. Toronto, 2005 cases compared to previous 5-year mean | 160 |
| Table 6.3: | Incidence of bacterial encephalitis/meningitis by agent. Toronto, 2005 cases compared to previous 5-year mean | 162 |

Rare Diseases

| | | |
|------------|--|-----|
| Table 7.1: | Summary of rare and reportable diseases. Toronto 1995 – 2005 | 165 |
|------------|--|-----|

Outbreaks

| | | |
|------------|---|-----|
| Table 8.1: | Outbreaks summary data. Toronto | 169 |
| Table 8.2: | Number and proportion of reported enteric outbreaks by agent. Toronto, 2001 – 2005 | 170 |
| Table 8.3: | Number and proportion of enteric outbreaks by risk setting. Toronto, 2001 – 2005 | 171 |
| Table 8.4: | Enteric outbreaks by risk setting and average size. Toronto, 2005 | 171 |
| Table 8.5: | Number and proportion of reported respiratory outbreaks by agent. Toronto, 2001/02 – 2005/06 | 173 |
| Table 8.6: | Number and proportion of reported respiratory outbreaks by risk setting. Toronto, 2001/02 – 2005/06 | 174 |
| Table 8.7: | Respiratory outbreaks by risk setting and average size. Toronto, 2005/06 | 174 |
| Table 8.8: | Other reported outbreaks by agent/disease. Toronto, 2001 – 2005 | 175 |



Overview

Communicable Diseases in Toronto

2005

Introduction to Report

This report updates previous annual summaries of reportable communicable diseases for the City of Toronto with 2005 data. These summaries deal specifically with diseases designated *reportable* and *communicable* under the *Health Protection and Promotion Act* and associated regulations. The report's descriptive format is designed for use by several audiences. Toronto Public Health can continue to use the new information to further guide prevention, promotion and control efforts, resource allocation and policy decisions. Regional, provincial and national counterparts may use the report to add to their understanding of the burden of communicable diseases in larger urban centers. As with all of our surveillance reports, we hope colleagues throughout the health sector and in academia find value in these data for further development of targeted interventions and strategies for communicable disease control in Toronto.

The descriptive data contained in *Communicable Diseases in Toronto 2005* are based on information collected in the course of usual public health investigations and stored in one of two Ministry of Health and Long-term Care (MOHLTC)-mandated information systems. The Reportable Disease Information System (RDIS) had been used to manage and store surveillance and case management data in Ontario since 1989. This system was replaced with the integrated Public Health Information System (iPHIS), which Toronto adopted in late November 2005. Data from both these databases were merged and reconciled to generate the foundation of this report. The arduous task of reconciling two disparate information systems for Toronto's extensive communicable disease records caused a delay in the release of these data. Given the ongoing complexities associated with extracting data from iPHIS, subsequent annual report information will be presented in a different format to facilitate a more timely release.

Information in this report is presented in a manner that builds upon the previous three communicable disease summaries published for Toronto. Together, the data in these reports can be used to understand current and historical communicable disease trends in Toronto.

The format previously used has been retained. Graphs and tables are updated with 2005 case data and key observations for 2005 trends are highlighted for each disease. Rare diseases are listed to provide basic information about the frequency of their occurrence. Accurate use of and extrapolation from the data in this report require understanding of the limitations and technical issues outlined in the appendices. The general format used in each disease summary is described in the next section and then applied to each disease, grouped in chapters reflecting the major modes of disease transmission. Disease groups are presented in an order reflecting their relative burden in Toronto. Within each disease grouping, diseases are presented in alphabetical order. □

Standard Report Format

Data in this report are derived and summarized as indicated below. The relevant measures and headings were included only where they were applicable and sufficient data were available.

Summary Data Table

Number of reported cases: For most diseases, this reflects cases of the disease with an episode date in the given time period (2005, most recent previous 5-year mean for 2000-2004, and overall previous 10-year mean for 1995-2004).

Incidence rates (reported as period rates per 100,000):

Overall: Number of all new cases in a time period divided by the Toronto population for that time period, multiplied by 100,000.

Male: Number of new male cases in a time period divided by the Toronto male population for that time period, multiplied by 100,000.

Female: Number of new female cases in a time period divided by the Toronto female population for that time period, multiplied by 100,000.

Mean age: Arithmetic mean age of all cases in the given time period.

Median age: The age that represents the midpoint of the sequence of all case ages for the given time period.

Age range: The age of the youngest and oldest cases in the given time period. With the exception of neonatal group B streptococcal reports, for cases under one year of age, less than one (<1) was used.

Case fatality rate (where applicable): The number of deaths in cases with the reportable disease in a given time period divided by the total number of incident cases within the same time period. This is expressed as a percentage. Note that deaths can occur a year or more after the disease was acquired and are likely underestimated given cases are followed for only a finite period. Deaths are counted in the year of the disease episode to capture the proportion of cases reported in a given year whose death was associated with the disease.

Hospitalization rate (where applicable): The number of cases with the reportable disease treated in a hospital (both in-patients and out-patients) divided by the total number of incident cases within the same time period. This is expressed as a percentage.

Outbreak-associated cases (where applicable): The number of cases with the reportable disease that were identified as being related to or part of an outbreak divided by the total number of incident cases within the same time period. This is expressed as a percentage.

Highlights

The report primarily focuses on 2005 data and highlights the significance of any changes from the previous year. Key observations and notable changes in trends for each disease are mentioned in a style consistent with past reports. Potential explanations of any significant changes or notable trends are offered when available. Several years of data are combined when reporting rates for disease with few reports, as described below.

Figures and Tables

In general, data presented in figures and tables for each disease focus on the following attributes:

Regional comparisons: An illustration of incidence rates in Toronto, the rest of Ontario and Canada over the entire surveillance period.

Rates for 'Ontario less Toronto' were calculated by dividing the number of cases in the rest of Ontario (Ontario cases – Toronto cases) by the population in the rest of Ontario (Ontario population – Toronto population) multiplied by 100.

Age and sex: Where data were available and sufficient to allow division of cases into different sexes for each age group, the age-sex specific rates were reported along with the overall age-specific rate. Where the annual number of cases for the more common diseases (such as chlamydia or salmonellosis) was large enough, age-specific rates were provided for the most current year of data (2005). For diseases with low

annual numbers of cases (e.g. hepatitis B and legionellosis), age-specific rates were based on combined data for all years starting in 1995 (or the earliest date that disease data were available, for those diseases not designated reportable until a few years into the surveillance period).

Several factors shaped the determination of the age categories used in this report. Age categories were created to have cell sizes with more than five observations. Every attempt was also made to report standard age groups within disease chapters (e.g. all STIs) to facilitate comparisons between diseases.

Sex: For diseases that tend to be differentially reported by sex and where there are many cases, an illustration of the sex-specific incidence rates for 1995 to 2005 was provided. These data were primarily presented for sexually transmitted infections and enteric diseases (e.g. Amebiasis, Shigellosis, Giardiasis) for which a large proportion of infections are transmitted via sexual contact.

Risk factors, risk settings and source of infection: Where applicable, the proportion of cases reporting specific risk factors, sources of infection, and risk settings was presented. Categories used are those available in RDIS, which vary by disease and time period. Additional risk factors captured in iPHIS and not in RDIS have been classified as 'Other'. In some circumstances, which have been noted, categories were combined.

Month: Where applicable, the number of cases that occurred during each month of 2005, compared to the previous 10-year (1995-2004 or the longest period available) mean and 95% confidence interval was presented. Given the small numbers that could be reported in any given month, confidence intervals were used as a means to ascertain whether reports for any single month of the current year were notably high or low.

Tuberculosis disease – additional tables and figures: The epidemiology of tuberculosis is best understood with the summary of additional factors and facets of the disease. Additional disease and case characteristics such as country

of origin, anatomical site, treatment outcomes, antibiotic resistance, and medical surveillance numbers were included. □

**Table 1.0: Number and proportion of cases for all reportable diseases by ranking.
Toronto, 2005**

| Ranking | Reportable disease | Number of cases | Proportion of cases (%) |
|---------|--|-----------------|-------------------------|
| 1 | Chlamydia | 6497 | 30 |
| 2 | Chickenpox | 3668 | 17 |
| 3 | Gonorrhoea | 1659 | 8 |
| 4 | Hepatitis B carriers | 1469 | 7 |
| 5 | Hepatitis C | 1165 | 5 |
| 6 | <i>Campylobacter</i> enteritis | 997 | 5 |
| 7 | Hepatitis B unclassified reports | 852 | 4 |
| 8 | Salmonellosis | 686 | 3 |
| 9 | HIV | 555 | 3 |
| 10 | Giardiasis | 547 | 3 |
| 11 | Influenza* | 517 | 2 |
| 12 | Syphilis, late latent | 484 | 2 |
| 13 | Amebiasis | 376 | 2 |
| 14 | Tuberculosis | 344 | 2 |
| 15 | Syphilis, infectious | 250 | 1 |
| 16 | <i>Streptococcus pneumoniae</i> , invasive | 216 | 1 |
| 17 | Pertussis | 177 | <1 |
| 18 | Yersiniosis | 117 | <1 |
| 19 | Shigellosis | 100 | <1 |
| 20 | Malaria | 90 | <1 |
| 21 | Streptococcal disease, Group A invasive | 72 | <1 |
| 22 | Encephalitis/meningitis: viral | 55 | <1 |
| 23 | Legionellosis | 53 | <1 |
| 24 | Cryptosporidiosis | 52 | <1 |
| 25 | Cyclosporiasis | 48 | <1 |
| 25 | Hepatitis A | 48 | <1 |
| 27 | West Nile Virus | 38 | <1 |
| 28 | Hepatitis B cases | 34 | <1 |
| 28 | Verotoxin-producing <i>E. coli</i> infection | 34 | <1 |
| 30 | Typhoid fever | 23 | <1 |
| 31 | Lyme disease | 13 | <1 |
| 31 | Paratyphoid fever | 13 | <1 |
| 33 | Streptococcal disease, Group B neonatal | 12 | <1 |
| 34 | Syphilis, other† | 11 | <1 |
| 35 | Listeriosis | 10 | <1 |
| 36 | Encephalitis/meningitis: unclassified | 7 | <1 |
| 36 | Mumps | 7 | <1 |
| 38 | Encephalitis/meningitis: other | 6 | <1 |
| 39 | Hepatitis D | 5 | <1 |
| 40 | Encephalitis/meningitis: bacterial | 4 | <1 |
| 40 | Rubella | 4 | <1 |
| 42 | Brucellosis | 3 | <1 |
| 42 | Cytomegalovirus infection, congenital | 3 | <1 |
| 42 | Meningococcal disease, invasive | 3 | <1 |
| 45 | Herpes, neonatal | 1 | <1 |
| 45 | Leprosy | 1 | <1 |
| 45 | Measles | 1 | <1 |
| | Total | 21327 | 100 |

* Seasonal year from July to June (e.g. 2005/06 includes cases from July 1, 2005 to June 30, 2006).

† Excludes infectious, late latent and congenital syphilis.

Communicable diseases without any reported activity in 2005 were not included in this table. These include: anthrax, botulism, chancroid, cholera, diphtheria, hantavirus, *Haemophilus influenzae* b, haemorrhagic fevers, lassa fever, ophthalmia neonatorum, plague, poliomyelitis, psittacosis/ornithosis, Q fever, rabies, rubella-congenital syndrome, severe acute respiratory syndrome (SARS), smallpox, syphilis-congenital, transmissible spongiform encephalopathies, tetanus, trichinosis, tularemia, and yellow fever.

Sexually Transmitted and Bloodborne Diseases

**Communicable Diseases
in Toronto**

2005

Sexually Transmitted and Bloodborne Diseases

This section focuses on diseases caused by infectious agents that are found in body fluids such as blood, semen, vaginal secretions, breast milk, and saliva. Transmission occurs primarily from person to person through sexual contact, through other means of direct entry into the blood system such as needle use or transfusions, perinatally from mother to infant or in the case of hepatitis B through household contact. This group of diseases is the most widespread in Toronto. Relative proportions of each disease within this grouping, and their ranking are listed below. In 2005, chlamydia accounted for 50% of reports falling into this category. □

Table 1.1: Number and proportion of reported cases of sexually transmitted and bloodborne diseases. Toronto, 2005

| Ranking | Reportable disease | Number of cases | Proportion of cases (%) |
|---------|---------------------------------------|-----------------|-------------------------|
| 1 | Chlamydia | 6497 | 50 |
| 2 | Gonorrhoea | 1659 | 13 |
| 3 | Hepatitis B carriers | 1469 | 11 |
| 4 | Hepatitis C | 1165 | 9 |
| 5 | Hepatitis B unclassified reports* | 852 | 7 |
| 6 | HIV | 555 | 4 |
| 7 | Syphilis, late latent | 484 | 4 |
| 8 | Syphilis, infectious | 250 | 2 |
| 9 | Hepatitis B cases | 34 | <1 |
| 10 | Syphilis, other [†] | 11 | <1 |
| 11 | Hepatitis D | 5 | <1 |
| 12 | Cytomegalovirus infection, congenital | 3 | <1 |
| 13 | Herpes, neonatal | 1 | <1 |
| - | AIDS [‡] | NA | NA |
| | Total | 12985 | 100 |

Rare reportable diseases not summarized in this section include chancroid, syphilis congenital and ophthalmia neonatorum.

*Unclassified hepatitis B reports are clients whose laboratory results indicate positive hepatitis B virus markers, but are lacking sufficient evidence to be classified as cases or carriers. These reports are most likely carriers.

[†]Excludes infectious, late latent and congenital syphilis.

[‡]Due to discrepancies associated with data conversion from RDIS to iPHIS, AIDS data are not available for reporting.


Chlamydia

| Table 1.2: Chlamydia summary data | | | |
|---|--------------------|--------------------------|---------------------------|
| Toronto | | | |
| | 2005 | 5-yr period 2000-2004 | 10-yr period 1995-2004 |
| | Total | Means | |
| Number of reported cases | 6497 | 5999 | 5202 |
| Incidence rate (per 100,000 population) | | | |
| Overall | 249.6 | 231.2 | 204.9 |
| Male | 212.1 | 179.6 | 144.8 |
| Female | 285.0 | 280.2 | 261.8 |
| Age at onset (years) | Summary Statistics | | |
| Mean | 27 | 26 | 26 |
| Median | 24 | 24 | 24 |
| Range | <1 84 | <1 80 | <1 94 |


Highlights

- Chlamydia continues to be the most frequently reported sexually transmitted infection (STI) and reportable disease in Toronto, accounting for 50% of all STI reports (Table 1.1) and 30% of all communicable disease reports (Table 1.0).
- In 2005, there were 6497 reported cases (249.6 cases per 100,000) of chlamydia. This represented an increase of 204 cases (3%) from the 2004 total of 6293 cases (Figure 1.1).
- Female rates of chlamydia continued to exceed male rate. However, since 2002 rates have remained steady among females while male rates continue to increase, further diminishing the gap between sexes (Figure 1.3).
- The incidence rate of chlamydia among males increased 7% from 197.7 cases per 100,000 in 2004 to 212.1 cases per 100,000 in 2005.
- Among the 5575 cases with a known risk factor in 2005, the most commonly reported risk factor for acquiring chlamydia was not using a condom or chemical barrier (89%) (Table 1.3).
- In Toronto, eight probable and 21 confirmed cases of lymphogranuloma venereum (LGV) were reported in 2005. Toronto cases accounted for 100% and 52% of all LGV cases reported in Ontario (N=29) and Canada (N=56), respectively. Among the 20 LGV cases with known HIV status, 80% (n=16) were co-infected with HIV. LGV is a systemic sexually transmitted infection caused by strains of the bacterium *Chlamydia trachomatis* (immunotypes L-1, L-2, L-3). Although rare in industrialized countries, an outbreak among men who have sex with men (MSM) in the Netherlands began in 2003 and cases have since been reported in several European and North American cities.

**Figure 1.1: Incidence of chlamydia by year.
Toronto, the rest of Ontario and Canada, 1995 - 2005**




**Figure 1.2: Incidence of chlamydia by age group and sex*.
Toronto, 2005**



*The age of three cases and sex of one case was not reported.

**Figure 1.3: Incidence rates of chlamydia by sex and year.
Toronto, 1995 - 2005**



**Table 1.3: Risk factors for reported cases of chlamydia by sex*.
Toronto, 2005**

| Reported risk factor | Number of cases [†] (%) | | | | | |
|--|----------------------------------|------|-------------|------|-------------|------|
| | Male | | Female | | Overall | |
| No condom or chemical barrier used | 1774 | (86) | 2964 | (90) | 4939 | (89) |
| New partner in past 2 months | 371 | (16) | 285 | (9) | 657 | (12) |
| Multiple sexual partners | 424 | (19) | 199 | (6) | 624 | (11) |
| Sexual contact of a confirmed case | 251 | (11) | 146 | (4) | 397 | (7) |
| Condom breakage | 159 | (7) | 176 | (5) | 336 | (6) |
| Homosexual/bisexual | 240 | (11) | 0 | (0) | 240 | (4) |
| Travel | 111 | (5) | 74 | (2) | 185 | (3) |
| Partner visiting from outside province/country | 18 | (<1) | 58 | (2) | 76 | (1) |
| Judgement impaired by alcohol/drugs | 25 | (1) | 17 | (<1) | 42 | (<1) |
| Homeless | 15 | (<1) | 23 | (<1) | 38 | (<1) |
| Sex trade worker | 10 | (<1) | 5 | (<1) | 15 | (<1) |
| Sex for drugs | 0 | (0) | 1 | (<1) | 1 | (<1) |
| Other | 122 | (5) | 131 | (4) | 253 | (5) |
| Total with a known risk factor | 2285 | | 3288 | | 5575 | |
| Number missing or unknown | 405 | | 516 | | 922 | |
| Total cases | 2690 | | 3804 | | 6497 | |

*The sex of three cases was not reported.

[†]Cases may report more than one risk factor. Risk factors for 65 cases were treated as missing due to multiple STI reports recorded in iPHIS. See technical notes on page 183.


Gonorrhoea

| Table 1.4: Gonorrhoea summary data | | | |
|---|--------------------|--------------------------|---------------------------|
| Toronto | | | |
| | 2005 | 5-yr period 2000-2004 | 10-yr period 1995-2004 |
| | Total | Means | |
| Number of reported cases | 1659 | 1776 | 1630 |
| Incidence rate (per 100,000 population) | | | |
| Overall | 63.7 | 68.4 | 64.2 |
| Male | 91.1 | 94.0 | 85.1 |
| Female | 37.5 | 44.1 | 44.3 |
| Age at onset (years) | Summary statistics | | |
| Mean | 30 | 28 | 28 |
| Median | 27 | 26 | 25 |
| Range | 13 78 | <1 85 | <1 85 |


Highlights

- In 2005, there were 1659 reported cases (63.7 cases per 100,000) of gonorrhoea. This represented a decrease of 78 cases (4%) from the 2004 total of 1737 cases. (Figure 1.4). The decline in gonorrhoea incidence is consistent with a decreased rates observed in the rest of Ontario and Canada in 2005.
- Gonorrhoea was reported more frequently in males who accounted for 70% (n=1156) of all cases in 2005. Both male and female rates of gonorrhoea declined in 2005 (Figure 1.6). Although women are more likely to be screened routinely for gonorrhoea, symptoms occur more commonly in infected males, which may lead them to seek medical care and diagnosis.
- Among the 1359 cases with a known risk factor in 2005, the most commonly reported risk factor for acquiring gonorrhoea was not using a condom or chemical barrier (84%) (Table 1.5).


**Figure 1.4: Incidence of gonorrhoea by year.
Toronto, the rest of Ontario and Canada, 1995 - 2005**



**Figure 1.5: Incidence of gonorrhoea by age group and sex*.
Toronto, 2005**



**Figure 1.6: Incidence rates of gonorrhoea by sex and year.
Toronto, 1995 - 2005**



**Table 1.5: Risk factors for reported cases of gonorrhoea by sex*.
Toronto, 2005**

| Reported risk factor | Number of cases [†] (%) | | |
|--|----------------------------------|------------|-------------|
| | Male | Female | Overall |
| No condom or chemical barrier used | 792 (83) | 350 (86) | 1143 (84) |
| Multiple sexual partners | 324 (34) | 34 (8) | 358 (26) |
| Homosexual/bisexual | 324 (34) | 0 (0) | 324 (24) |
| New partner in past 2 months | 245 (26) | 49 (12) | 294 (22) |
| Condom breakage | 76 (8) | 23 (6) | 99 (7) |
| Sexual contact of a confirmed case | 52 (5) | 25 (6) | 77 (6) |
| Travel | 34 (4) | 10 (2) | 44 (3) |
| Homeless | 19 (2) | 10 (2) | 29 (2) |
| Judgement impaired by alcohol/drugs | 16 (2) | 8 (2) | 24 (2) |
| Sex trade worker | 14 (1) | 5 (1) | 19 (1) |
| Partner visiting from outside province/country | 8 (<1) | 2 (<1) | 10 (<1) |
| Sex for drugs | 1 (<1) | 2 (<1) | 3 (<1) |
| Other | 103 (11) | 30 (7) | 134 (10) |
| Total with a known risk factor | 950 | 407 | 1359 |
| Number missing or unknown | 206 | 94 | 300 |
| Total cases | 1156 | 501 | 1659 |

*The sex of two cases was not reported.

[†]Cases may report more than one risk factor. Risk factors for 29 cases were treated as missing due to multiple STI reports recorded in iPHIS. See technical notes on page 183.


Hepatitis B

| Table 1.6: Hepatitis B summary data | | | | | | |
|---|--------------------|----------|--------------------------|----------|---------------------------|----------|
| Toronto | | | | | | |
| | 2005 | | 5-yr period 2000-2004 | | 10-yr period 1995-2004 | |
| | Total | | Means | | | |
| | Cases | Carriers | Cases | Carriers | Cases | Carriers |
| Number of reports | 34 | 1469 | 39 | 2120 | 49 | 2247 |
| Incidence rate (per 100,000 population) | | | | | | |
| Overall | 1.3 | 56.4 | 1.5 | 81.7 | 1.9 | 88.5 |
| Male | 2.0 | 61.0 | 2.1 | 89.8 | 2.6 | 97.3 |
| Female | 0.6 | 51.5 | 1.0 | 73.0 | 1.3 | 78.4 |
| Age at onset (years) | Summary statistics | | | | | |
| Mean | 40 | 38 | 38 | 38 | 37 | 38 |
| Median | 36 | 35 | 37 | 35 | 35 | 36 |
| Range | 20 - 76 | 1 - 94 | <1 - 85 | <1 - 100 | <1 - 88 | <1 - 100 |


Highlights

- In 2005, there were 34 reported cases (1.3 cases per 100,000) of acute hepatitis B. This represented a decrease of four (11%) cases from the 2004 total of 38 cases (Figure 1.7).
- There were 1469 hepatitis B carriers and 852 unclassified hepatitis B reports in 2005 (Figure 1.9). Unclassified hepatitis B reports are clients whose laboratory results indicate hepatitis B infection but are lacking sufficient evidence to be classified as cases or carriers. These unclassified case are most likely carriers.
- Acute hepatitis B was reported more frequently in males who accounted for 76% (n=26) of all cases in 2005.
- In 2005, travel to or living in an endemic area (63%) was the most commonly reported risk factor for all acute hepatitis B cases (Table 1.7). Sexual activity with a same sex partner (43%) was the second most commonly reported risk factor among males.


**Figure 1.7: Incidence of acute hepatitis B by year.
Toronto, the rest of Ontario and Canada, 1995 - 2005**



**Figure 1.8: Incidence of acute hepatitis B by age group and sex.
Toronto, 1995 - 2005 combined**



**Figure 1.9: Number of hepatitis B cases, carriers and unclassified reports* by year.
Toronto, 1995 - 2005**



*Unclassified hepatitis B reports are clients whose laboratory results indicate positive hepatitis B virus markers but are lacking sufficient evidence to be classified as cases or carriers. These reports are most likely carriers.

**Table 1.7: Risk factors for reported acute cases of hepatitis B by sex.
Toronto, 2005**

| Reported risk factor | Number of cases* (%) | | |
|--|----------------------|----------|-----------|
| | Male | Female | Overall |
| Travel to or living in an endemic area | 9 (64) | 1 (50) | 10 (63) |
| Homosexual/bisexual | 6 (43) | 0 (0) | 6 (38) |
| Multiple sexual partners | 4 (29) | 0 (0) | 4 (25) |
| No condom or chemical barrier used | 4 (29) | 0 (0) | 4 (25) |
| Sexual contact of a confirmed case | 3 (21) | 0 (0) | 3 (19) |
| Other | 2 (14) | 1 (50) | 3 (19) |
| Total with a known risk factor | 14 | 2 | 16 |
| Number missing or unknown | 12 | 6 | 18 |
| Total cases | 26 | 8 | 34 |

*Cases may report more than one risk factor.


Hepatitis C

| Table 1.8: Hepatitis C summary data | | | |
|---|--------------------|--------------------------|---------------------------|
| Toronto | | | |
| | 2005 | 5-yr period 2000-2004 | 10-yr period 1995-2004 |
| | Total | Means | |
| Number of reported cases | 1165 | 1430 | 1846 |
| Incidence rate (per 100,000 population) | | | |
| Overall | 44.8 | 55.1 | 72.7 |
| Male | 57.9 | 69.9 | 93.9 |
| Female | 32.0 | 40.2 | 51.7 |
| Age at onset (years) | Summary statistics | | |
| Mean | 46 | 46 | 44 |
| Median | 45 | 45 | 42 |
| Range | <1 92 | <1 98 | <1 110 |
| Case fatality (%) | 0.3 | <0.1 | 0.2 |


Highlights

- In 2005, there were 1165 reported cases (44.8 cases per 100,000) of hepatitis C. This represented a decrease of 171 cases (13%) from the 2004 total of 1336 cases. The incidence rate for hepatitis C in 2005 was the lowest rate observed in the entire 11 year surveillance period (Figure 1.10).
- Toronto's rate of incident hepatitis C exceeded the rate reported in the rest of Ontario in 2005 (Figure 1.10).
- The age group with the highest incidence rate was the 40 to 44 year age group (92.2 cases per 100,000) in 2005 (Figure 1.11).
- Male rates of hepatitis C continued to exceed female rates in all age groups except 0 to 9 and 10 to 19 years old (Figure 1.11). Hepatitis C rates for both females and males decreased in 2005 compared to 2004 (Figure 1.12).
- Among the 621 cases with a known risk factor in 2005, the most commonly reported risk factor for acquiring hepatitis C was injection drug use (47%). Tattoo/acupuncture/earpiercing (24%) became the second most commonly reported risk factor in 2005 replacing the receipt of blood or blood products which was the second most commonly reported risk factor for cases in 2004 (17%) (Table 1.9).

**Figure 1.10: Incidence of hepatitis C by year.
Toronto, the rest of Ontario and Canada, 1995 - 2005**




**Figure 1.11: Incidence of hepatitis C by age group and sex*.
Toronto, 2005**



*The sex of three cases was not reported.

**Figure 1.12: Incidence rates of hepatitis C by sex and year.
Toronto, 1995 - 2005**



**Table 1.9: Risk factors for reported cases of hepatitis C by sex*.
Toronto, 2005**

| Reported risk factor | Number of cases [†] (%) | | |
|---|----------------------------------|------------|-------------|
| | Male | Female | Overall |
| Injection drug user | 203 (51) | 86 (39) | 289 (47) |
| Tattoo/acupuncture/ear piercing | 95 (24) | 53 (24) | 149 (24) |
| Recipient of blood or blood products [‡] | 52 (13) | 56 (25) | 108 (17) |
| Multiple sexual partners | 61 (15) | 21 (9) | 82 (13) |
| Sexual contact of a confirmed case | 20 (5) | 26 (12) | 46 (7) |
| Travel | 24 (6) | 11 (5) | 35 (6) |
| Homeless | 29 (7) | 3 (1) | 32 (5) |
| Household contact of a case or carrier | 12 (3) | 11 (5) | 23 (4) |
| No condom or chemical barrier used | 11 (3) | 7 (3) | 18 (3) |
| Health care worker | 6 (2) | 7 (3) | 13 (2) |
| Infant born to case or carrier | 4 (1) | 4 (2) | 8 (1) |
| Other occupational exposure | 2 (<1) | 0 (<1) | 2 (<1) |
| Dialysis | 0 (<1) | 1 (<1) | 1 (<1) |
| Resident of facility for the developmentally disabled | 1 (<1) | 0 (<1) | 1 (<1) |
| Other | 60 (15) | 44 (20) | 104 (17) |
| Total with a known risk factor | 398 | 222 | 621 |
| Number missing or unknown | 337 | 205 | 544 |
| Total cases | 735 | 427 | 1165 |

*The sex of three cases was not reported. [†]Cases may report more than one risk factor.

[‡]Cases that reported recipient of blood or blood products as a risk factor were diagnosed but not infected with hepatitis C in 2005.

HIV


| Table 1.10: HIV* summary data | | | |
|---|--------------------|--------------------------|---------------------------|
| Toronto | | | |
| | 2005 | 5-yr period 2000-2004 | 10-yr period 1995-2004 |
| | Totals | Means | |
| Number of reported cases | 555 | 546 | 519 |
| Incidence rate (per 100,000 population) | | | |
| Overall | 21.3 | 21.0 | 20.5 |
| Male | 35.5 | 33.6 | 34.3 |
| Female | 7.6 | 8.9 | 7.1 |
| Age at onset (years) | Summary statistics | | |
| Mean | 37 | 36 | 36 |
| Median | 37 | 36 | 35 |
| Range | 12 78 | <1 81 | <1 81 |

*Due to discrepancies associated with data conversion from RDIS to iPHIS, AIDS data are not available for reporting. See the Technical Notes section (page 183) on Data Limitations regarding the omission of AIDS data for 2005.

Highlights: HIV


- In 2005, there were 555 reported cases (21.3 cases per 100,000) of human immunodeficiency virus (HIV). This represented a decrease of 14 cases (2%) from the 2004 total of 569 cases and the third consecutive year of decline in the incidence rate (Figure 1.13).
- HIV continues to be more frequently reported in males who accounted for 81% (n=450) of all HIV cases in 2005. The HIV rate among males increased 4% from 34.2 cases per 100,000 in 2004 to 35.5 cases per 100,000 in 2005, while the HIV rate among females decreased 23% from 10.1 cases per 100,000 in 2004 to 7.6 cases per 100,000 in 2005.
- Among males, the largest increase in HIV occurred in those 20 to 24 years of age. In this age group, rates almost doubled from 27.9 cases per 100,000 in 2004 to 48.0 cases per 100,000 in 2005.
- Among the 412 male cases with a known risk factor in 2005, the most commonly reported risk factor for acquiring HIV was having sex with other men (74% in 2005 as compared with 79% in 2004). (Table 1.11).
- Among the 87 female cases with a known risk factor, the most commonly reported risk factors were living or travelling in an HIV-endemic country (59%) and heterosexual contact with a partner that has no identified risk (NIR-HET) (18%) (Table 1.11).
- There were no reported cases of perinatal transmission among children born in 2005.
- The proportion of HIV infections associated with endemic countries decreased from 21% in 2004 to 19% in 2005. The top three countries of origin for foreign-born HIV cases in 2005 were Zimbabwe, Ethiopia and Jamaica.

**Figure 1.13: Incidence of HIV* infection by year.
Toronto, the rest of Ontario and Canada, 1995 - 2005**




*HIV reports have been counted by year of test for Ontario less Toronto and Canada rate calculations.

**Figure 1.14: Incidence rates of HIV infection by age group and sex*.
Toronto, 2005**



*The age of one case and sex for three cases was not reported.

**Figure 1.15: Incidence rates of HIV infection by sex and year.
Toronto, 1995 - 2005**



**Table 1.11: Number and proportion of HIV-positive diagnoses by exposure category* and sex†.
Toronto, 2005**

| Exposure category* | Number of cases‡ (%) | | | | |
|--|----------------------|--------------|------------|--------------|------------------|
| | Male | | Female | | Overall |
| MSM | 303 | (74) | - | - | 303 (61) |
| MSM/IDU | 4 | (<1) | - | - | 4 (<1) |
| IDU | 10 | (2) | 7 | (8) | 17 (3) |
| Clotting factor/transfusion pre 1985 | 0 | (0) | 0 | (0) | 0 (0) |
| Clotting factor/transfusion post 1985§ | 0 | (0) | 1 | (1) | 1 (<1) |
| HIV-endemic | 43 | (10) | 51 | (59) | 94 (19) |
| HET-partner | 20 | (5) | 11 | (13) | 31 (6) |
| NIR-HET | 26 | (6) | 16 | (18) | 42 (8) |
| Other | 3 | (<1) | 1 | (1) | 4 (<1) |
| No identifiable risk | 3 | (<1) | 0 | (0) | 3 (<1) |
| Total with a known exposure | 412 | (100) | 87 | (100) | 499 (100) |
| Number missing or unknown | 38 | | 15 | | 56 |
| Total cases | 450 | | 102 | | 555 |

*See the glossary for definitions of each exposure category.

†The sex for three cases was not reported.

‡Cases may report one or more risks but are counted in the category considered the highest risk according to an exposure category hierarchy. The categories are listed in descending order from those that are considered to carry the highest risk of HIV infection to those considered to carry the lowest risk. Risk factors for five cases were treated as missing due to multiple STI reports recorded in iPHIS. See technical notes on page 183.

§The one case whose exposure to HIV occurred via a blood transfusion after 1985 received the transfusion outside of Canada.

Syphilis, infectious

(Primary, secondary and early latent syphilis)


Table 1.12: Infectious syphilis summary data

| Toronto | | | |
|---|--------------------|--------------------------|---------------------------|
| | 2005 | 5-yr period 2000-2004 | 10-yr period 1995-2004 |
| | Total | Means | |
| Number of reported cases | 250 | 194 | 118 |
| Incidence rate (per 100,000 population) | | | |
| Overall | 9.6 | 7.5 | 4.6 |
| Male | 18.9 | 14.5 | 8.5 |
| Female | 0.7 | 0.8 | 1.0 |
| Age at onset (years) | Summary statistics | | |
| Mean | 38 | 38 | 38 |
| Median | 38 | 38 | 38 |
| Range | 17 72 | 15 72 | 15 73 |


Highlights

- In 2005, there were 250 reported cases (9.6 cases per 100,000) of infectious syphilis. This represented a decrease of 134 cases (35%) from the 2004 total of 384 cases (Figure 1.16). This marks the first year the rate of infectious syphilis has decreased since an outbreak began in 2002 among men who have sex with men (MSM). This decrease does not appear to be related to syphilis testing since recent data indicate a 1% increase in syphilis testing at the Toronto Public Health Laboratory from 2004 to 2005.
- Males continued to experience the highest burden of infectious syphilis, exceeding the incidence rates of females in all age groups (Figure 1.17), however, the gap between the sexes is narrowing (Figure 1.18). Age specific rates for males decreased from 2004 rates in all age groups except those 20 to 24 and 25 to 29 years of age.
- The majority (41%) of infectious syphilis cases were diagnosed during the secondary stage of syphilis (Figure 1.19).
- In 2005, 30% (n=74) of infectious syphilis cases were co-infected with HIV, which is the lowest level observed since the outbreak began in 2002 (Figure 1.20).
- Among the 204 cases with a known risk factor in 2005, the most commonly reported risk factor for acquiring infectious syphilis was not using a condom or chemical barrier (87%) (Table 1.13). The proportion of male infectious syphilis cases reporting sexual activity with a same sex partner as a risk factor for acquiring syphilis decreased from 79% in 2004 to 69% in 2005.


**Figure 1.16: Incidence of infectious syphilis by year.
Toronto, the rest of Ontario and Canada, 1995 - 2005**




**Figure 1.17: Incidence of infectious syphilis by age group and sex.
Toronto, 2005**




**Figure 1.18: Incidence rates of infectious syphilis by sex and year.
Toronto, 1995 - 2005**



**Figure 1.19: Incidence of infectious syphilis by staging and year.
Toronto, 1995 - 2005**



**Figure 1.20: Incidence of HIV and infectious syphilis co-infections by year.
Toronto, 1995 - 2005**



**Table 1.13: Risk factors for reported cases of infectious syphilis by sex.
Toronto, 2005**

| Reported risk factor | Number of cases* (%) | | |
|---------------------------------------|----------------------|-----------|------------|
| | Male | Female | Overall |
| No condom or chemical barrier used | 168 (86) | 9 (100) | 177 (87) |
| Homosexual/bisexual | 135 (69) | 0 (0) | 135 (66) |
| Multiple sexual partners | 89 (46) | 1 (11) | 90 (44) |
| Sexual contact of a confirmed case | 22 (11) | 1 (11) | 23 (11) |
| Sex trade worker | 3 (2) | 0 (0) | 3 (1) |
| Genital ulcers | 1 (<1) | 0 (0) | 1 (<1) |
| Other | 114 (58) | 0 (0) | 114 (56) |
| Total with a known risk factor | 195 | 9 | 204 |
| Number missing or unknown | 45 | 1 | 46 |
| Total cases | 240 | 10 | 250 |

*Cases may report more than one risk factor. Risk factors for seven cases were treated as missing due to multiple STI reports recorded in iPHIS. See technical notes on page 183.


Syphilis, late latent

| Table 1.14: Late latent syphilis summary data | | | |
|---|--------------------|--------------------------|---------------------------|
| Toronto | | | |
| | 2005 | 5-yr period 2000-2004 | 10-yr period 1995-2004 |
| | Total | Means | |
| Number of reported cases | 484 | 144 | 135 |
| Incidence rate (per 100,000 population) | | | |
| Overall | 18.6 | 5.5 | 5.3 |
| Male | 21.0 | 6.5 | 6.0 |
| Female | 16.3 | 4.6 | 4.6 |
| Age at onset (years) | Summary statistics | | |
| Mean | 50 | 47 | 47 |
| Median | 48 | 44 | 43 |
| Range | 18 91 | 15 99 | 15 99 |

Highlights


- In 2005, there were 484 reported cases (18.6 cases per 100,000) of late latent syphilis. This represented an increase of 335 cases (225%) over the 2004 total of 149 cases (Figure 1.21). This is the highest incidence of late latent syphilis observed since 1989 (when electronic record keeping was implemented). Recent data indicate only a 1% increase in syphilis testing at the Toronto Public Health Laboratory from 2004 to 2005. However, in August 2005, more sensitive enzyme immunoassay (EIA) testing was introduced and would explain most of the increase in case reports.
- For males and females respectively, late latent syphilis rates were three and five times higher in 2005 compared to 2004 (Figure 1.23). Sex-specific rates indicate that although male rates of late latent syphilis continue to exceed female rates, the gap between the sexes decreased in 2005 compared to 2004 (Figure 1.23). In 2005, female rates of late latent syphilis surpassed male rates in age groups 25 to 29 and 30 to 34 years (Figure 1.22). This may further reflect the use of a more sensitive lab test during routine pregnancy screening.
- Among males, the largest increases were observed in both age groups 40 to 44 and 65 years and older, where rates were four times higher than in 2004. Among females, the largest increases were observed in age groups 30 to 34 and 35 to 39 years, where rates were 20 and 18 times higher than in 2004.
- Following a peak in the proportion of HIV and late latent syphilis co-infected cases in 2004, the proportion of co-infected cases dropped to levels comparable to earlier years (Figure 1.24).
- Among the 304 late latent syphilis cases with a known risk factor in 2005, the most commonly reported risk factor for acquiring late latent syphilis was not using a condom or chemical barrier (81%) (Table 1.15). The proportion of cases that reported engaging in sexual activity with a same sex partner as a risk factor decreased from 32% in 2004 to 8% in 2005.

**Figure 1.21: Incidence of late latent syphilis by year.
Toronto, the rest of Ontario and Canada*, 1995 - 2005**




*Canada data includes all syphilis stages except infectious and congenital, but is equivalent to late latent syphilis for comparison purposes.
NA: Ontario data for 2005 are not available.


**Figure 1.22: Incidence of late latent syphilis by age group and sex.
Toronto, 2005**



**Figure 1.23: Incidence rates of late latent syphilis by sex and year.
Toronto, 1995 - 2005**



**Figure 1.24: Incidence of HIV and late latent syphilis co-infections by year.
Toronto, 1995 - 2005**



**Table 1.15: Risk factors for reported cases of late latent syphilis by sex.
Toronto, 2005**

| Reported risk factor | Number of cases* (%) | | | | | |
|---------------------------------------|----------------------|------|------------|------|------------|------|
| | Male | | Female | | Overall | |
| No condom or chemical barrier used | 133 | (76) | 113 | (88) | 246 | (81) |
| Homosexual/bisexual | 24 | (14) | 0 | (0) | 24 | (8) |
| Multiple sexual partners | 19 | (11) | 1 | (<1) | 20 | (7) |
| Sexual contact of a confirmed case | 4 | (2) | 1 | (<1) | 5 | (2) |
| Sex trade worker | 3 | (2) | 0 | (0) | 3 | (1) |
| Other | 79 | (45) | 34 | (26) | 113 | (37) |
| Total with a known risk factor | 175 | | 129 | | 304 | |
| Number missing or unknown | 91 | | 89 | | 180 | |
| Total cases | 266 | | 218 | | 484 | |

*Cases may report more than one risk factor. Risk factors for five cases were treated as missing due to multiple STI reports recorded in iPHIS. See technical notes on page 183.

Enteric, Food and Waterborne Diseases

**Communicable Diseases
in Toronto**

2005

Enteric, Food and Waterborne Diseases

This section focuses on diseases caused by infectious agents that are shed in the feces and can contaminate food or water sources. Transmission occurs primarily through ingestion of infected food or water, and more rarely through direct or fecal-oral contact with an infected person (e.g. oral-anal contact). This group of diseases is widespread in Toronto. Relative proportions of each disease within this grouping, and their ranking are listed below. In 2005, there was an 11% increase from 2004 reports of diseases falling in this category. *Campylobacter* enteritis accounted for 33% of reports falling into this category. □

Table 2.1: Number and proportion of reported cases of enteric, food and waterborne diseases. Toronto, 2005

| Ranking | Reportable disease | Number of cases | Proportion of cases (%) |
|---------|--|-----------------|-------------------------|
| 1 | <i>Campylobacter</i> enteritis | 997 | 33 |
| 2 | Salmonellosis | 686 | 22 |
| 3 | Giardiasis | 547 | 18 |
| 4 | Amebiasis | 376 | 12 |
| 5 | Yersiniosis | 117 | 4 |
| 6 | Shigellosis | 100 | 3 |
| 7 | Cryptosporidiosis | 52 | 2 |
| 8 | Cyclosporiasis | 48 | 2 |
| 8 | Hepatitis A | 48 | 2 |
| 10 | Verotoxin-producing <i>E. coli</i> infection | 34 | 1 |
| 11 | Typhoid fever | 23 | <1 |
| 12 | Paratyphoid fever | 13 | <1 |
| 13 | Listeriosis | 10 | <1 |
| | Total | 3051 | 100 |

Rare reportable diseases not summarized in this section include botulism, cholera and trichinosis.


Amebiasis

| Table 2.2: Amebiasis summary data | | | |
|---|--------------------|--------------------------|---------------------------|
| Toronto | | | |
| | 2005 | 5-yr period 2000-2004 | 10-yr period 1995-2004 |
| | Total | Means | |
| Number of reported cases | 376 | 404 | 398 |
| Incidence rate (per 100,000 population) | | | |
| Overall | 14.4 | 15.6 | 15.7 |
| Male | 22.2 | 23.6 | 23.6 |
| Female | 7.1 | 7.9 | 8.1 |
| Age at onset (years) | Summary statistics | | |
| Mean | 39 | 37 | 36 |
| Median | 39 | 37 | 36 |
| Range | 1 103 | 1 93 | <1 98 |


Highlights

- In 2005, there were 376 reported cases (14.4 cases per 100,000) of amebiasis. This represented an increase of 49 cases (15%) from the 2004 total of 327 cases (Figure 2.1).
- Toronto's rate of amebiasis continued to exceed the rate reported in the rest of Ontario. In 2005, Toronto's rate was four times the rate in the rest of Ontario (Figure 2.1).
- The age groups with the highest incidence rates in 2005 were 35 to 39 years (31.7 cases per 100,000) and 40 to 44 years (30.4 cases per 100,000) (Figure 2.2). Males in the 50 to 54 year age group experienced the greatest increase among all subgroups from 2004.
- Males accounted for 75% (n=281) of all cases in 2005 and had a rate (22.2 cases per 100,000) more than three times the rate for females (7.1 cases per 100,000) (Figure 2.3). The rate for males exceeded female rates for all age groups (Figure 2.2). The largest differences were detected in the 35 to 39 and 65 and over age groups, in which males experienced approximately four times the rate of amebiasis. These differences may be related to the increased risk of sexual transmission among men who have sex with men (MSM).
- With the exceptions of January, April, and June, the number of reported cases for each month in 2005 was comparable to, or lower than, the historical mean. (Figure 2.4)
- The most commonly reported sources of infection in 2005 were water (5%) and person-to-person transmission (5%) (Figure 2.5). The most commonly reported risk setting was travel outside of Canada to an endemic area (22%) (Figure 2.6).


**Figure 2.1: Incidence of amebiasis by year.
Toronto, the rest of Ontario and Canada, 1995 - 2005**



**Figure 2.2: Incidence of amebiasis by age group and sex.
Toronto, 2005**



**Figure 2.3: Incidence rates of amebiasis by sex and year.
Toronto, 1995 - 2005**



**Figure 2.4: Number of reported cases of amebiasis by month.
Toronto, 2005 compared to 1995 - 2004 mean**




Figure 2.5: Proportion of reported cases of amebiasis by suspected source of infection. Toronto, 2005 (N=376)





Figure 2.6: Proportion of reported cases of amebiasis by suspected risk setting. Toronto, 2005 (N=376)



Campylobacter enteritis


Table 2.3: *Campylobacter* enteritis summary data

| Toronto | | | |
|---|--------------------|--------------------------|---------------------------|
| | 2005 | 5-yr period 2000-2004 | 10-yr period 1995-2004 |
| | Total | Means | |
| Number of reported cases | 997 | 1303 | 1464 |
| Incidence rate (per 100,000 population) | | | |
| Overall | 38.3 | 50.2 | 57.7 |
| Male | 43.6 | 55.9 | 63.1 |
| Female | 33.3 | 44.7 | 52.3 |
| Age at onset (years) | Summary statistics | | |
| Mean | 35 | 32 | 31 |
| Median | 34 | 30 | 29 |
| Range | <1 96 | <1 100 | <1 100 |
| Hospitalization rate (%) | 6 | 3 | 2 |

Highlights

- *Campylobacter* continues to be the most commonly reported enteric pathogen in Toronto, accounting for 33% of all enteric cases reported in 2005 (Table 2.1).
- In 2005, there were 997 reported cases (38.3 cases per 100,000) of *Campylobacter* enteritis. This represented an increase of 21 cases (2%) from the 2004 total of 976 (Figure 2.7). The rate of hospitalization among cases was higher than in previous 5-year and 10-year surveillance periods (Table 2.3), but in keeping with last year.
- The age groups with the highest incidence rates in 2005 were 0 to 4 years (68.6 cases per 100,000) and 25 to 29 years (49.0 cases per 100,000) (Figure 2.2).
- Males accounted for 55% (n=553) of all cases in 2005 and experienced rates of disease that exceeded female rates in all age groups, except among those 20 to 24 years of age (Figure 2.8). The largest differences were detected in the 40 to 44 year age group, in which males experienced a rate of *Campylobacter* enteritis more than twice that of females.
- The number of reported cases for each month in 2005 was lower than the historical mean (Figure 2.9).
- The most commonly reported source of infection was food (17%) (Figure 2.10). The most commonly reported risk settings were travel outside of Canada to an endemic area (19%) and the home environment (10%) (Figure 2.11).

**Figure 2.7: Incidence of *Campylobacter* enteritis by year.
Toronto, the rest of Ontario and Canada, 1995 - 2005**



**Figure 2.8: Incidence of *Campylobacter* enteritis by age group and sex.
Toronto, 2005**




Figure 2.9: Number of reported cases of *Campylobacter* enteritis by month. Toronto, 2005 compared to 1995 - 2004 mean






Figure 2.10: Proportion of reported cases of *Campylobacter* enteritis by suspected source of infection. Toronto, 2005 (N=997)



*Includes animal contact.

Figure 2.11: Proportion of reported cases of *Campylobacter* enteritis by suspected risk setting. Toronto, 2005 (N=997)



*Includes travel to a local vacation property and camping.

Cryptosporidiosis


| Table 2.4: Cryptosporidiosis summary data* | | |
|--|--------------------|--------------------------|
| Toronto | | |
| | 2005 | 5-yr period 2000-2004 |
| | Total | Mean |
| Number of reported cases | 52 | 42 |
| Incidence rate (per 100,000 population) | | |
| Overall | 2.0 | 1.6 |
| Male | 3.0 | 2.4 |
| Female | 1.0 | 0.9 |
| Age at onset (years) | Summary statistics | |
| Mean | 26 | 22 |
| Median | 31 | 19 |
| Range | <1 84 | <1 75 |

*Cryptosporidiosis became reportable in Ontario in 1996.

Highlights

- In 2005, there were 52 reported cases (2.0 cases per 100,000) of cryptosporidiosis. This represented an increase of three cases (6%) over the 2004 total of 49 cases and the highest annual total reported since 1996 when cryptosporidiosis became reportable in Ontario (Figure 2.12).
- Males accounted for 73% (n=38) of all cases in 2005 and had a rate (3.0 cases per 100,000) three times the rate for females (1.0 cases per 100,000) (Table 2.4). This difference may be associated with the increased risk of sexual transmission among men who have sex with other men (MSM). Over the 10-year period, the rate for males exceeded female rates for all age groups except the 0 to 4 year and 5 to 9 year age groups. The largest differences were detected in the 30 to 39 and 40 to 49 year age groups in which males experienced more than 10 times the rate of cryptosporidiosis (Figure 2.13).
- The median age of cases continued to increase to 31 years in 2005 from the 19-year median that was reported during the previous 5-year period (Table 2.4).
- Reports of cryptosporidiosis in 2005 exhibited no marked seasonality. In January, February, April, June, and October the number of reported cases exceeded the historical mean for those months (Figure 2.14).
- The most commonly reported source of infection was person-to-person transmission (6%) (Figure 2.15). As in 2004, the most commonly reported risk setting was travel outside of Canada to an endemic area (31%) (Figure 2.16).

**Figure 2.12: Incidence of cryptosporidiosis by year.
Toronto, the rest of Ontario* and Canada†, 1996 - 2005**



*Cryptosporidiosis became reportable in Ontario in 1996.

†Starting January 1, 2000 Cryptosporidiosis became nationally notifiable. Cryptosporidiosis was not reportable in Quebec for 2000 to 2003. NR: Not reportable.

**Figure 2.13: Incidence of cryptosporidiosis by age group and sex.
Toronto, 1996 - 2005 combined**




Figure 2.14: Number of reported cases of cryptosporidiosis by month. Toronto, 2005 compared to 1996 - 2004 mean




Figure 2.15: Proportion of reported cases of cryptosporidiosis by suspected source of infection. Toronto, 2005 (N=52)





Figure 2.16: Proportion of reported cases of cryptosporidiosis by suspected risk setting. Toronto, 2005 (N=52)



Cyclosporiasis


| Table 2.5: Cyclosporiasis summary data* | | | | |
|---|--------------------|----------|-----------|----------|
| Toronto | | | | |
| | 2005 | 2004 | 2003 | 2002 |
| Number of reported cases | 48 | 30 | 14 | 28 |
| Incidence rate (per 100,000 population) | | | | |
| Overall | 1.8 | 1.2 | 0.5 | 1.1 |
| Male | 1.9 | 1.1 | 0.8 | 1.1 |
| Female | 1.8 | 1.2 | 0.3 | 1.0 |
| Age at onset (years) | Summary statistics | | | |
| Mean | 38 | 49 | 34 | 40 |
| Median | 33 | 48 | 33 | 37 |
| Range | 1 79 | 24 84 | 2 67 | 24 80 |
| Outbreak associated cases (%) | 33 | 0 | 0 | 4 |

*Cyclosporiasis became reportable in Ontario in 2002.

Highlights

- In 2005, there were 48 reported cases of cyclosporiasis (1.8 cases per 100,000). This represented an increase of 18 cases (60%) over the 2004 total of 30 cases and the highest total since it became reportable in 2002 (Table 2.5). Among the reported cases for 2005, 33% (n=16) were associated with food consumed at a three-day high school retreat in early April.
- Reports of cyclospora for April 2005, the month of the outbreak, were almost nine times higher than the previous three-year average for April (Figure 2.18).
- The most commonly identified source of infection was food (25%) (Figure 2.19). The most commonly reported risk settings were travel outside of Canada to an endemic area (53%) and local travel, including local vacation properties and camping (33%) (Figure 2.20).

**Figure 2.17: Incidence of cyclosporin by age group and sex.
Toronto, 2002 - 2005 combined**



**Figure 2.18: Number of reported cases of cyclosporin by month.
Toronto, 2005 compared to 2002 - 2004 mean**




Figure 2.19: Proportion of cases of cyclosporiasis by suspected source of infection. Toronto, 2005 (N=48)





Figure 2.20: Proportion of cases of cyclosporiasis by suspected risk setting. Toronto, 2005 (N=48)



*Includes travel to a local vacation property and camping.


Giardiasis

| Table 2.6: Giardiasis summary data | | | |
|---|--------------------|--------------------------|---------------------------|
| Toronto | | | |
| | 2005 | 5-yr period 2000-2004 | 10-yr period 1995-2004 |
| | Total | Means | |
| Number of reported cases | 547 | 557 | 560 |
| Incidence rate (per 100,000 population) | | | |
| Overall | 21.0 | 21.5 | 22.1 |
| Male | 28.3 | 28.2 | 28.5 |
| Female | 14.1 | 15.1 | 16.0 |
| Age at onset (years) | Summary statistics | | |
| Mean | 30 | 29 | 28 |
| Median | 31 | 30 | 29 |
| Range | <1 84 | <1 93 | <1 99 |


Highlights

- In 2005, there were 547 reported cases (21.0 cases per 100,000) of giardiasis. This represented an increase of 24 cases (5%) from the 2004 total of 523 cases (Figure 2.21).
- Toronto's rate of giardiasis continued to exceed the rate reported in the rest of Ontario in 2005 by almost two times (Figure 2.21).
- Males accounted for 66% (n=359) of all cases in 2005. The rate for males exceeded female rates for all age groups (Figure 2.22). The largest difference was observed in the 25 to 29 and 45 to 49 year age groups, for which the male rates were at least three times higher than the rate for females. As with other enteric agents, these gender differences may be related to the increased risk of sexual transmission among men who have sex with men (MSM).
- With the exception of April, August and December, the number of reports for each month in 2005 was either comparable to or lower than the historical mean (Figure 2.23).
- The most commonly reported sources of infection were water (9%) and person-to-person transmission (4%) (Figure 2.24). The most commonly reported risk setting was travel outside of Canada to an endemic area (31%) (Figure 2.25).


**Figure 2.21: Incidence of giardiasis by year.
Toronto, the rest of Ontario and Canada*, 1995 - 2005**



**Figure 2.22: Incidence of giardiasis by age group and sex.
Toronto, 2005**



**Figure 2.23: Number of reported cases of giardiasis by month.
Toronto, 2004 compared to 1995 - 2004 mean**



**Figure 2.24: Proportion of reported cases of giardiasis by suspected source of infection.
Toronto, 2005 (N=547)**





Figure 2.25: Proportion of reported cases of giardiasis by suspected risk setting. Toronto, 2005 (N=547)



*Includes travel to a local vacation property and camping.


Hepatitis A

| Table 2.7: Hepatitis A summary data | | | |
|---|--------------------|--------------------------|---------------------------|
| Toronto | | | |
| | 2005 | 5-yr period 2000-2004 | 10-yr period 1995-2004 |
| | Total | Means | |
| Number of reported cases | 48 | 55 | 114 |
| Incidence rate (per 100,000 population) | | | |
| Overall | 1.8 | 2.1 | 4.5 |
| Male | 2.4 | 2.5 | 6.0 |
| Female | 1.3 | 1.8 | 3.0 |
| Age at onset (years) | Summary statistics | | |
| Mean | 26 | 25 | 30 |
| Median | 20 | 22 | 31 |
| Range | 1 76 | <1 92 | <1 92 |
| Outbreak associated cases (%) | 4 | 12 | 6 |
| Hospitalization rate (%) | 19 | 14 | 6 |


Highlights

- In 2005, there were 48 reported cases (1.8 cases per 100,000) of hepatitis A. This remains unchanged from 2004 (Figure 2.26). Among these cases, 4% (n=2) were outbreak related and 19% (n=9) were treated in a hospital (Table 2.7). The hospitalization rate in 2005 was higher than the rate for the previous 5-year and 10-year periods, but a decrease from 2004 (25%).
- Males accounted for 63% (n=30) of all cases in 2005. The incidence rate for males exceeded female rates except in the 5 to 9 and 10 to 19 year age groups. The greatest difference was in the 40 to 59 year age groups, for which males had more than eight times the reported rate for females (Figure 2.27). As with other enteric agents, the increased adult male rates may be related to the increased risk of sexual transmission among men who have sex with men (MSM).
- Reports of Hepatitis A cases in 2005 did not follow a seasonal trend (Figure 2.28). The highest numbers of cases were reported in June and September.
- The most commonly reported sources of infection were food (17%) and person-to-person transmission (15%) (Figure 2.29). The most commonly reported risk setting was travel outside of Canada to an endemic area (71%) (Figure 2.30).


**Figure 2.26: Incidence of hepatitis A by year.
Toronto, the rest of Ontario and Canada, 1995 - 2005**




**Figure 2.27: Incidence of hepatitis A by age group and sex.
Toronto, 2005**




**Figure 2.28: Number of reported cases of hepatitis A by month.
Toronto, 2005 compared to 1995 - 2004 mean**



**Figure 2.29: Proportion of reported cases of hepatitis A by suspected source of infection.
Toronto, 2005 (N=48)**



**Figure 2.30: Proportion of reported cases of hepatitis A by suspected risk setting.
Toronto, 2005 (N=48)**



Listeriosis

| Table 2.8: Listeriosis summary data | | | |
|---|--------------------|--------------------------|---------------------------|
| Toronto | | | |
| | 2005 | 5-yr period 2000-2004 | 10-yr period 1995-2004 |
| | Total | Means | |
| Number of reported cases | 10 | 11 | 10 |
| Incidence rate (per 100,000 population) | | | |
| Overall | 0.4 | 0.4 | 0.4 |
| Male | 0.2 | 0.3 | 0.3 |
| Female | 0.5 | 0.5 | 0.4 |
| Age at onset (years) | Summary statistics | | |
| Mean | 69 | 59 | 60 |
| Median | 76 | 68 | 68 |
| Range | 25 90 | <1 95 | <1 95 |
| Hospitalization rate (%) | 70 | 64 | 69 |
| Case fatality (%) | 0 | 16 | 20 |


Highlights

- In 2005, there were 10 reported cases (0.4 cases per 100,000) of listeriosis. This represented a decrease of four cases (29%) from the 2004 total of 14 cases (Figure 2.31).
- Of the 10 cases reported in 2005, seven (70%) were treated in a hospital, and no related deaths were reported (Table 2.8).
- Over the 10-year period, older age groups were particularly vulnerable to listeriosis (Figure 2.32). In 2005, 70% (n=7) of reported cases were over 65 years of age. The median age of cases in 2005 was 76 years of age, older than the previous 5-year and 10-year medians (68 and 68 years, respectively) (Table 2.8). This may explain the higher hospitalization rate observed in 2005 compared to the previous 5-year and 10-year periods.
- The source of infection was unknown in 80% (n=8) of listeriosis cases reported in 2005. Of the cases with a reported source of infection (n=2), food was identified as the source of infection.

**Figure 2.31: Incidence of listeriosis by year.
Toronto, the rest of Ontario and Canada, 1995 - 2005**



**Figure 2.32: Incidence of listeriosis by age group and sex.
Toronto, 1995 - 2005 combined**




Paratyphoid fever

| Table 2.9: Paratyphoid fever summary data | | | |
|---|--------------------|--------------------------|---------------------------|
| Toronto | | | |
| | 2005 | 5-yr period 2000-2004 | 10-yr period 1995-2004 |
| | Total | Means | |
| Number of reported cases | 13 | 9 | 7 |
| Incidence rate (per 100,000 population) | | | |
| Overall | 0.5 | 0.3 | 0.3 |
| Male | 0.4 | 0.4 | 0.3 |
| Female | 0.6 | 0.3 | 0.2 |
| Age at onset (years) | Summary statistics | | |
| Mean | 30 | 29 | 27 |
| Median | 30 | 28 | 27 |
| Range | 3 52 | 1 87 | <1 87 |

Highlights


- In 2005, there were 13 reported cases (0.5 cases per 100,000) of paratyphoid fever. This represented a decrease of three cases (19%) from the 2004 total of 16 (Figure 2.33).
- Travel outside of Canada to an endemic area was the identified risk setting for 92% (n=12) of cases. Of the 12 cases with a known risk setting, 58% (n=7) travelled to India, 25% (n=3) traveled to Pakistan, and one case each travelled to Bangladesh and Sri Lanka. The risk setting was unknown for the one remaining case (8%).

**Figure 2.33: Incidence of paratyphoid fever by year.
Toronto, the rest of Ontario and Canada, 1995 - 2005**



NR: Not reportable. Paratyphoid fever was no longer nationally notifiable in Canada as of 2000.

**Figure 2.34: Incidence of paratyphoid fever by age group and sex.
Toronto, 1995 - 2005 combined**



Salmonellosis

(non-typhoidal *Salmonella*)


Table 2.10: Salmonellosis summary data

| Toronto | | | |
|---|--------------------|--------------------------|---------------------------|
| | 2005 | 5-yr period 2000-2004 | 10-yr period 1995-2004 |
| | Total | Means | |
| Number of reported cases | 686 | 597 | 718 |
| Incidence rate (per 100,000 population) | | | |
| Overall | 26.4 | 23.0 | 28.3 |
| Male | 27.4 | 23.6 | 28.3 |
| Female | 25.4 | 22.4 | 28.1 |
| Age at onset (years) | Summary statistics | | |
| Mean | 31 | 26 | 25 |
| Median | 28 | 23 | 21 |
| Range | <1 101 | <1 100 | <1 100 |
| Outbreak associated cases (%) | 25 | 3 | 4 |
| Hospitalization rate (%) | 11 | 6 | 5 |


Highlights

- In 2005, there were 686 reported cases (26.4 cases per 100,000) of salmonellosis. This represented an increase of 204 (42%) cases from the 2004 total of 482 cases and the highest number of reported cases since 1998 (Figure 2.35).
- The number of outbreak associated cases was the highest observed in the previous 10-year surveillance period and accounted for 25% (n=172) of salmonellosis cases in 2005 (Table 2.10). The increase in outbreak related cases was due to a province-wide outbreak of *Salmonella enteritidis* PT 13 connected with the consumption of contaminated mung bean sprouts. Eleven percent (n=78) were treated in a hospital and no deaths occurred.
- The age group with the highest incidence rate in 2005 was once again in children under 5 years of age (72.8 cases per 100,000). The largest increases from 2004, however, were recorded in the age groups most affected by the outbreak: 20 to 29 and 30 to 39 year olds (Figure 2.36).
- With the exception of July, October, November, and December, the number of reports for each month in 2005 was lower than the historical mean (Figure 2.37).
- A specific *Salmonella* species was identified in 84% (n=577) of reported cases in 2005. Among these cases, the most commonly isolated agent was also responsible for the bean sprout outbreak, *S. enteritidis* (47%). *Salmonella typhimurium* (18%), and *S. heidelberg* (8%) were the next two most reported species (Table 2.11).
- The most commonly reported source of infection was food (26%) (Figure 2.38). The most commonly reported risk settings were travel outside of Canada to an endemic area (16%) and a restaurant or food vendor (16%) (Figure 2.39).


**Figure 2.35: Incidence of salmonellosis by year.
Toronto, the rest of Ontario and Canada, 1995 - 2005**



**Figure 2.36: Incidence of salmonellosis by age group and sex.
Toronto, 2005**



**Figure 2.37: Number of reported cases of salmonellosis by month.
Toronto, 2005 compared to 1995 - 2004 mean**



**Table 2.11: Ten most prevalent *Salmonella* species.
Toronto, 2005 cases compared to previous 5-year mean**

| <i>Salmonella</i> species | Number of cases (%) | |
|---------------------------|---------------------|-----------------------------------|
| | 2005 (N = 577)* | 5-yr mean 2000-2004 (N = 431)* |
| <i>S. enteritidis</i> | 272 (47) | 102 (24) |
| <i>S. typhimurium</i> | 105 (18) | 109 (25) |
| <i>S. heidelberg</i> | 48 (8) | 76 (18) |
| <i>S. muenchen</i> | 22 (4) | 4 (1) |
| <i>S. thompson</i> | 16 (3) | 22 (5) |
| <i>S. infantis</i> | 13 (2) | 15 (3) |
| <i>S. berta</i> | 12 (2) | 9 (2) |
| <i>S. hadar</i> | 12 (2) | 26 (6) |
| <i>S. newport</i> | 10 (2) | 14 (3) |
| <i>S. schwarzengrund</i> | 8 (1) | 2 (<1) |

*Denominator (N) = number of infections with a type isolated.

Figure 2.38: Proportion of reported cases of salmonellosis by suspected source of infection. Toronto, 2005 (N=686)





Figure 2.39: Proportion of reported cases of salmonellosis by suspected risk setting. Toronto, 2005 (N=686)



*Includes travel to a local vacation property and camping.


Shigellosis

| Table 2.12: Shigellosis summary data | | | |
|---|--------------------|--------------------------|---------------------------|
| Toronto | | | |
| | 2005 | 5-yr period 2000-2004 | 10-yr period 1995-2004 |
| | Total | Means | |
| Number of reported cases | 100 | 152 | 150 |
| Incidence rate (per 100,000 population) | | | |
| Overall | 3.8 | 5.8 | 5.9 |
| Male | 4.1 | 6.5 | 6.4 |
| Female | 3.6 | 5.2 | 5.4 |
| Age at onset (years) | Summary statistics | | |
| Mean | 27 | 32 | 29 |
| Median | 30 | 33 | 30 |
| Range | 1 77 | <1 83 | <1 84 |
| Outbreak associated cases (%) | 0 | 33 | 19 |
| Hospitalization rate (%) | 14 | 8 | 6 |


Highlights

- In 2005, there were 100 reported cases (3.8 cases per 100,000) of shigellosis. This remained unchanged from the number of cases reported in 2004 (Figure 2.40).
- There were no outbreak related shigellosis cases in 2005 (Table 2.12). Fourteen percent of all cases (n=14) were treated in hospital. This is higher than both the 5-year and 10-year means, but lower than the 2004 hospitalization rate (22%). The increase in hospitalization may be related to the increased proportion of the more virulent *Shigella flexneri* reported in 2005.
- The age group with the highest incidence rate in 2005 was 0 to 4 year olds (11.2 cases per 100,000), followed by 5 to 9 year olds (9.5 cases per 100,000) (Figure 2.41).
- Males accounted for 52% (n=52) of all shigellosis cases in 2005 and had a rate (4.1 cases per 100,000) greater than that of females (3.6 cases per 100,000) (Table 2.12). The greatest differences were seen in the 40 to 49 year age group, with rates in males more than twice that of females (Table 2.41).
- The number of reports for each month in 2005 was comparable to, or lower than, the historical mean (Figure 2.43).
- Among the 100 shigella cases reported in 2005, the most commonly isolated agents were *S. sonnei* (60%) and *S. flexneri* (36%) (Figure 2.44). The proportion of *S. flexneri* cases reported in 2005 represented an increase from 26% in 2004.
- The most commonly reported sources of infection were food (24%) and person-to-person transmission (14%) (Figure 2.45). The most commonly reported risk setting was travel outside of Canada to an endemic area (37%) (Figure 2.46).


**Figure 2.40: Incidence of shigellosis by year.
Toronto, the rest of Ontario and Canada, 1995 - 2005**




**Figure 2.41: Incidence of shigellosis by age group and sex.
Toronto, 2005**



**Figure 2.42: Incidence rates of shigellosis by sex and year.
Toronto, 1995 - 2005**




**Figure 2.43: Number of reported cases of shigellosis by month.
Toronto 2005 compared to 1995 - 2004 mean***




*Excludes the 218 cases associated with a large province-wide shigellosis outbreak in 2002.


**Figure 2.44: Proportion of reported cases of shigellosis by agent.
Toronto, 2005 (N=100)**



**Figure 2.45: Proportion of reported cases of shigellosis by suspected source of infection.
Toronto, 2005 (N=100)**



**Figure 2.46: Proportion of reported cases of shigellosis by suspected risk setting.
Toronto, 2005 (N=100)**




Typhoid fever

| Table 2.13: Typhoid fever summary data | | | |
|---|--------------------|--------------------------|---------------------------|
| Toronto | | | |
| | 2005 | 5-yr period 2000-2004 | 10-yr period 1995-2004 |
| | Total | Means | |
| Number of reported cases | 23 | 28 | 22 |
| Incidence rate (per 100,000 population) | | | |
| Overall | 0.9 | 1.1 | 0.9 |
| Male | 0.8 | 1.0 | 0.9 |
| Female | 1.0 | 1.1 | 0.8 |
| Age at onset (years) | Summary statistics | | |
| Mean | 24 | 22 | 22 |
| Median | 20 | 20 | 20 |
| Range | 1 60 | <1 58 | <1 83 |


Highlights

- In 2005, there were 23 reported cases (0.9 cases per 100,000) of typhoid fever. This represented a decrease of five cases (18%) from the 2004 total of 28 cases (Figure 2.47).
- The number of reports in June, August, October and November exceeded the historical means for those months (Figure 2.49). The highest numbers of cases were reported in June, August, and October.
- The source of infection was unknown in 83% (n=19) of typhoid fever cases reported in 2005. Of the cases with a recorded source of infection, the most commonly reported sources of infection were water (13%) and food (4%) (Figure 2.50). Travel outside of Canada to an endemic area was the most common risk setting for acquiring typhoid fever (87%) (Figure 2.51). Of the 20 cases with known travel destinations, 45% (n=9) travelled to India, 25% (n=5) traveled to Bangladesh, 20% (n=4) travelled to Pakistan, and one case reported travel to each of Afghanistan and the Philippines.


**Figure 2.47: Incidence of typhoid fever by year.
Toronto, the rest of Ontario and Canada, 1995 - 2005**




**Figure 2.48: Incidence of typhoid fever by age group and sex.
Toronto, 1995 - 2005 combined**




**Figure 2.49: Number of reported cases of typhoid fever by month.
Toronto, 2005 compared to 1995 - 2004 mean**



**Figure 2.50: Proportion of reported cases of typhoid fever by suspected source of infection.
Toronto, 2005 (N=23)**



**Figure 2.51: Proportion of reported cases of typhoid fever by suspected risk setting.
Toronto, 2005 (N=23)**



Verotoxin-producing *E. coli* (VTEC) infection

| Table 2.14: Verotoxin-producing <i>E. coli</i> infection summary data | | | |
|---|--------------------|--------------------------|---------------------------|
| Toronto | | | |
| | 2005 | 5-yr period 2000-2004 | 10-yr period 1995-2004 |
| | Total | Means | |
| Number of reported cases | 34 | 56 | 69 |
| Incidence rate (per 100,000 population) | | | |
| Overall | 1.3 | 2.2 | 2.7 |
| Male | 1.2 | 2.1 | 2.7 |
| Female | 1.4 | 2.2 | 2.7 |
| Age at onset (years) | Summary statistics | | |
| Mean | 29 | 27 | 26 |
| Median | 18 | 16 | 15 |
| Range | 2 82 | <1 87 | <1 92 |
| Outbreak associated cases (%) | 0 | 14 | 7 |
| Hospitalization rate (%) | 38 | 23 | 23 |

Highlights

- In 2005, there were 34 reported cases (1.3 cases per 100,000) of verotoxin-producing *E. coli* (VTEC). This represented a decrease of 16 cases (32%) from the 2004 total of 50 cases (Figure 2.52). This was the lowest number of reported cases in the previous 10-year surveillance period.
- Of the 34 reported cases, 38% (n=13) were treated in a hospital and no related deaths were reported (Table 2.14). The hospitalization rate in 2005 was higher than the rate in previous 5-year and 10-year periods. Hemolytic-uremic syndrome (HUS) was reported in two cases (6%). No cases were outbreak associated.
- In 2005, 32% (n=11) of reported cases were under 10 years of age. This is expected, as VTEC typically affects younger age groups disproportionately.
- The number of reports for each month in 2005 was comparable to, or lower than, the historical mean (Figure 2.54). The highest number of cases was reported in July.
- The most commonly reported source of infection was food (24%) (Figure 2.55). The most commonly reported risk setting was the home environment (12%) and local travel (12%) (Figure 2.56).

Figure 2.52: Incidence of verotoxin-producing *E. coli* infection by year. Toronto, the rest of Ontario and Canada, 1995 - 2005




Figure 2.53: Incidence of verotoxin-producing *E. coli* infection by age group* and sex. Toronto, 1995 - 2005 combined




Figure 2.54: Number of reported cases of verotoxin-producing *E. coli* infection by month. Toronto, 2005 compared to 1995 - 2004 mean




Figure 2.55: Proportion of reported cases of verotoxin-producing *E. coli* infection by suspected source of infection. Toronto, 2005 (N=34)





Figure 2.56: Proportion of reported cases of verotoxin-producing *E. coli* infection by suspected risk setting. Toronto, 2005 (N=34)



*Includes travel to a local vacation property and camping.


Yersiniosis

| Table 2.15: Yersiniosis summary data | | | |
|---|--------------------|--------------------------|---------------------------|
| Toronto | | | |
| | 2005 | 5-yr period 2000-2004 | 10-yr period 1995-2004 |
| | Total | Means | |
| Number of reported cases | 117 | 126 | 139 |
| Incidence rate (per 100,000 population) | | | |
| Overall | 4.5 | 4.9 | 5.5 |
| Male | 5.8 | 5.5 | 6.3 |
| Female | 3.2 | 4.2 | 4.7 |
| Age at onset (years) | Summary statistics | | |
| Mean | 18 | 20 | 20 |
| Median | 10 | 11 | 10 |
| Range | <1 89 | <1 101 | <1 101 |


Highlights

- In 2005, there were 117 reported cases (4.5 cases per 100,000) of yersiniosis. This represented an increase of 25 cases (27%) from the 2004 total of 92 cases (Figure 2.57).
- Males accounted for 63% (n=74) of all yersiniosis cases in 2005 and experienced higher or comparable rates of disease than females in all age groups (Figure 2.58). The largest difference was detected in the 5 to 9 year age groups, in which males experienced more than four times the rate of yersiniosis than females.
- The numbers of reported cases in April and May were higher than the historical mean (Figure 2.59). The highest number of cases was reported in April.
- The most commonly reported source of infection was food (10%) (Figure 2.60). The most commonly reported risk setting was the home environment (22%) (Figure 2.61).


**Figure 2.57: Incidence of yersiniosis by year.
Toronto and the rest of Ontario, 1995 - 2005**




**Figure 2.58: Incidence of yersiniosis by age group and sex.
Toronto, 2005**




**Figure 2.59: Number of reported cases of yersiniosis by month.
Toronto, 2005 compared to 1995 - 2004 mean**



**Figure 2.60: Proportion of reported cases of yersiniosis by suspected source of infection.
Toronto, 2005 (N=117)**



**Figure 2.61: Proportion of reported cases of yersiniosis by suspected risk setting.
Toronto, 2005 (N=117)**



Diseases Preventable by Routine Vaccination

**Communicable Diseases
in Toronto**

2005

Diseases Preventable by Routine Vaccination

This section focuses on diseases caused by agents that can be spread through a variety of ways, but for which there is an effective vaccine that is readily available and routinely used. Due in large part to the successful use and efficacy of the respective vaccines, the majority of these diseases are rare in Toronto. Relative proportions of each disease within this grouping, and their ranking are listed below. In 2005, influenza accounted for 73% of reports falling into this category. □

**Table 3.1: Number and proportion of reported cases of vaccine preventable diseases.
Toronto, 2005**

| Ranking | Reportable disease | Number of cases | Proportion of cases (%) |
|---------|--------------------|-----------------|-------------------------|
| 1 | Influenza* | 517 | 73 |
| 2 | Pertussis | 177 | 25 |
| 3 | Mumps | 7 | 1 |
| 4 | Rubella | 4 | <1 |
| 5 | Measles | 1 | <1 |
| | Total | 706 | 100 |

*Seasonal year from July to June (e.g. 2005/06 includes cases from July 1, 2005 to June 30, 2006)

Rare reportable diseases not summarized in this section include diphtheria, Haemophilus influenzae type b disease (invasive), poliomyelitis, rubella (congenital syndrome), smallpox and tetanus.

Influenza

Note: Only laboratory-confirmed cases of influenza are captured in this report. These data are mostly sporadic cases, which tend to be younger and healthier than outbreak associated cases reported to public health.


| Table 3.2: Influenza summary data | | | | | | |
|---|--------------------|-----|--------------------------------|-----|---------------------------------|-----|
| Toronto | | | | | | |
| | 2005/06 | | 5-yr period 2000/01-2004/05 | | 10-yr period 1995/96-2004/05 | |
| | Total | | Means | | | |
| Number of reported cases | 517 | | 433 | | 382 | |
| Incidence rate (per 100,000 population) | | | | | | |
| Overall | 19.9 | | 16.7 | | 15.0 | |
| Male | 21.1 | | 15.9 | | 14.8 | |
| Female | 18.6 | | 17.4 | | 15.2 | |
| Age at onset (years) | Summary statistics | | | | | |
| Mean | 29 | | 41 | | 38 | |
| Median | 8 | | 34 | | 23 | |
| Range | <1 | 110 | <1 | 104 | <1 | 106 |
| Case fatality (%) | 1 | | 1 | | 1 | |
| Influenza outbreaks | 29 | | 41 | | NA | |

In Ontario, respiratory outbreaks in institutions became formally reportable in 2001, however, Toronto Public Health began the routine collection of these data in 1998.

Highlights


- In the 2005/06 season, there were 517 reported laboratory-confirmed cases (19.9 cases per 100,000) of influenza. This represented a decrease of 424 cases (45%) from the previous season total of 941 cases (Figure 3.1).
- As in the previous season, influenza type A was the predominant strain reported in Toronto during the 2005/06 season. It accounted for 61% (n=316) of all the laboratory-confirmed cases and was identified as the etiologic agent in 96% (n=72) of outbreak associated cases.
- In the 2005/06 season, there were 29 influenza outbreaks reported and they were all institutional (Table 3.2). This represented a decrease of 74 outbreaks (72%) from the 103 outbreaks during the previous season.
- As in the previous two seasons, Toronto's rate of influenza was lower than the rate reported for the rest of Ontario during the 2005/06 season (Figure 3.2).
- Compared to the 2004/05 season, influenza rates decreased in all age groups except those 1 to 4, 5 to 9 and 10 to 14 years of age. Although the lowest rate was among those 30 to 39 years of age, the largest decrease was noted among those 70 to 74 years of age (almost one-seventh the rate reported for 2004/05 season). The young age of those affected by influenza during this season was further reflected in the low median age of eight years, compared to the 65 year median in 2004 and the 5-year median of 34 years.
- During the 2005/06 season, the seasonal distribution of cases shifted to later in the year than 2004/05 season. The first laboratory-confirmed case for the 2005/06 season had a later onset date (December 6, 2005) than what was reported in the previous season (October 2, 2004). The number of reports for each month from March to May exceeded historical means for those months (Figure 3.4). Influenza reports for March were four times the 10-year historical mean.

**Figure 3.1: Incidence of influenza by seasonal year*.
Toronto, 1995/96 - 2005/06**



*Seasonal year from July to June (i.e. 2005/06 includes cases from July 1, 2005 to June 30, 2006).

**Figure 3.2: Incidence of influenza by seasonal year*.
Toronto, the rest of Ontario and Canada†, 1995/96 - 2005/06**




*For Toronto, the seasonal year includes July to June (e.g. 2005/06 includes cases from July 1, 2005 to June 30, 2006).

For Ontario, the seasonal year is from October to June (e.g. 2005/06 includes cases from October 1, 2005 to June 30, 2006).


For Canada, the seasonal year is from August to August (e.g. 2005/06 includes cases from August 28, 2005 to August 26, 2006).

†Canadian data for 2003/04 does not include New Brunswick.

**Figure 3.3: Incidence of influenza by age group and sex*.
Toronto, 2005/06**



**Figure 3.4: Number of reported cases of influenza by month.
Toronto, 2005/06 compared to 1995/96 - 2004/05 mean**




Measles

| Table 3.3: Measles summary data | | | |
|---|--------------------|--------------------------|---------------------------|
| Toronto | | | |
| | 2005 | 5-yr period 2000-2004 | 10-yr period 1995-2004 |
| | Total | Means | |
| Number of reported cases | 1 | 5 | 34 |
| Incidence rate (per 100,000 population) | | | |
| Overall | <0.1 | 0.2 | 1.4 |
| Male | 0.0 | 0.2 | 1.5 |
| Female | <0.1 | 0.2 | 1.2 |
| Age at onset (years) | Summary statistics | | |
| Mean | <1 | 14 | 12 |
| Median | <1 | 8 | 12 |
| Range | <1 <1 | <1 42 | <1 42 |


Highlights

- In 2005, there was one reported case (<0.1 cases per 100,000) of measles. This represented a decrease of one case (50%) from the 2004 total of two cases (Figure 3.5), and is more in keeping with numbers reported in the recent past.
- This measles case was an unvaccinated infant 10 months of age who was born in Canada. This case had no history of travel to an endemic country and was not related to an outbreak. An investigation failed to determine the source of this infection.
- Toronto's rate of measles was comparable to the rate reported for the rest of Ontario and Canada in 2005 (Figure 3.5).

**Figure 3.5: Incidence of measles by year.
Toronto, the rest of Ontario and Canada, 1995 - 2005**



**Figure 3.6: Incidence of measles by age group.
Toronto, 1995 - 2005 combined**




Mumps

| Table 3.4: Mumps summary data | | | |
|---|--------------------|--------------------------|---------------------------|
| Toronto | | | |
| | 2005 | 5-yr period 2000-2004 | 10-yr period 1995-2004 |
| | Total | Means | |
| Number of reported cases | 7 | 4 | 10 |
| Incidence rate (per 100,000 population) | | | |
| Overall | 0.3 | 0.1 | 0.4 |
| Male | 0.4 | 0.1 | 0.4 |
| Female | 0.1 | 0.2 | 0.4 |
| Age at onset (years) | Summary statistics | | |
| Mean | 22 | 26 | 19 |
| Median | 20 | 25 | 12 |
| Range | 5 40 | 2 63 | 1 67 |


Highlights

- In 2005, there were seven reported cases (0.3 cases per 100,000) of mumps. This represented an increase of five cases (250%) over the 2004 total of two cases (Figure 3.7).
- Toronto's rate of mumps was higher than the rate reported for the rest of Ontario and Canada in 2005 (Figure 3.7).
- Six (86%) of the seven mumps cases were born outside of Canada. Only three cases had previously received the MMR vaccination and two of these cases traveled to the Philippines prior to developing symptoms. The Canadian born case with no travel history completed two doses of the MMR vaccination as recommended but acquired mumps in school. One of the four unvaccinated mumps cases also traveled to the Philippines prior to developing mumps.

**Figure 3.7: Incidence of mumps by year.
Toronto, the rest of Ontario and Canada, 1995 - 2005**



**Figure 3.8: Incidence of mumps by age group.
Toronto, 1995 - 2005 combined**




Pertussis

| Table 3.5: Pertussis summary data | | | |
|---|--------------------|--------------------------|---------------------------|
| Toronto | | | |
| | 2005 | 5-yr period 2000-2004 | 10-yr period 1995-2004 |
| | Total | Means | |
| Number of reported cases | 177 | 89 | 107 |
| Incidence rate (per 100,000 population) | | | |
| Overall | 6.8 | 3.4 | 4.2 |
| Male | 6.8 | 3.4 | 4.2 |
| Female | 6.8 | 3.4 | 4.2 |
| Age at onset (years) | Summary statistics | | |
| Mean | 9 | 14 | 11 |
| Median | 3 | 10 | 8 |
| Range | <1 83 | <1 78 | <1 78 |
| Outbreak associated cases (%) | 14 | 6 | 5 |


Highlights

- In 2005, there were 177 reported cases (6.8 cases per 100,000) of pertussis. This represented an increase of 83 cases (88%) over the 2004 total of 94 cases (Figure 3.9), and the highest number of cases during the 11-year surveillance period (Figure 3.9). This increase in reports was related to a pertussis outbreak that began in Toronto in November 2005. Increased testing and a more sensitive PCR test to detect pertussis may also explain some of the increase in cases seen across Toronto.
- For the first time in the 11-year surveillance period, Toronto's rate of pertussis in 2005 was higher (1.5 times) than the rate reported for the rest of Ontario. As in all other years covered by this report Toronto's rate in 2005 was lower than the rate for Canada (Figure 3.9).
- The median age of pertussis cases in 2005 was three years, lower than the previous 5- and 10-year medians of 10 and eight years respectively. This reflected the age groups most affected by the outbreak.
- The age groups with the highest incidence rates in 2005 were children under one year of age (164.2 cases per 100,000) and those 1 to 4 years of age (59.0 cases per 100,000) (Figure 3.10).
- The most commonly reported risk settings in 2005 were the home environment (14%) and school (8%).
- One hundred and fifty-six (88%) of the 177 pertussis cases had a known vaccination history, of which 89% (n=139) had received at least one dose of pertussis vaccine.
- Pertussis reports for November and December were three and eight times higher, respectively, than the previous 10-year historical means for those months (Figure 3.11).


**Figure 3.9: Incidence of pertussis by year.
Toronto, the rest of Ontario and Canada, 1995 - 2005**



**Figure 3.10: Incidence of pertussis by age group.
Toronto, 2005**



**Figure 3.11: Number of reported cases of pertussis by month.
Toronto, 2005 compared to 1995 - 2004 mean**



Rubella


| Table 3.6: Rubella summary data* | | | |
|---|--------------------|--------------------------|---------------------------|
| Toronto | | | |
| | 2005 | 5-yr period 2000-2004 | 10-yr period 1995-2004 |
| | Total | Means | |
| Number of reported cases | 4 | 5 | 7 |
| Incidence rate (per 100,000 population) | | | |
| Overall | 0.2 | 0.2 | 0.3 |
| Male | 0.0 | 0.2 | 0.3 |
| Female | 0.3 | 0.2 | 0.3 |
| Age at onset (years) | Summary statistics | | |
| Mean | 38 | 34 | 27 |
| Median | 47 | 41 | 30 |
| Range | 5 53 | 2 65 | <1 65 |

*Only cases of rubella are summarized in this table. Congenital rubella syndrome reports are summarized in the rare diseases section.

Highlights


- In 2005, there were four reported cases (0.2 cases per 100,000) of rubella. This represented an increase of one case (33%) over the 2004 total of three cases (Figure 3.12).
- Toronto's rate of rubella was higher than the rate reported for Canada in 2005 (Figure 3.12).
- One of the four rubella cases was in a Canadian born individual who had previously received one dose of the MMR vaccination. The remaining three cases were foreign born; one had no prior vaccination and the vaccination history of the other two was unknown.
- None of the rubella cases were travel-related; one case each was associated with a daycare, the home environment and a hospital, and the risk setting for the remaining case was unknown.

**Figure 3.12: Incidence of rubella* by year.
Toronto, the rest of Ontario and Canada, 1995 - 2005**



*Only cases of rubella are summarized in this figure. Congenital rubella syndrome reports are summarized in the rare diseases section.
NA: Ontario data for 2005 are not available.

**Figure 3.13: Incidence of rubella* by age group†.
Toronto, 1995 - 2005 combined**



*Only cases of rubella are summarized in this figure. Congenital rubella syndrome reports are summarized in the rare diseases section.

†The age was not reported for one case.

Diseases Transmitted by Direct Contact and Respiratory Routes

**Communicable Diseases
in Toronto**

2005

Diseases Transmitted by Direct Contact and Respiratory Routes

This section focuses on diseases caused by infectious agents transmitted through direct contact with and/or airborne spread of contagious secretions of an infected person, usually secretions from the respiratory tract. This group of diseases includes one of the most contagious and common reportable diseases, chickenpox. Relative proportions of each disease within this grouping, and their ranking are listed below. In 2005, chickenpox accounted for 84% of reports falling into this category. □

Table 4.1: Number and proportion of reported cases of direct contact and respiratory diseases. Toronto, 2005

| Ranking | Reportable disease | Number of cases | Proportion of cases (%) |
|---------|--|-----------------|-------------------------|
| 1 | Chickenpox | 3668 | 84 |
| 2 | Tuberculosis | 344 | 8 |
| 3 | <i>Streptococcus pneumoniae</i> , invasive | 216 | 5 |
| 4 | Streptococcal disease, Group A invasive | 72 | 2 |
| 5 | Legionellosis | 53 | 1 |
| 6 | Streptococcal disease, Group B neonatal | 12 | <1 |
| 7 | Meningococcal disease, invasive | 3 | <1 |
| 8 | Leprosy | 1 | <1 |
| | Total | 4369 | 100 |

Rare reportable diseases not summarized in this section include severe acute respiratory syndrome (SARS).

Chickenpox (Varicella Zoster virus)


| Table 4.2: Chickenpox summary data* | | | |
|---|--------------------|--------------------------|---------------------------|
| Toronto | | | |
| | 2005 | 5-yr period 2000-2004 | 10-yr period 1995-2004 |
| | Total | Means | |
| Number of reported cases | 3668 | 3578 | 3385 |
| Incidence rate (per 100,000 population) | 140.9 | 137.9 | 133.3 |
| Age at onset (years) | Summary statistics | | |
| Grouped mean | 7 | 7 | 7 |
| Grouped median | 7 | 7 | 7 |
| Range | <1 > 60 | <1 29 | <1 29 |

*Reports of chickenpox are received in aggregate numbers based on defined age categories.

Highlights


- In September 2004, chickenpox vaccine became publicly funded for all one year old children born after September 1, 2003. All individuals with high risk medical conditions were eligible to receive this vaccine free beginning in January 2005. Thus 2005 was the first complete year of public funding for this vaccine.
- In 2005, there were 3668 reported cases (140.9 cases per 100,000) of chickenpox. This represented a decrease of 1649 cases (31%) from the 2004 total of 5317 cases (Figure 4.1).
- Toronto's rate of chickenpox was five times the rate reported for Canada in 2005 (Figure 4.1).
- The highest incidence rates of chickenpox were seen in those ages 1 to 4 years (680.2 cases per 100,000) and 5 to 9 years (1411.0 cases per 100,000) (Figure 4.2).
- In 2005, cases of chickenpox were reported in older age groups (those from 30 years and older) (Figure 4.2). There were no reports recorded in these age groups in 2004.
- With the exception of January and February, the number of reports for each month in 2005 was either comparable to or lower than the historical mean. The highest number of cases was reported in January 2005.

**Figure 4.1: Incidence of chickenpox by year.
Toronto, the rest of Ontario and Canada*, 1995 - 2005**




*From 1993 to 2001 Chickenpox was not reportable in British Columbia, Manitoba, and Quebec. Saskatchewan provided data only for 1995, 1998, 1999 and 2000. NA: Ontario data for 2005 are not available.

**Figure 4.2: Incidence of chickenpox by age group*.
Toronto, 2005**



*The age group was not reported for 71 cases.

**Figure 4.3: Number of reported cases of chickenpox by month.
Toronto, 2005 compared to 1995 - 2004 mean**




Legionellosis

| Table 4.3: Legionellosis summary data | | | |
|---|--------------------|--------------------------|---------------------------|
| Toronto | | | |
| | 2005 | 5-yr period 2000-2004 | 10-yr period 1995-2004 |
| | Total | Means | |
| Number of reported cases | 53 | 9 | 13 |
| Incidence rate (per 100,000 population) | | | |
| Overall | 2.0 | 0.4 | 0.5 |
| Male | 1.8 | 0.5 | 0.7 |
| Female | 2.2 | 0.3 | 0.4 |
| Age at onset (years) | Summary statistics | | |
| Mean | 76 | 68 | 65 |
| Median | 81 | 72 | 68 |
| Range | 28 99 | 32 87 | 2 93 |
| Case fatality (%) | 40 | 26 | 25 |


Highlights

- In 2005, there were 53 lab-confirmed reported cases (2.0 cases per 100,000) of legionellosis. This represented an increase of 50 cases over the 2004 total of three cases (Figure 4.4) and the highest rate reported in the 11-year surveillance period. Thirty-eight of these lab-confirmed cases were associated with a large outbreak at a long term care facility, which involved a total of 134 people who met the outbreak case definition (details in the Outbreaks Highlight section, page 169).
- The case fatality (40%) was higher than in past years due to the large number of high risk elderly cases involved in the outbreak (Table 4.3). Nineteen (90%) of the 21 deaths were in outbreak-associated cases. While the proportion of deaths among the 38 lab-confirmed cases was 50%, there was only a 13% mortality rate among the 15 sporadic cases.
- Toronto’s rate of legionellosis was 10 times the rate reported for the rest of Ontario in 2005 and five times the rate reported for Canada (Figure 4.4).
- Heating/ventilation/air conditioning was the only source of infection associated with the large scale outbreak. When data from this outbreak were excluded, the most commonly reported sources of infection among the remaining 15 cases in 2005 were water (43%) and heating/ventilation/air conditioning (7%).
- In 2005, all of the 38 cases associated with the large outbreak occurred in either September or October. For all the remaining cases, with the exception of February and November, the number of reports for each month in 2005 was either comparable to or lower than the historical mean. The highest number of cases was reported in November.


**Figure 4.4: Incidence of legionellosis by year.
Toronto, the rest of Ontario and Canada, 1995 - 2005**



**Figure 4.5: Incidence of legionellosis by age group and sex.
Toronto, 1995 - 2005 combined**



**Figure 4.6: Number of reported cases of legionellosis by month.
Toronto, 2005 compared to 1995 - 2004 mean**




Meningococcal disease, invasive

| Table 4.4: Invasive meningococcal disease summary data | | | |
|--|--------------------|--------------------------|---------------------------|
| Toronto | | | |
| | 2005 | 5-yr period 2000-2004 | 10-yr period 1995-2004 |
| | Total | Means | |
| Number of reported cases | 3 | 15 | 16 |
| Incidence rate (per 100,000 population) | | | |
| Overall | 0.1 | 0.6 | 0.6 |
| Male | <0.1 | 0.5 | 0.6 |
| Female | 0.1 | 0.6 | 0.7 |
| Age at onset (years) | Summary statistics | | |
| Mean | 21 | 33 | 29 |
| Median | 20 | 28 | 23 |
| Range | 17 26 | <1 79 | <1 88 |
| Case fatality (%) | 0 | 14 | 14 |

Highlights

- In 2005, there were three reported cases (0.1 cases per 100,000) of invasive meningococcal disease (IMD). This represented a decrease of three cases (50%) from the 2004 total of six cases and the lowest incidence of IMD in the 11-year surveillance period (Figure 4.7). There were no reported deaths related to IMD in 2005 (Table 4.4).
- Toronto's rate of IMD has continued to decline since 2001, and has remained lower than the rates reported for the rest of Ontario and Canada since 2003 (Figure 4.7).
- Among the three reported cases in 2005, only meningococcal serogroup Y was identified (Figure 4.9). This was the first year in the 11-year surveillance period (1995-2005) that a case of serogroup C was not reported. In 2005, the Ontario government funded a meningococcal serogroup C vaccine campaign for group C meningococcal disease targeted at people born between January 1, 1985 and December 31, 1990 (15 to 20 year olds).
- In 2005, the youngest reported case of IMD was 17 years of age; the mean and median ages of cases in 2005 were lower than both the previous 5- and 10-year equivalents (Table 4.4).

**Figure 4.7: Incidence of invasive meningococcal disease by year.
Toronto, the rest of Ontario and Canada*, 1995 - 2005**



**Figure 4.8: Incidence of invasive meningococcal disease by age group and sex.
Toronto, 1995 - 2005 combined**





Figure 4.9: Number of reported cases of invasive meningococcal disease by serogroup* and year. Toronto, 1995 - 2005



Streptococcal infections, Group A invasive

Table 4.5: Invasive group A streptococcal infections summary data*


| Toronto | | |
|---|--------------------|--------------------------|
| | 2005 | 5-yr period 2000-2004 |
| | Total | Mean |
| Number of reported cases | 72 | 75 |
| Incidence rate (per 100,000 population) | | |
| Overall | 2.8 | 2.9 |
| Male | 3.2 | 3.1 |
| Female | 2.3 | 2.7 |
| Age at onset (years) | Summary statistics | |
| Mean | 56 | 51 |
| Median | 58 | 52 |
| Range | <1 94 | <1 100 |
| Case fatality (%) | 15 | 17 |
| Hospitalization rate (%) | 85 | 81 |

*Since April 1995 all forms of invasive GAS were reportable to Toronto Public Health.

Highlights


- In 2005, there were 72 reported cases (2.8 cases per 100,000) of invasive group A streptococcal (GAS) disease. This represented an increase of 20 cases (38%) over the 2004 total of 52 cases (Figure 4.10).
- The hospitalization rate for GAS decreased from 94% in 2004 to 85% in 2005. Necrotizing fasciitis was reported in 8% (n=6) of reported cases.
- Compared to 2004, incidence rates of GAS infection either increased or remained unchanged in all age groups except those 5 to 9 and 80 to 84 years of age. Although the highest age-specific rate occurred among those 85 years and older, the largest rate increase, for 2005 compared to 2004, was noted in the 75 to 79 year age group (four-fold increase).
- The most commonly reported risk factor for acquiring GAS was the presence of an underlying medical condition (53%) (Table 4.6).
- Risk setting information was available for 57% (n=41) of cases reported in 2005. Among these cases, the most commonly reported risk settings were the home environment (44%), hospitals (10%) and residential facilities (10%).

Figure 4.10: Incidence of invasive group A streptococcal infections by year. Toronto*, the rest of Ontario and Canada, 1996 - 2005



*Since April 1995 all forms of invasive GAS were reportable to Toronto Public Health.
 NR: Not reportable. Starting January 1, 2000, invasive Group A Streptococcal disease was added to the list of national notifiable diseases.

Figure 4.11: Incidence of invasive group A streptococcal infections by age group and sex. Toronto, 2005



**Table 4.6: Risk factors for reported cases of invasive group A streptococcal infections.
Toronto, 2005**

| Reported risk factor | Number of cases* | Proportion of cases (%) |
|---------------------------------------|-------------------------|--------------------------------|
| Underlying medical conditions | 19 | (53) |
| Trauma within past month | 7 | (19) |
| Homeless | 4 | (11) |
| Illicit drug user | 4 | (11) |
| Chronic dermatological condition | 3 | (8) |
| Dialysis | 3 | (8) |
| Other | 3 | (8) |
| Total with a known risk factor | 36 | |
| Number missing or unknown | 36 | |
| Total cases | 72 | |

*Cases may report more than one risk factor.

Streptococcal infections, Group B neonatal

Table 4.7: Neonatal group B streptococcal infections summary data*


| Toronto | | |
|---|--------------------|--------------------------|
| | 2005 | 5-yr period 2000-2004 |
| | Total | Mean |
| Number of reported cases | 12 | 17 |
| Incidence rate (per 100,000 population) | | |
| Overall | 0.5 | 0.7 |
| Male | 0.6 | 0.7 |
| Female | 0.3 | 0.6 |
| Age at onset (days) | Summary statistics | |
| Mean | 4 | 6 |
| Median | 0 | 0 |
| Range | 0 20 | 0 28 |
| Case fatality (%) | 0 | 9 |

*Neonatal group B streptococcal infections first became reportable in Ontario in 1996. Only disease occurring within the first 28 days of life is reportable.

Highlights

- In 2005, there were 12 reported cases (0.5 cases per 100,000) of neonatal group B streptococcal (GBS) infections. This represented a decrease of four cases (25%) from the 2004 total of 16 cases (Figure 4.12).
- Toronto's rate of GBS has continued to decline since 2001, however, it remains 1.3 and 2.5 times the rate in the rest of Ontario and Canada, respectively (Figure 4.12).
- The most commonly reported type of GBS in 2005 was early onset (0 to 7 days) disease, which accounted for 83% (n=10) of cases. The remaining two reported cases were late onset disease (8 to 28 days).
- There were no reported deaths related to GBS in 2005.

Figure 4.12: Incidence of neonatal group B streptococcal infections by year. Toronto, the rest of Ontario* and Canada, 1996 - 2005



*Neonatal group B streptococcal infections became reportable in Ontario in 1996.
 Starting January 1, 2000, neonatal group B streptococcal disease was added to the list of national notifiable diseases.
 NR: Not reportable

Streptococcus pneumoniae, invasive

| Table 4.8: Invasive <i>Streptococcus pneumoniae</i> summary data* | | | | |
|---|--------------------|----------|----------|-----------|
| Toronto | | | | |
| | 2005 | 2004 | 2003 | 2002 |
| Number of reported cases | 216 | 263 | 235 | 276 |
| Incidence rate (per 100,000 population) | | | | |
| Overall | 8.3 | 10.1 | 9.0 | 10.5 |
| Male | 10.3 | 12.9 | 9.8 | 11.8 |
| Female | 6.4 | 7.3 | 8.2 | 9.3 |
| Age at onset (years) | Summary statistics | | | |
| Mean | 54 | 52 | 51 | 51 |
| Median | 56 | 57 | 58 | 58 |
| Range | <1 104 | <1 97 | <1 99 | <1 108 |
| Case fatality (%) | 6 | 9 | 6 | 11 |
| Hospitalization rate (%) | 84 | 86 | 86 | 91 |

*Invasive *Streptococcus pneumoniae* became reportable in fall 2001.

Highlights

- In 2005, there were 216 reported cases (8.3 cases per 100,000) of invasive *Streptococcus pneumoniae* (ISP) (Table 4.8). This represented a decrease of 47 cases (18%) from the 2004 total of 263 cases.
- Eighty-four percent (n=182) of ISP cases were hospitalized. This represented the lowest hospitalization rate during the surveillance period 2002 to 2005 (Table 4.8).
- Males accounted for 61% (n=131) of ISP cases in 2005 and exceeded the female rates for all age groups except those 5 to 9 and 10 to 19 years of age (Figure 4.13).
- Compared to 2004, ISP rates decreased in all age groups except those 20 to 29, 40 to 49 and 70 to 74 years of age. Although the lowest rate was among those 10 to 19 years of age, the largest decrease was noted in the 5 to 9 year age group (almost one-third the rate reported for 2004).

Figure 4.13: Incidence of invasive *Streptococcus pneumoniae* by age group and sex. Toronto, 2005





Figure 4.14: Number of reported cases of invasive *Streptococcus pneumoniae* by month. Toronto, 2005 compared to 2002 - 2004 mean



Tuberculosis

Table 4.9: Tuberculosis summary data


| Toronto | | | |
|---|--------------------|--------------------------|---------------------------|
| | 2005 | 5-yr period 2000-2004 | 10-yr period 1995-2004 |
| | Total | Means | |
| Number of reported cases | 344 | 373 | 406 |
| Incidence rate (per 100,000 population) | | | |
| Overall | 13.2 | 14.4 | 16.0 |
| Male | 14.2 | 16.0 | 17.5 |
| Female | 12.3 | 12.8 | 14.6 |
| Age at onset (years) | Summary statistics | | |
| Mean | 43 | 44 | 45 |
| Median | 41 | 40 | 39 |
| Range | 2 98 | < 1 106 | < 1 106 |
| Case fatality (%) | 8 | 8 | 9 |

Highlights


- In 2005, there were 344 cases (13.2 cases per 100,000) of tuberculosis (TB) reported. This represented a decrease of 17 cases (5%) from the 2004 total of 361 cases. Incidence rates for TB have been decreasing steadily in Toronto, reaching the lowest level for the 11-year surveillance period in 2005 (Figure 4.15).
- Toronto's rate of TB continued to exceed the rate reported in the rest of Ontario by a factor of almost five (Figure 4.15). Toronto cases accounted for 55% of all TB cases in Ontario (N=623).
- The age groups with the highest incidence rates of disease were 20 to 24 year olds (20.0 cases per 100,000) followed by both those between 30 to 34 years old (18.8 cases per 100,000) and those 65 years and older (18.5 cases per 100,000) (Figure 4.16). The highest age-specific increase in rates in 2005 occurred in the 10 to 14 year age group, which increased almost 10-fold from 2004, although the overall number of cases in that age group remains small.
- In 2005, males accounted for 52% (n=180) of all TB cases. The male rates of TB were more than double the female rates among those aged 45-49, and significantly higher in all ages over 40 (Figure 4.16). Overall rates for males remained higher than rates for females, as in 2004 (Figure 4.17).
- As in 2004, travel to or residence outside of Canada in an endemic area was the most commonly reported risk setting for cases of tuberculosis in 2005 (Table 4.10). This risk setting was reported by 91% (n=306) of all cases with a known risk setting. Risk setting captures the site where transmission most likely occurred.
- In 2005, only 10 (3%) of the TB cases reported a shelter/rooming house as a risk setting for acquiring TB, a slight decrease from the 15 such cases in 2004 (Table 4.10). Toronto Public Health conducted an active case finding initiative with large scale screening in Toronto shelters in 2004, which may account for the larger number of shelter-associated cases in that year.

-
- The proportion of TB cases who were foreign-born was 92% in 2005 (Figure 4.18). Given that approximately 44% of Toronto's population is foreign-born (2001 census) this confirms that TB continues to disproportionately affect the foreign-born population, reflecting TB rates in other parts of the world. The top ten countries of origin for TB cases were similar to last year, with Hong Kong and Bangladesh appearing in the place of South Korea and Portugal (Figure 4.19).
 - Of the 344 reported TB cases in 2005, 20 (6%) were known to be co-infected with HIV, similar to the 4% reported in 2004.
 - In 2005, the lungs continued to be the most commonly reported anatomic site of tuberculosis (69%) (Table 4.11).
 - Overall, 56% (n=194) of TB cases treated in 2004 (the most recent cohort expected to have completed their treatment at the time of this report) were enrolled in the directly observed therapy (DOT) program (Table 4.12). Eighty-seven percent (n=169) of those cases successfully completed treatment as compared with 73% of the cases not on DOT. Seventy-two percent (n=167) of pulmonary cases in 2004 were enrolled in DOT.
 - In 2005, the proportion of isolates resistant to one or more drugs was 16%, a slight decrease from the 19% resistant in 2004 (Figure 4.20). A total of 276 cases (80%) were culture confirmed in 2005. The largest proportion of drug resistant isolates continued to be those exhibiting any INH resistance pattern (excluding rifampin), which accounted for 8% of all isolates that were tested. The proportion of multidrug-resistant TB strains (i.e. strains resistant to at least rifampin and isoniazid) has continued to fluctuate and accounted for 3% of all isolates that were tested in 2005. The proportion of isolates exhibiting other patterns of resistance has decreased slightly to 5%.


**Figure 4.15: Incidence of tuberculosis by year.
Toronto, the rest of Ontario and Canada, 1995 - 2005**



**Figure 4.16: Incidence of tuberculosis by age group and sex.
Toronto, 2005**




**Figure 4.17: Incidence rates of tuberculosis by sex and year.
Toronto, 1995- 2005**



**Table 4.10: Risk settings of reported cases of tuberculosis.
Toronto, 2005**


| Reported risk setting | Number of cases | Proportion of cases (%) |
|--|-----------------|-------------------------|
| Travel or lived in endemic area | 306 | 91 |
| Home | 12 | 4 |
| Shelter or rooming house | 10 | 3 |
| Residential/Long-term care facility | 2 | <1 |
| Hospital | 2 | <1 |
| Workplace | 1 | <1 |
| Correctional facility | 1 | <1 |
| Other | 1 | <1 |
| Total with a known risk setting | 335 | 100 |
| Number missing or unknown | 9 | |
| Total cases | 344 | |

**Figure 4.18: Reported cases of tuberculosis by origin* and year.
Toronto, 1995 - 2005**



*Numbers may not add up to total cases for any given year because the origin was unknown or missing for some cases.

**Figure 4.19: Proportion of foreign-born tuberculosis cases by top 10 countries* of birth.
Toronto, 2005**



*Other countries of birth were reported by foreign-born tuberculosis cases in 2005.

Table 4.11: Number and proportion of reported cases of tuberculosis by anatomic site and country of origin. Toronto, 2005

| Site of tuberculosis* | Canadian-born cases (%) | | Foreign-born cases (%) | | Overall cases [†] (%) | |
|---------------------------------|-------------------------|------|------------------------|------|--------------------------------|------|
| Pulmonary | 17 | (65) | 186 | (58) | 203 | (59) |
| Lymph node | 1 | (4) | 91 | (29) | 92 | (27) |
| Pleurisy | 1 | (4) | 15 | (5) | 16 | (5) |
| Primary pulmonary | 6 | (23) | 13 | (4) | 19 | (6) |
| Abdominal | 0 | (0) | 11 | (3) | 11 | (3) |
| Genitourinary | 0 | (0) | 8 | (3) | 8 | (2) |
| Central nervous system | 0 | (0) | 9 | (3) | 9 | (3) |
| Miliary | 0 | (0) | 7 | (2) | 7 | (2) |
| Bone and joint | 0 | (0) | 8 | (3) | 8 | (2) |
| Skin | 0 | (0) | 1 | (<1) | 1 | (<1) |
| Other respiratory | 0 | (0) | 2 | (<1) | 2 | (<1) |
| Other | 1 | (4) | 8 | (3) | 9 | (3) |
| Total sites of infection | 26 | | 359 | | 385 | |
| Total cases | 26 | | 318 | | 344 | |

*Cases may have tuberculosis at more than one anatomic site.


Table 4.12: Reported cases of tuberculosis by treatment status and treatment method. Toronto, 2005*

| Treatment status | DOT (%) | | Non-DOT (%) | |
|----------------------------------|------------|--------------|-------------|--------------|
| Successfully treated | 169 | (87) | 111 | (73) |
| Undergoing treatment | 19 | (10) | 25 | (16) |
| Not completed, side effects | 0 | (0) | 1 | (<1) |
| Not completed, non-compliant | 0 | (0) | 1 | (<1) |
| Referred to another jurisdiction | 3 | (2) | 3 | (2) |
| Lost to follow up | 1 | (<1) | 4 | (3) |
| Expired | 2 | (1) | 7 | (5) |
| Total cases[†] | 194 | (100) | 152 | (100) |

*Treatment status is reported for 2004 since this is the most recent cohort expected to have completed their treatment at the time of the report.

[†]The total number of cases by treatment status does not add up because 15 cases never started treatment, either because of diagnosis after death, or due to another serious condition.

**Figure 4.20: Proportion of drug resistant tuberculosis cases by year.
Toronto, 1995 - 2005**



*MDR-TB cases are resistant to at least isoniazid (INH) and rifampin (RMP).

Year

Vectorborne and Zoonotic Diseases

**Communicable Diseases
in Toronto**

2005

Vectorborne and Zoonotic Diseases

This section focuses on diseases caused by infectious agents transmitted through contact with an infected animal. Most transmission occurs through the bite of an arthropod (mosquito or tick), which introduces infectious agents into the bloodstream. Given that the vectors and animal reservoirs for many of these diseases are not naturally found in Toronto, this group of diseases is rare. Relative proportions of each disease within this grouping, and their ranking are listed below. In 2005, malaria accounted for 63% of reports falling into this category. □

Table 5.1: Number and proportion of reported cases of vectorborne and zoonotic diseases. Toronto, 2005

| Ranking | Reportable disease | Number of cases | Proportion of cases (%) |
|---------|--------------------|-----------------|-------------------------|
| 1 | Malaria | 90 | 63 |
| 2 | West Nile Virus | 38 | 26 |
| 3 | Lyme disease | 13 | 9 |
| 4 | Brucellosis | 3 | 2 |
| | Total | 144 | 100 |

Rare reportable diseases not summarized in this section include hantavirus, hemorrhagic fevers, lassa fever, plague, psittacosis/ornithosis, Q fever, rabies, tularemia, yellow fever.

Lyme disease

| Table 5.2: Lyme disease summary data | | | |
|---|--------------------|--------------------------|---------------------------|
| Toronto | | | |
| | 2005 | 5-yr period 2000-2004 | 10-yr period 1995-2004 |
| | Total | Means | |
| Number of reported cases | 13 | 7 | 7 |
| Incidence rate (per 100,000 population) | | | |
| Overall | 0.5 | 0.3 | 0.3 |
| Male | 0.6 | 0.2 | 0.2 |
| Female | 0.4 | 0.3 | 0.3 |
| Age at onset (years) | Summary statistics | | |
| Mean | 37 | 36 | 38 |
| Median | 37 | 32 | 37 |
| Range | 6 76 | 3 67 | 3 76 |


Highlights

- In 2005, there were 13 reported cases (0.5 cases per 100,000) of lyme disease. This represented an increase of nine cases over the 2004 total of four cases and the highest incidence of lyme disease in the 11-year surveillance period (Figure 5.1).
- The median age of lyme disease in 2005 was 37 years. This median age was lower than for 2004 (49 years) but comparable to the previous 5-and 10-year medians (Table 5.2).
- In the 12 cases where risk setting was identified, 11 cases (92%) reported travel outside of Canada.

**Figure 5.1: Incidence of lyme disease by year.
Toronto and the rest of Ontario, 1995 - 2005**



**Figure 5.2: Incidence of lyme disease by age group and sex*.
Toronto, 1995 - 2005 combined**




Malaria

| Table 5.3: Malaria summary data | | | |
|---|--------------------|--------------------------|---------------------------|
| Toronto | | | |
| | 2005 | 5-yr period 2000-2004 | 10-yr period 1995-2004 |
| | Total | Means | |
| Number of reported cases | 90 | 90 | 119 |
| Incidence rate (per 100,000 population) | | | |
| Overall | 3.5 | 3.5 | 4.7 |
| Male | 5.0 | 5.1 | 6.2 |
| Female | 1.9 | 1.9 | 3.2 |
| Age at onset (years) | Summary statistics | | |
| Mean | 38 | 34 | 34 |
| Median | 39 | 36 | 34 |
| Range | 1 68 | <1 83 | <1 96 |


Highlights

- In 2005, there were 90 reported cases (3.5 cases per 100,000) of malaria. This represented a decrease of three cases (3%) from the 2004 total of 93 cases (Figure 5.3).
- Toronto's rate of malaria was almost four times the rate reported for the rest of Ontario in 2005 and three times the rate reported for Canada (Figure 5.3). This may reflect Toronto's large immigrant population and associated travel to malaria endemic areas of the world. In 2005, cases from Toronto accounted for 49% of all malaria cases reported in Ontario (n=184).
- The age groups with the highest incidence rates of malaria included all three groups from 30 to 59 year olds (Figure 5.4).
- Males accounted for 71% (n=64) of all malaria cases in 2005 and experienced age-specific rates which exceeded their female counterparts in the age groups from 30 to 60 years and older (Figure 5.4).
- With the exception of December, the number of reports for each month in 2005 was either comparable to or lower than the historical mean (Figure 5.5).
- Of the 83 cases where a travel destination was reported, 30% (n=25) traveled to Ghana, 30% (n=25) traveled to India, 17% (n=14) traveled to Nigeria, 11% (n=9) traveled to the African continent, and 4% (n=3) traveled to Pakistan. The remaining seven reported cases traveled to six different countries. The risk setting for seven cases where no travel was reported is unknown.


**Figure 5.3: Incidence of malaria by year.
Toronto, the rest of Ontario and Canada, 1995 - 2005**



**Figure 5.4: Incidence of malaria by age group and sex.
Toronto, 2005**



**Figure 5.5: Number of reported cases of malaria by month.
Toronto, 2005 compared to 1995 - 2004 mean**




West Nile Virus (WNV)

| Table 5.4: West Nile Virus summary data | | | | |
|---|--------------------|------------|------------|------------|
| Toronto | | | | |
| | 2005 | 2004 | 2003 | 2002 |
| Number of reported cases | 38 | 6 | 44 | 163 |
| Incidence rate (per 100,000 population) | | | | |
| Overall | 1.5 | 0.2 | 1.7 | 6.2 |
| Male | 1.3 | 0.2 | 1.6 | 5.8 |
| Female | 1.6 | 0.3 | 1.8 | 6.6 |
| Age at onset (years) | Summary statistics | | | |
| Mean | 57 | 62 | 51 | 54 |
| Median | 57 | 60 | 51 | 52 |
| Range | 23 92 | 39 88 | 13 90 | 19 89 |
| Hospitalization rate (%) | 45 | 50 | 18 | 52 |
| Case fatality (%) | 16 | 0 | 0 | 6 |


Highlights

- In 2005, there were 38 reported cases of West Nile Virus (WNV). This represented an increase of 32 cases, more than six times the 2004 total of six cases (Table 5.4).
- Among WNV cases reported in 2005, 45% of all cases (n=17) were hospitalized (Table 5.4). There were six reported deaths related to WNV infection in 2005. This represented a case fatality rate of 16%.
- The age group with the highest incidence rate of WNV in the combined years (2002-2005) continued to be 60 years and older (4.9 cases per 100,000) (Figure 5.6).
- With the exception of July, the number of reports for each month in 2005 was either comparable to or lower than the historical mean (Figure 5.7).
- The most commonly reported risk settings were the home environment (70%), visiting a local park or recreational area (11%) and visiting a local vacation property (11%) (Figure 5.8).


**Figure 5.6: Incidence of West Nile Virus by age group and sex.
Toronto, 2002 - 2005 combined**



**Figure 5.7: Number of reported cases of West Nile Virus by month.
Toronto, 2005 compared to 2002 - 2004 mean**



**Figure 5.8: Proportion of reported cases of West Nile Virus by reported risk setting.
Toronto, 2005 (N=38)**



Encephalitis/ Meningitis

**Communicable Diseases
in Toronto**

2005

Encephalitis/Meningitis

(excluding all other reportable diseases known to cause encephalitis/meningitis)

| Table 6.1: Encephalitis/meningitis summary data | | | | | | |
|---|--------------------|-----------|--------------------------|-----------|---------------------------|-----------|
| Toronto | | | | | | |
| | 2005 | | 5-yr period 2000-2004 | | 10-yr period 1995-2004 | |
| | Totals | | Means | | | |
| | Viral | Bacterial | Viral | Bacterial | Viral | Bacterial |
| Number of reported cases | 55 | 4 | 60 | 13 | 47 | 14 |
| Incidence rate (per 100,000 population) | | | | | | |
| Overall | 2.1 | 0.2 | 2.3 | 0.5 | 1.9 | 0.5 |
| Male | 2.4 | 0.2 | 2.7 | 0.6 | 2.1 | 0.6 |
| Female | 1.8 | 0.1 | 2.0 | 0.4 | 1.6 | 0.5 |
| Age at onset (years) | Summary statistics | | | | | |
| Mean | 17 | 43 | 27 | 28 | 26 | 33 |
| Median | 12 | 44 | 24 | 24 | 24 | 35 |
| Range | <1 - 88 | <1 - 83 | <1 - 94 | <1 - 84 | <1 - 94 | <1 - 84 |
| Case fatality (%) | 0 | 0 | 2 | 8 | 2 | 14 |
| *Other cases | 6 | | 5 | | 6 | |
| †Unclassified cases | 7 | | 7 | | 6 | |

*Cases for which a fungal agent was identified.

†Cases for which no agent was identified.

Highlights: Viral

- In 2005, there were 55 reported cases (2.1 cases per 100,000) of viral encephalitis/meningitis. This represented an increase of eight cases (17%) over the 2004 total of 47 cases (Figure 6.1).
- The number of cases reported for each month except June and July was comparable to or lower than the historical mean.
- The most commonly identified viral agents in 2005 were Enterovirus - unspecified (47%) and Herpes simplex virus (16%) (Table 6.2).

Figure 6.1: Incidence of encephalitis/meningitis, viral and bacterial causes by year. Toronto, 1995 - 2005






Figure 6.2: Incidence rates of encephalitis/meningitis, viral by year. Toronto compared to the rest of Ontario, 1995 - 2005



NA: Ontario data for 2005 are not available.

**Figure 6.3: Incidence of encephalitis/meningitis, viral by age group* and sex.
Toronto, 1995 - 2005 combined**



**Figure 6.4: Number of reported cases of encephalitis/meningitis, viral by month.
Toronto, 2005 compared to 1995 - 2004 mean**




Table 6.2: Incidence of viral encephalitis/meningitis by agent. Toronto, 2005 cases compared to previous 5-year mean

| Agent organism | Number of cases (%) | |
|-----------------------------------|---------------------|-------------------------------|
| | 2005 (N=55) | 5-yr mean 2000-2004 (N=60) |
| Enterovirus - unspecified | 26 (47) | 14 (23) |
| Suspect viral* | 14 (25) | 18 (29) |
| Herpes simplex virus [†] | 9 (16) | 11 (18) |
| Enterovirus - Coxsackievirus | 3 (5) | 2 (4) |
| Enterovirus - Echovirus | 2 (4) | 1 (2) |
| Other | 1 (2) | 7 (12) |
| Dengue virus [‡] | 0 (0) | 6 (10) |
| St. Louis virus | 0 (0) | 1 (2) |
| Total | 55 (100) | 60 (100) |

*Suspect viral cases were those without a confirmed viral agent but with clinical signs and symptoms indicating a viral infection.

[†]Includes Herpes simplex virus type 1, type 2 and unspecified.

[‡]Not endemic.

Highlights: Bacterial

- In 2005, there were four cases (0.2 cases per 100,000) of bacterial encephalitis/meningitis reported. The incidence rate of bacterial encephalitis/meningitis was less than half the rate reported for 2004 (Figure 6.1).
- The number of reports for each month in 2005 was either comparable to or lower than the historical mean (Figure 6.7).
- The most common bacterial encephalitis/meningitis agent identified in 2005 was *Escherichia coli* (50%) (Table 6.3).

Figure 6.5: Incidence rates of encephalitis/meningitis, bacterial by year. Toronto compared to the rest of Ontario, 1995 - 2005




Figure 6.6: Incidence of encephalitis/meningitis, bacterial by age group and sex. Toronto, 1995 - 2005 combined




Figure 6.7: Number of reported cases of encephalitis/meningitis, bacterial by month. Toronto, 2005 compared to 1995 - 2004 mean




Table 6.3: Incidence of bacterial encephalitis/meningitis by agent. Toronto, 2005 cases compared to previous 5-year mean

| Agent organism* | Number of cases (%) | |
|----------------------------------|---------------------|----------------------------|
| | 2005 (N=4) | 5-yr mean 2000-2004 (N=13) |
| Suspect bacterial [†] | 2 (50) | 4 (30) |
| <i>Escherichia coli</i> | 2 (50) | 2 (13) |
| <i>Streptococcus</i> | 0 (0) | 4 (30) |
| <i>Pneumococcus</i> [‡] | 0 (0) | 1 (9) |
| <i>Klebsiella</i> | 0 (0) | <1 (5) |
| <i>Staphylococcus aureus</i> | 0 (0) | <1 (5) |
| <i>Enterobacter</i> | 0 (0) | <1 (3) |
| <i>Serratia</i> | 0 (0) | <1 (2) |
| <i>Salmonella</i> | 0 (0) | <1 (2) |
| Other | 0 (0) | <1 (3) |
| Total | 4 (100) | 13 (100) |

*Excludes encephalitis/meningitis caused by *Neisseria meningitidis*.

[†]Suspect bacterial cases were those without a confirmed bacterial agent but with clinical signs and symptoms indicating a bacterial infection.

[‡]Reported as *Streptococcus pneumoniae* since fall 2001.

Rare Diseases

**Communicable Diseases
in Toronto**

2005

Rare Communicable Reportable Diseases

There are several reportable diseases that are rare in Toronto and have insufficient data to generate rates or trends across time. Some of these diseases were once widespread and have been successfully controlled through public health programs, evolving technologies and development of new medications, and increased awareness. Other diseases are not endemic to North America but contagious enough that their rare appearance is monitored. Table 7.1 summarizes SARS and all those diseases that had less than 50 cases reported during the 11-year surveillance period 1995 to 2005. These diseases vary in their modes of transmission, but are categorized according to the main chapters and sections of this report to which they correspond. They share several of the attributes of other diseases in these respective sections. □

**Table 7.1: Summary of rare reportable diseases.
Toronto, 1995 - 2005**

| Disease | Disease category | Year of last report | Total number of cases for period 1995 - 2005 |
|---|-------------------------------------|---------------------|--|
| Botulism | Enteric, food and waterborne | 2004 | 6 |
| Brucellosis | Vectorborne and zoonotic | 2005 | 11 |
| Cholera | Enteric, food and waterborne | 1998 | 3 |
| Cytomegalovirus infection, congenital | Sexually transmitted and bloodborne | 2005 | 19 |
| <i>Haemophilus influenzae</i> b disease, invasive | Preventable by routine vaccination | 2004 | 19 |
| Haemorrhagic fevers | Vectorborne and zoonotic | 1997 | 2 |
| Hepatitis D | Sexually transmitted and bloodborne | 2005 | 31 |
| Herpes, neonatal | Sexually transmitted and bloodborne | 2005 | 13 |
| Leprosy | Direct contact and respiratory | 2005 | 19 |
| Ophthalmia neonatorum | Sexually transmitted and bloodborne | 2004 | 34 |
| Psittacosis/Ornithosis | Vectorborne and zoonotic | 1996 | 3 |
| Q fever | Vectorborne and zoonotic | 2004 | 10 |
| Rubella, congenital syndrome | Preventable by routine vaccination | 2004 | 5 |
| Severe Acute Respiratory Syndrome | Direct contact and respiratory | 2003 | 228 |
| Syphilis, congenital | Sexually transmitted and bloodborne | 1999 | 2 |
| Tetanus | Preventable by routine vaccination | 1997 | 2 |
| Tularemia | Vectorborne and zoonotic | 1997 | 1 |

Rare reportable diseases not summarized in this section include anthrax, chancroid, diphtheria, hantavirus, lassa fever, plague, poliomyelitis, rabies, smallpox, transmissible spongiform encephalopathies, trichinosis, yellow fever.

Outbreaks

**Communicable Diseases
in Toronto**

2005

Outbreaks

| Table 8.1: Outbreak summary data | | | | | | |
|-----------------------------------|---------|--------------|-------|--------------------------|--------------|-------|
| Toronto | | | | | | |
| | 2005 | | | 5-yr period 2000-2004 | | |
| | Total | | | Mean | | |
| | Enteric | Respiratory* | Other | Enteric | Respiratory* | Other |
| Number of reported outbreaks | 139 | 129 | 5 | 183 | 123 | 3 |
| Number of cases | 3030 | 2321 | 17 | 4886 | 2709 | 25 |
| Mean number of cases per outbreak | 22 | 18 | 3 | 27 | 22 | 10 |
| Number of deaths | 1 | 71 | 0 | 10 | 66 | 1 |

*Seasonal year from July to June (i.e. 2005/06 includes cases from July 1, 2005 to June 30, 2006).

Highlights: Enteric Outbreaks

- There were 139 enteric outbreaks reported in 2005. This represented a decrease of 45 outbreaks (24%) from the 2004 total of 184 outbreaks (Table 8.2). There was one enteric outbreak-related death reported in 2005. This was a decrease from the 16 reported deaths for 2004 and the mean of 10 deaths for the previous 5-year period.
- Although the proportion of Norovirus outbreaks was lower in 2005 than any year during the surveillance period (2001 to 2005), Norovirus continued to be the most commonly identified agent (8%) associated with enteric outbreaks in 2005 (Table 8.2).
- Just over half (53%) the enteric outbreaks reported in Toronto were from child care centres (Table 8.3).
- There were 3,030 individuals identified as cases in enteric outbreaks reported in 2005 (Table 8.4). This represented a decrease of 113 cases (4%) from the 3,143 reported cases in 2004. However, the mean and median number of cases per enteric outbreak increased from 17 and 12 in 2004 to 22 and 14, respectively for 2005. Long term care facilities reported the highest number of cases (n=1,788) and cases per outbreak (n=38) in 2005 (Table 8.4).
- The number of enteric outbreaks reported for each month of 2005 was either comparable to or lower than the historical mean (Figure 8.1).

**Table 8.2: Number and proportion of reported enteric outbreaks by agent.
Toronto, 2001 - 2005**

| Etiological agent/disease | Number of reported outbreaks (%) | | | | | |
|----------------------------------|----------------------------------|----------------|------------------|----------------|----------------|------------------|
| | Overall | 2001 | 2002 | 2003 | 2004 | 2005 |
| Bacteria | | | | | | |
| Clostridium difficile | 7 (<1) | 4 (3) | 0 (0) | 1 (<1) | 1 (<1) | 1 (<1) |
| Campylobacter spp. | 6 (<1) | 2 (1) | 2 (<1) | 0 (0) | 2 (1) | 0 (0) |
| Clostridium perfringens | 5 (<1) | 2 (1) | 1 (<1) | 1 (<1) | 0 (0) | 1 (<1) |
| Salmonella spp. | 4 (<1) | 3 (2) | 0 (0) | 1 (<1) | 0 (0) | 0 (0) |
| Shigella spp. | 4 (<1) | 0 (0) | 2 (<1) | 1 (<1) | 0 (0) | 1 (<1) |
| E. coli O157:H7 | 2 (<1) | 2 (1) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| Bacillus cereus | 1 (<1) | 1 (<1) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| Salmonella typhi | 1 (<1) | 1 (<1) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| Scromboid poisoning | 1 (<1) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 1 (<1) |
| Total - Bacteria | 31 (3) | 15 (10) | 5 (2) | 4 (3) | 3 (2) | 4 (3) |
| Viruses | | | | | | |
| Norovirus* | 184 (21) | 18 (12) | 102 (34) | 25 (20) | 28 (15) | 11 (8) |
| Rotavirus | 34 (4) | 8 (5) | 6 (2) | 8 (6) | 7 (4) | 5 (4) |
| Adenovirus | 19 (2) | 5 (3) | 2 (1) | 5 (4) | 4 (2) | 3 (2) |
| Enterovirus | 6 (<1) | 0 (0) | 1 (<1) | 3 (2) | 2 (1) | 0 (0) |
| Astrovirus | 5 (<1) | 0 (0) | 4 (1) | 1 (<1) | 0 (0) | 0 (0) |
| Hepatitis A Virus | 3 (<1) | 2 (1) | 1 (<1) | 0 (0) | 0 (0) | 0 (0) |
| Picorna-like Virus | 3 (<1) | 1 (<1) | 0 (0) | 1 (<1) | 1 (<1) | 0 (0) |
| Echovirus | 1 (<1) | 1 (<1) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| Total - Viruses | 255 (29) | 35 (23) | 116 (39) | 43 (35) | 42 (23) | 19 (14) |
| Parasites | | | | | | |
| Cyclospora cayetanensis | 1 (<1) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 1 (<1) |
| Giardia lamblia | 1 (<1) | 0 (0) | 1 (<1) | 0 (0) | 0 (0) | 0 (0) |
| Total - Parasites | 2 (<1) | 0 (0) | 1 (<1) | 0 (0) | 0 (0) | 1 (<1) |
| Unknown etiology | 606 (68) | 99 (66) | 176 (59) | 77 (62) | 139 (76) | 115 (83) |
| Total number of outbreaks | 894 | 149 | 298 | 124 | 184 | 139 |

*Norovirus is the new official genus name for what was previously named 'Norwalk-like virus'. These terms may appear interchangeably in other publications.

**Table 8.3: Number and proportion of reported enteric outbreaks by risk setting* .
Toronto, 2001 - 2005**

| Risk setting | Number of reported outbreaks (%) | | | | | | | | | |
|--|----------------------------------|------------------|------------------|------------------|------------------|------------------|--|--|--|--|
| | Overall | 2001 | 2002 | 2003 | 2004 | 2005 | | | | |
| Institutional | | | | | | | | | | |
| Child care centre | 384 (43) | 44 (30) | 106 (36) | 53 (43) | 107 (58) | 74 (53) | | | | |
| Long term care facility | 332 (37) | 66 (44) | 120 (40) | 46 (37) | 53 (29) | 47 (34) | | | | |
| Acute care hospital | 50 (6) | 7 (5) | 18 (6) | 10 (8) | 8 (4) | 7 (5) | | | | |
| Chronic care hospital | 25 (3) | 1 (<1) | 14 (5) | 2 (2) | 5 (3) | 3 (2) | | | | |
| School/college/university | 22 (2) | 4 (3) | 10 (3) | 2 (2) | 3 (2) | 3 (2) | | | | |
| Other (e.g. shelter, group home) | 8 (<1) | 3 (2) | 5 (2) | 0 (0) | 0 (0) | 0 (0) | | | | |
| Total - Institutional | 821 (92) | 125 (84) | 273 (92) | 113 (91) | 176 (96) | 134 (96) | | | | |
| Community | | | | | | | | | | |
| Food services | 47 (5) | 16 (11) | 13 (4) | 9 (7) | 7 (4) | 2 (1) | | | | |
| Other (e.g. camping, community centre) | 26 (3) | 8 (5) | 12 (4) | 2 (2) | 1 (<1) | 3 (2) | | | | |
| Total - Community | 73 (8) | 24 (16) | 25 (8) | 11 (9) | 8 (4) | 5 (4) | | | | |
| Grand Total | 894 (100) | 149 (100) | 298 (100) | 124 (100) | 184 (100) | 139 (100) | | | | |


*Excludes family outbreaks.

**Table 8.4: Enteric outbreaks by risk setting and average size.
Toronto, 2005**

| Risk setting | Total number | | | Mean per outbreak | |
|---|--------------|-------------|----------|-------------------|--------------|
| | Outbreaks | Cases | Deaths | Cases | Deaths |
| Institutional | | | | | |
| Child care centre | 74 | 976 | 0 | 13 | 0 |
| Long term care facility | 47 | 1788 | 1 | 38 | <1 |
| Acute care hospital | 7 | 87 | 0 | 12 | 0 |
| Chronic care hospital | 3 | 50 | 0 | 17 | 0 |
| School/college/university | 3 | 93 | 0 | 31 | 0 |
| Total - Institutional | 134 | 2994 | 1 | 22 | <1 |
| Community | | | | | |
| Food services | 3 | 36 | 0 | 12 | 0 |
| Other (e.g. camping, community centre) [†] | 2 | NA | NA | NA | NA |
| Total - Community | 5 | 36 | 0 | 7 | 0 |
| Grand Total | 139 | 3030 | 1 | 22 | <1 |

[†]Number of cases was not available

**Figure 8.1: Number of reported enteric outbreaks by month.
Toronto, 2005 compared to 2000 - 2004 mean**



Highlights: Respiratory Outbreaks

- There were 129 respiratory outbreaks reported during the 2005/06 season. This represented a decrease of 57 outbreaks (31%) from the 2004/05 season total of 186 outbreaks (Table 8.5).
- Influenza A was the most commonly identified agent in 21% (n=27) of respiratory outbreaks reported during the 2005/06 season (Table 8.5). This was a decrease from the 44% (n=81) of outbreaks reported for the 2004/05 season. Enterovirus (12%) and RSV (6%) both surpassed Influenza B (2%) and were the next most identified agents in respiratory outbreaks, respectively.
- Long term care facilities (LTCF) accounted for the majority (90%) of outbreak reports in the 2005/06 season and the highest proportion reported for the surveillance period (Table 8.6).
- The continued occurrence of outbreaks among the elderly in LTCFs contributed to a death rate of 3.1%. This represented no change from the death rate reported last season.
- There were 2,321 people identified as cases in respiratory outbreaks reported in 2005/06 season (Table 8.7). This was a decrease of 1,373 (37%) from the 2004/05 season total of 3,694 cases. The mean and median number of cases per respiratory outbreak in 2005/06 season was 18 and 14, respectively.
- With the exception of April and October, the number of respiratory outbreaks reported for each month in 2005/06 season was either comparable to or lower than the historical mean (Figure 8.2).

**Table 8.5: Number and proportion of reported respiratory outbreaks by agent*.
Toronto, 2001/02 - 2005/06**

| Etiological agent/disease | Number of reported outbreaks (%) | | | | | |
|---|----------------------------------|------------------|----------------|----------------|-----------------|----------------|
| | Overall | 2001/02 | 2002/03 | 2003/04 | 2004/05 | 2005/06 |
| Bacteria | | | | | | |
| <i>Bordetella pertussis</i> | 7 (1) | 0 (0) | 2 (3) | 2 (1) | 1 (<1) | 2 (2) |
| <i>Chlamydia pneumoniae</i> | 4 (<1) | 0 (0) | 1 (2) | 3 (2) | 0 (0) | 0 (0) |
| <i>Mycobacterium tuberculosis</i> | 2 (<1) | 1 (<1) | 0 (0) | 0 (0) | 1 (<1) | 0 (0) |
| <i>Legionella</i> spp. | 1 (<1) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 1 (<1) |
| <i>Mycoplasma pneumoniae</i> | 1 (<1) | 0 (0) | 0 (0) | 0 (0) | 1 (<1) | 0 (0) |
| <i>Streptococcus pneumoniae</i> | 1 (<1) | 0 (0) | 0 (0) | 1 (<1) | 0 (0) | 0 (0) |
| Total - Bacteria | 16 (2) | 1 (<1) | 3 (5) | 6 (3) | 3 (2) | 3 (2) |
| Viruses | | | | | | |
| Influenza A | 205 (31) | 32 (31) | 5 (8) | 60 (34) | 81 (44) | 27 (21) |
| Respiratory syncytial virus (RSV) | 55 (8) | 9 (9) | 3 (5) | 19 (11) | 16 (9) | 8 (6) |
| Influenza B | 34 (5) | 2 (2) | 0 (0) | 0 (0) | 30 (16) | 2 (2) |
| Parainfluenza virus type 3 | 24 (4) | 2 (2) | 5 (8) | 5 (3) | 7 (4) | 5 (4) |
| Enterovirus | 19 (3) | 0 (0) | 0 (0) | 2 (1) | 2 (1) | 15 (12) |
| Parainfluenza virus type 1 | 15 (2) | 2 (2) | 2 (3) | 2 (1) | 1 (<1) | 8 (6) |
| Rhinovirus | 13 (2) | 1 (<1) | 1 (2) | 3 (2) | 5 (3) | 3 (2) |
| Parainfluenza virus type 2 | 6 (1) | 0 (0) | 0 (0) | 2 (1) | 0 (0) | 4 (3) |
| Parainfluenza virus type 4 | 3 (<1) | 0 (0) | 2 (3) | 0 (0) | 1 (<1) | 0 (0) |
| Measles | 2 (<1) | 0 (0) | 1 (2) | 1 (<1) | 0 (0) | 0 (0) |
| Adenovirus | 1 (<1) | 0 (0) | 0 (0) | 1 (<1) | 0 (0) | 0 (0) |
| Chickenpox | 1 (<1) | 0 (0) | 0 (0) | 0 (0) | 1 (<1) | 0 (0) |
| Human metapneumovirus | 1 (<1) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 1 (<1) |
| Severe acute respiratory syndrome (SARS) corona virus | 1 (<1) | 0 (0) | 1 (2) | 0 (0) | 0 (0) | 0 (0) |
| Total - Viruses | 380 (58) | 48 (47) | 20 (34) | 95 (54) | 144 (77) | 73 (57) |
| Unknown etiology | 285 (44) | 56 (54) | 40 (68) | 79 (45) | 52 (28) | 58 (45) |
| Total number of outbreaks | 652 | 103 | 59 | 175 | 186 | 129 |

*Between 2001/02 and 2005/06, multiple agents were isolated from 29 outbreaks. Therefore, the total number of agents (identified and unknown) will differ from the total number of outbreaks.

**Table 8.6: Number and proportion of reported respiratory outbreaks* by risk setting.
Toronto, 2001/02 - 2005/06**

| Risk setting | Number of reported outbreaks (%) | | | | | | | | | | | |
|----------------------------------|----------------------------------|-------------|------------|--------------|-----------|--------------|------------|-------------|------------|--------------|------------|--------------|
| | Overall | | 2001/02 | | 2002/03 | | 2003/04 | | 2004/05 | | 2005/06 | |
| Institutional | | | | | | | | | | | | |
| Long term care facility | 533 | (82) | 71 | (69) | 48 | (81) | 150 | (86) | 148 | (80) | 116 | (90) |
| Chronic care hospital | 45 | (7) | 3 | (3) | 4 | (7) | 15 | (9) | 16 | (9) | 7 | (5) |
| Child care centre | 35 | (5) | 22 | (21) | 1 | (2) | 5 | (3) | 5 | (3) | 2 | (2) |
| Acute care hospital | 28 | (4) | 7 | (7) | 2 | (3) | 2 | (1) | 13 | (7) | 4 | (3) |
| School/college /university | 7 | (1) | 0 | (0) | 4 | (7) | 1 | (<1) | 2 | (1) | 0 | (0) |
| Other (e.g. shelter, group home) | 4 | (<1) | 0 | (0) | 0 | (0) | 2 | (1) | 2 | (1) | 0 | (0) |
| Total - Institutional | 652 | (99) | 103 | (100) | 59 | (100) | 175 | (99) | 186 | (100) | 129 | (100) |


*Although SARS transmission was reported in chronic care hospital and community settings, given that the majority of SARS transmission occurred within acute care hospitals, the SARS outbreak has been included as a single outbreak occurring within this risk setting category.

*No community respiratory outbreaks were reported

**Table 8.7: Respiratory outbreaks by risk setting and average size.
Toronto, 2005/06**

| Risk setting | Total number | | | Mean per outbreak | |
|------------------------------|--------------|-------------|-----------|-------------------|--------------|
| | Outbreaks | Cases | Deaths | Cases | Deaths |
| Institutional | | | | | |
| Long term care facility | 116 | 2199 | 67 | 19 | <1 |
| Chronic care hospital | 7 | 81 | 1 | 12 | <1 |
| Acute care hospital | 4 | 38 | 3 | 10 | <1 |
| Child care centre | 2 | 3 | 0 | 2 | 0 |
| Total - Institutional | 129 | 2321 | 71 | 18 | <1 |

**Figure 8.2: Number of reported respiratory outbreaks by month.
Toronto, 2005/06 compared to 2000/01 - 2004/05 mean**



Highlights: Other Outbreaks

- There were five other outbreaks reported in Toronto in 2005 (Table 8.8). Four were caused by Methicillin-resistant *Staphylococcus aureus* (MRSA) and the fifth was caused by Vancomycin-resistant enterococci.

**Table 8.8: Other reported outbreaks by agent/disease.
Toronto, 2001 - 2005**

| Agent/disease | Number of reported outbreaks | | | | | |
|--|------------------------------|----------|----------|----------|----------|----------|
| | Overall | 2001 | 2002 | 2003 | 2004 | 2005 |
| <i>Streptococcus pyogenes</i> , group A streptococci (GAS) | 6 | 2 | 2 | 1 | 1 | 0 |
| Methicillin-resistant <i>Staphylococcus aureus</i> (MRSA) | 5 | 0 | 0 | 1 | 0 | 4 |
| Vancomycin-resistant enterococci | 3 | 0 | 0 | 2 | 0 | 1 |
| Infectious syphilis | 1 | 0 | 1 | 0 | 0 | 0 |
| <i>Mycobacterium abscessus</i> | 1 | 0 | 1 | 0 | 0 | 0 |
| <i>Neisseria meningitidis</i> | 1 | 1 | 0 | 0 | 0 | 0 |
| <i>Stenotrophomonas maltophilia</i> | 1 | 1 | 0 | 0 | 0 | 0 |
| West Nile virus | 1 | 0 | 1 | 0 | 0 | 0 |
| Total | 19 | 4 | 5 | 4 | 1 | 5 |

Highlights: Disease Specific Outbreak Investigation

Cyclosporiasis

A cluster of cyclosporiasis cases was detected in Toronto in April of 2005. Cyclosporiasis is caused by infection with the rare parasite *Cyclospora cayetanensis*, which is acquired through ingesting fecally contaminated fresh produce or water. There were 40 cases detected and all were part of a group who attended a Toronto school retreat just west of the City. Epidemiologic analyses revealed a significant association with consumption of a pasta salad dish which contained fresh basil. The basil was believed to have originated in a Latin American country.

Legionellosis

A respiratory outbreak reported to TPH in September of 2005 from a long term care facility was caused by exposure to *Legionella pneumophila* bacteria. The confirmation of bacteria in the cooling tower that matched clinical isolates confirmed the source of the outbreak. There were 134 identified cases of legionellosis linked to this outbreak (38 were lab-confirmed), making it one of the largest documented *Legionella* outbreaks affecting a long term care facility. A total of 23 deaths were reported among the frail and elderly population exposed in this outbreak.

Salmonella Phage Type (PT) 13

A total of 32 health units and 522 (162 were Toronto residents) laboratory confirmed cases of *Salmonella enteritidis* PT13 were part of a province-wide outbreak related to consumption of mung bean sprouts. A sole local supplier of the sprouts was implicated as the source of contamination for what is the largest documented salmonellosis outbreak related to mung bean sprouts.

References

**Communicable Diseases
in Toronto**

2005

References

The resources and publications listed below by report section were referenced in the creation of this report.

Diseases Preventable by Routine Vaccination

Bang H, Glismann S, Muscat M. *Measles in Europe in 2001-2002*. Eurosurveillance Monthly June 2003; Vol. 8. No. 6. By internet: URL: <http://www.eurosurveillance.org/em/v08n06/0806-221.asp>

Centers for Disease Control and Prevention. *Epidemiology of Measles – United States, 2001-2003*. MMWR 2004; Vol. 53. Mo. 31. By internet: URL: <http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5331a3.htm>

Ministry of Health and Long-Term Care. *New Vaccinations to Keep Ontarians Healthy*. By internet: URL: http://www.health.gov.on.ca/english/providers/program/immun/prof_immunization.html

Nsubuga J, Winter AL. *Summary Report of the 2002/03 Ontario "Influenza and Respiratory Outbreak Surveillance Season"*. PHERO 2004; Vol. 15 No. 2. By internet: URL: http://www.health.gov.on.ca/english/providers/pub/phero/pdf/2004/phero_0404.pdf

Public Health Agency of Canada. *Vaccine Preventable Diseases*. By internet: URL: <http://www.phac-aspc.gc.ca/im/vpd-mev/index.html>

Diseases Transmitted by Direct Contact and Respiratory Routes

Centers for Disease Control and Prevention, National Center for Infectious Diseases. *Group B Strep Disease*. November 2002. By internet: URL: http://www.cdc.gov/groupBstrep/general/gen_public_faq.htm

Diaz R. *Invasive Meningococcal Disease in Ontario, January 1, 2002 to December 31, 2003*. PHERO 2004; Vol. 15 No. 1. By internet: URL: http://www.health.gov.on.ca/english/providers/pub/phero/pdf/2004/phero_0104.pdf

Immunization Action Coalition. *Vaccine Information for the Public and Health Professionals: Pneumococcal Disease*. By internet: URL: <http://www.vaccineinformation.org/pneumchild/qandadis.asp>

National Foundation for Infectious Disease. *Facts About Pneumococcal Disease*. By internet: URL: <http://www.nfid.org/factsheets/pneumofacts.html>

Public Health Agency of Canada. *Tuberculosis in Canada, Pre-Release 2004*. By internet: URL: <http://www.phac-aspc.gc.ca/publicat/tbcan-pre04/index.html>

Public Health Agency of Canada, *Tuberculosis in Canada, Pre-Release 2005*. By internet: URL: <http://www.phac-aspc.gc.ca/publicat/tbcan-pre05/index.html>

Enteric, Food and Waterborne Diseases

Health Canada. *Canadian Integrated Surveillance Report: Salmonella, Campylobacter, pathogenic E.coli and Shigella, from 1996 to 1999*. CCDR 2003; 29S1. By internet: URL: <http://www.phac-aspc.gc.ca/publicat/ccdr-rmtc/03vol29/29s1/index.html>

Sexually Transmitted and Blood-borne Diseases

Canadian AIDS Society and Health Canada, Centre for Infectious Disease Prevention and Control. *A Guide to HIV/AIDS Epidemiological and Surveillance Terms*. November 2001. By internet: URL: <http://www.phac-aspc.gc.ca/publicat/haest-tesvs/index.html>

Gully M. *Reported LGV cases for Toronto and Canada 2005*. Public Health Agency of Canada. September 2006. (Personal communication).

Okura T. *Syphilis Screen Testing: Data for Toronto Public Health Laboratory*. Ministry of Health and Long-Term Care. June 2006. (Personal communication).

Public Health Agency of Canada. *HIV and AIDS in Canada: Surveillance Report to December 31, 2005*. By internet: URL:
<http://www.phac-aspc.gc.ca/publicat/aids-sida/haic-vsac1205/index.html>

Public Health Agency of Canada. *Lymphogranuloma Venereum (LGV) Epi Update, July 2006*. By internet: URL:
http://www.phac-aspc.gc.ca/publicat/epiu-aepi/std-mts/lgv_e.html

Remis RS. Ontario HIV Epidemiologic Monitoring Unit. November 2006. (Personal communication).

Outbreaks

Centers for Disease Control and Prevention, National Center for Infectious Diseases. *CDC Technical Fact Sheet About Noroviruses*. By internet: URL:
<http://www.cdc.gov/ncidod/dvrd/revb/gastro/norovirus-factsheet.htm>

Do MT, Ratnasingham S. *Review of Reported Respiratory Infection Outbreaks in Institutions in Ontario 2001-2003*. PHERO 2004; Vol. 15 No. 3. By internet: URL:
http://www.health.gov.on.ca/english/providers/pub/phero/pdf/2004/phero_0504.pdf

Vectorborne and Zoonotic Diseases

Centers for Disease Control and Prevention, National Center for Infectious Diseases, Division of Bacterial and Mycotic Diseases. *Brucellosis – General Information*. By internet: URL:
http://www.cdc.gov/ncidod/dbmd/diseaseinfo/brucellosis_g.htm

Centers for Disease Control and Prevention, National Center for Infectious Diseases, Division of Bacterial and Mycotic Diseases. *Brucellosis – Technical Information*. By internet: URL:
http://www.cdc.gov/ncidod/dbmd/diseaseinfo/brucellosis_t.htm

General CD Summary Reports from other Public Health Departments

Haldimand-Norfolk Health Unit. *Haldimand-Norfolk Communicable Diseases Report 2004*. By internet: URL:
http://www.hnhu.org/images/reports/cd_report_online.pdf

Public Health Agency of Canada. *Notifiable Diseases On-Line*. By internet: URL:
http://dsol-smed.phac-aspc.gc.ca/dsol-smed/ndis/index_e.html

Region of Peel. *Communicable Disease 2003 – A Peel Health Status Report*. 2003. By internet: URL:
<http://www.region.peel.on.ca/health/health-status-report/comm-dis-report/comm-dis03-index.htm>

Other

Statistics Canada. *Annual Demographic Estimates: Canada, Provinces and Territories, 2005 – 2006*. Demography Division. Catalogue no. 91-215-XIE. September, 2006. By internet: URL:
<http://dsp-psd.pwgsc.gc.ca/Collection/Statcan/91-215-X/91-215-XIE2006000.pdf>

Toronto Public Health. *Communicable Diseases in Toronto 2004*. City of Toronto: Toronto, Canada. February 2006. By internet: URL:
http://www.toronto.ca/health/communicable_diseases/pdf/communicable_diseases2004.pdf

Appendices

**Communicable Diseases
in Toronto**

2005

Data Sources and Technical Notes

Data Sources

Toronto data

Legal authority to collect

All reports of communicable disease for Toronto included in this summary were collected by Toronto Public Health (TPH) under the authority of the Health Protection and Promotion Act, Ontario Regulations 559/91, which mandates notification of all confirmed or suspect reportable diseases to the Medical Officer of Health where the patient resides (see page 189 for latest list). Reports of diseases included in this document are for individuals who lived in Toronto at the time of their illness.

Dates

Information on past episodes of disease can be added or updated at any time. The information summarized in this report represents what was known to TPH at the following times, by disease(s):

- 1) HIV data were extracted in August 2006,
- 2) All other Toronto data summarized in this report were extracted in May 2006.

Information Systems

Note: the publication of this report was delayed due to the adoption of a new information system and the associated reconciliation issues when converting data between two disparate systems.

Reportable Disease Information System (RDIS)

In 2005, each public health unit in Ontario utilized the Ministry of Health and Long-Term Care's (MOHLTC) Reportable Disease Information System (RDIS) to record and transmit aggregate-level information to the Province's Infectious Disease Branch for the purpose of provincial and national surveillance. RDIS was first introduced in Ontario in 1990 and had been used to store all reportable disease information for the city of Toronto up until and including November 27, 2005. This system was used to record information for all reportable diseases except SARS.

Integrated Public Health Information System (iPHIS)

As of November 28, 2005, Toronto Public Health joined the other 35 health units in Ontario in fully implementing the new provincial communicable disease information system,

integrated Public Health Information System (iPHIS). Each public health unit in Ontario utilized iPHIS to record and share reportable disease data with the province's Infectious Disease Branch for the purpose of provincial and national surveillance. With the exception of chickenpox all reportable disease data are stored in and retrieved from iPHIS.

Case and Contact Management System (CCMS)

During the SARS outbreak in 2003, Toronto developed an interim database to assist staff with tracking the large volumes of suspect cases and contacts that were being reported and needed follow-up. All SARS data summarized in this report are stored in the CCMS.

CDSU Outbreak Log Database (COLD)

The data presented in the Outbreak section of this report were retrieved from COLD, which was created in 1998. Summary data for all institutional and non-institutional outbreaks in Toronto are captured in the database. It was redesigned in 2004 to automatically report on active daily institutional and weekly non-institutional outbreaks. In Ontario, respiratory outbreaks in institutions became formally reportable in 2001. Toronto Public Health, however, began routine collection of these data in 1998.

Ministry of Health and Long-Term Care's Summary Chickenpox Reporting System

(Used to report November and December 2005 chickenpox cases).

The MOHLTC implemented a new system to capture aggregate data on chickenpox cases with a date of onset on or after November 1, 2005 as iPHIS did not offer the ability to collect aggregate information on chickenpox cases.

Ontario and Canadian data

Ontario and Canadian data summarized in this report were acquired from multiple sources:

Ontario

With the exception of HIV and tuberculosis, all disease incidence data for 1995 through 2005 were provided directly by the MOHLTC (as of September 2006) with the proviso that they are provisional and subject to change. Disease

incidence data for 2005 was not available from the MOHLTC for HIV, chickenpox, encephalitis, rubella, syphilis late latent and tuberculosis. HIV data for 2005 were obtained from the *Ontario HIV Epidemiologic Monitoring Unit*. Tuberculosis data for 1995 to 2005 were obtained from *Tuberculosis in Canada: Pre-release. 2005*. In this report 2005 TB cases and rates are provisional until publication of the *Tuberculosis in Canada – 2005 Annual Report*.

With the exception of HIV, all STI data for 2005 exclude cases under ten years of age.

Canada

With the exception of HIV, tuberculosis and influenza, all disease incidence rates for 1995 through 2005 were provided directly by the Public Health Agency of Canada (PHAC) – Population and Public Health Branch (PPHB) (as of October 2006) with the proviso that summaries for 2005 are provisional and subject to change. HIV data for 1995 to 2005 were obtained from *HIV and AIDS in Canada, Surveillance Report to June 30, 2005*. Tuberculosis data for 1995 to 2005 were obtained from *Tuberculosis in Canada: Pre-release. 2005*. In this report, 2005 cases and rates are provisional until publication of the *Tuberculosis in Canada – 2005 Annual Report*. Influenza data for 1995 through 2005 were provided directly by PHAC-PPHB (as of November 2006) with the proviso that summaries for 2004 to 2005 are provisional and subject to change.

Population data

Incidence rates for Toronto and Ontario were calculated using population estimates provided by Statistics Canada. These estimates adjust for census under-coverage, and include non-permanent residents (e.g. visa students, refugee claimants). Ontario and Toronto rates calculated for 1995-1999 were based on the July 2002 postcensal population estimates, while Toronto rates calculated for 2000-2005 were based on the February 2005 postcensal estimates, and Ontario rates calculated for 2003-2005 were based on the September 2006 postcensal estimates.

Data Limitations and Technical Notes

RDIS to iPHIS conversion

Some of the information recorded in RDIS was not converted to iPHIS, therefore RDIS data was used for cases reported prior to November 28th, 2005. RDIS data were used to report:

- Birth origin
- Complications
- Deaths
- Hospitalized cases
- Outbreak associated cases
- Risk factors
- Risk setting
- Source of infection
- TB drug resistance, treatment status and method of diagnosis
- Travel history
- Vaccination history

iPHIS data were selected over RDIS data where both were available.

To report source of infection, risk factors and risk settings in a manner that was consistent with previous annual reports the exposures, behavioural and medical risk factor categories recorded in iPHIS were matched to the comparable categories of source of infection, risk setting and risk factors in RDIS. Those categories of iPHIS that did not match to RDIS were then reclassified as 'other'.

AIDS data are not summarized in this year's report because the AIDS diagnosis date was not converted from RDIS to iPHIS. This date is used in surveillance to signify the beginning of illness for AIDS cases.

Amendments from the previous annual report

General considerations

Canadian rates may differ from the preceding 2004 report since the calculated rates were received directly from PHAC-PPHB for this report. Previous reports were based on case counts received by PHAC that were calculated by TPH.

Sexually Transmitted and Bloodborne Diseases

Syphilis and HIV coinfection rate calculations

were corrected to ensure that only syphilis episodes reported *following* the HIV episode date were included as coinfecting cases. As a result, HIV coinfection rates for infectious syphilis and late latent syphilis in previous reports may differ from those reported in the present report.

Reporting of disease

The number of cases and rates are underreported for several reasons including:


Not all infections with a reportable communicable disease cause clinical signs and symptoms.

Individuals who do experience illness do not all seek medical care.

Health care providers do not always recognize that a diagnostic laboratory test is warranted.

Reports rely on a passive surveillance system, wherein laboratories, physicians, other health care providers, and institution administrators are entrusted to know the regulations, recognize a disease they are suspecting is on the reportable disease list, and promptly inform public health.

The following burden of illness pyramid is often used to illustrate the fraction of communicable diseases that may actually get reported through traditional surveillance, and the type of surveys that might be useful to gain a better understanding of true disease burden.



Source: CDC website:
<http://www.cdc.gov/foodnet/Surveys.htm>

The proportion of cases that are not reported varies for each disease. For diseases with mild clinical manifestations such as some of the

enteric diseases, the proportion of unreported cases may be quite high. More clinically severe infectious, such as meningococcal disease and invasive group A streptococcus are likely more accurately reflected in surveillance data.

Case definitions

Suspect cases of a reportable communicable disease are most commonly identified through laboratory notification of confirmed test results. Physicians are also required to report cases that fulfill laboratory and/or clinical case definitions.

Public health staff assesses all suspect cases to see if they meet a case definition provided by the MOHLTC for the purposes of reporting. Case definitions are based on laboratory test results and/or clinical diagnostic criteria. Consistent application of the MOHLTC case definitions ensures that disease rates are comparable from region to region within Ontario, but does not necessarily apply to other provinces or the rest of Canada.

Episode dates

Dates for episodes of diseases refer to the best estimates for when the disease was acquired. The date of symptom onset is usually the preferred date, but when that is unavailable the date a specimen was collected or the date the report was made to TPH are used.

Data revisions

In some instances, the annual number of reported cases may change in succeeding annual publications due to periodic data quality assurance checks and corrections that result in the reclassification of individual reports.

Lag in reporting

Although theoretically the lag in reporting of disease can be as short as the time it takes to collect a specimen, carry out a diagnostic test, and inform the MOH, this is not the case for some diseases. As such, historical data for Toronto, Ontario and Canada may change in future publications to reflect additional reports that are made for diseases that were acquired in previous years. For example, tuberculosis (TB)

can take up to two years to be reported from the time they were known to be acquired.

Place disease acquired

It should be recognized that the city where a disease was diagnosed may differ from where it was acquired. The known epidemiology and geographic distribution of each disease should be considered to truly understand the likelihood of community transmission (e.g. there is no evidence that malaria has been transmitted locally in recent years, due to the natural habitat of its vector). Cases summarized in this report reflect the city of residence of each individual at the time of their diagnosis, not necessarily where they acquired the disease.

Reliability of rare reports

Rates based on large numbers generally yield stable estimates of the true underlying rate. Conversely, rates based on small numbers may fluctuate widely from year to year, even when there is no meaningful change in the true rate. Therefore, rates based on small numbers of reports, and instances of rare events, are more likely to be unstable, and hence less reliable. The observation of zero reports in a specific sub-group or category can be especially uncertain. As such, rates based on diseases, years, and categories (e.g. males of a certain age group) with few or no reports should be interpreted with caution. Diseases that were seldom reported over a long period of time have been presented separately in this report.

Crude rates

Rates of disease are reported as crude rates. Although it may be more epidemiologically sound, rates were not adjusted to reflect the age distribution effects for Toronto's population. Crude rates and numbers were reported to allow a direct comparison with the relevant published data from the MOHLTC and PHAC.

Underestimated case fatality rates

Data for the field capturing deceased status were frequently missing. This was taken to indicate no death occurred, but may have resulted in an underestimate in the calculation of some case fatality rates.

With the exception of AIDS, cases of most diseases are not followed indefinitely by public health, and illness may be a contributing factor in deaths that occur in much later years. Public health authorities are not notified of these deaths and as a result, case fatality rates may be underestimated.

Underestimated hospitalization rates and proportion of outbreak associated cases

Data for the fields capturing hospitalization and outbreak association status were frequently missing. For these fields, missing data were assumed to indicate negative entries. This may have resulted in an underestimate in the calculation of hospitalization rates and the proportion of outbreak associated cases.

Population estimates

The population estimates used to calculate rates are based on a set of assumptions on the patterns of fertility, mortality, immigration, refugees, and internal mobility of population.

Therefore, the quality of the population estimates is dependent on the validity of these assumptions over time.

Missing data

Instances with large proportions of missing information for a particular data field (risk factor, risk setting, or source of infection for some diseases), could lead to summaries that may not be representative of the community. The proportions of available and missing data are indicated for each variable summarized.

Risk settings/risk factors

In RDIS, the risk setting and risk factor variables provide investigators with a pre-defined set of categories from which to choose. The specific subset of categories varies by disease but is often not adequate or specific enough. In some cases, the available categories are not consistent with standard categories used by the larger public health surveillance community or they may not be consistent with categories used by members of the community in which the disease is occurring. For example, the risk

factor category 'Homosexual/Bisexual' was not available as a valid RDIS risk factor category for gonorrhoea until 2002.

Unlike in RDIS where risk factors were specific to a disease episode, in iPHIS, risk factors are client specific. As a result, for clients with more than one disease episode it is not possible to determine which risk factors are related to which disease episode. These clients have been excluded from the risk factor summary tables. Therefore, risk factors associated with multiple infections may be underestimated.

Etiologic agents and outbreaks

In over half of the outbreaks reported to Toronto Public Health in each of the last five years, the responsible agent was unknown. There are many possible explanations why a responsible agent is not identified during an outbreak investigation. It is possible that for some of these outbreaks the agents known to cause illness may not have been identified because laboratory investigations were late or incomplete. In others, the responsible pathogen may have escaped detection even after thorough laboratory investigation, either because the pathogen may not have been recognized as a cause of disease or because the pathogen could not be identified by available laboratory techniques.

Interpreting differences between rates

Any differences noted between groups of data (years, age groups, sex, etc.) are not implied to be statistically significant. Instead this report describes trends and compares crude rates and numbers. All comparative words are intended to describe absolute differences (e.g. four reports were less than five) with no statistical meaning. Any extrapolations about statistical inferences and decisions that might require this level of comparison are not warranted by what is presented in this report.

HIV infections and AIDS cases

Prior to 2002, only AIDS cases and not HIV infections were reportable in Ontario. In response to this change Toronto Public Health is continuing to review all of the HIV infections and AIDS

cases that have ever been entered in RDIS. The results of this review may lead to changes in the number of HIV infections and AIDS cases reported in future reports.

This report includes HIV infections that have occurred among Toronto residents and those positive anonymous HIV test results that were identified in RDIS or iPHIS as having been received from Toronto-area official anonymous test sites. Due to discrepancies associated with data conversion from RDIS to iPHIS, AIDS data are not available for reporting.

Outbreak associated cases

The number of outbreak associated cases reported in some disease sections may not match the number reported in the outbreak section. The outbreak associated cases reported in the disease sections are primarily laboratory confirmed cases. In addition, some cases were part of family outbreaks that were not included in the outbreak section. □

Reportable Diseases 2005

The following specified Reportable Communicable Diseases (Ontario Regulations 559/91 and amendments under the Health Protection and Promotion Act) are to be reported to the local Medical Officer of Health:

Acquired Immunodeficiency Syndrome (AIDS)

Amebiasis

- **Anthrax**
- **Botulism**
- **Brucellosis**

Campylobacter enteritis

Chancroid

Chickenpox (Varicella)

Chlamydia trachomatis infections

- **Cholera**
- **Cryptosporidiosis**
- **Cyclosporiasis**

Cytomegalovirus infection, congenital

- **Diphtheria**
- **Encephalitis, including:**
 - **1. Primary, viral**
 - 2. Post-infectious
 - 3. Vaccine-related
 - 4. Subacute sclerosing panencephalitis
 - 5. Unspecified

- **Food poisoning, all causes**
- **Gastroenteritis, institutional outbreaks**
- **Giardiasis, except asymptomatic cases**

Gonorrhoea

- ***Haemophilus influenzae* b disease, invasive**
- **Hantavirus Pulmonary Syndrome**
- **Hemorrhagic fevers, including:**
 - 1. Ebola virus disease**
 - 2. Marburg virus disease**
 - 3. Other viral causes**

- **Hepatitis, viral**
 - **1. Hepatitis A**
 - 2. Hepatitis B
 - 3. Hepatitis C
 - 4. Hepatitis D (Delta hepatitis)

Herpes, neonatal

Influenza

- **Lassa fever**
- **Legionellosis**

Leprosy

- **Listeriosis**

Lyme disease

Malaria

- **Measles**

- **Meningitis, acute**

- **1. Bacterial**
 - 2. Viral
 - 3. Other

- **Meningococcal disease, invasive**

Mumps

Ophthalmia neonatorum

- **Paratyphoid fever**

Pertussis (Whooping Cough)

- **Plague**
- **Poliomyelitis, acute**

Psittacosis/Ornithosis

- **Q fever**

- **Rabies**

- **Respiratory infection outbreaks in institutions**

Rubella

Rubella, congenital syndrome

Salmonellosis

- **Severe Acute Respiratory Syndrome (SARS)**

- **Shigellosis**

- **Smallpox**

- **Streptococcal infections, Group A invasive**

Streptococcal infections, Group B neonatal

Streptococcus pneumoniae, invasive

Syphilis

Tetanus

Transmissible Spongiform Encephalopathy, including:

1. Creutzfeldt-Jakob Disease
2. Gerstmann-Sträussler-Scheinker Syndrome
3. Fatal Familial Insomnia
4. Kuru

Trichinosis

Tuberculosis

- **Tularemia**

Typhoid fever

- **Verotoxin-producing *E. coli* infection indicator conditions including Hemolytic Uremic Syndrome (HUS)**

- **West Nile virus illness, including:**

- 1. West Nile fever**
- 2. West Nile neurological manifestations**

- **Yellow fever**

Yersiniosis

Note: Diseases marked “•” (and influenza in institutions) should be reported immediately to the Medical Officer of Health by telephone. Other diseases are to be reported by the next working day by fax or mail.

Glossary of Terms

ACTIVE TRANSMISSION

The spread of an infectious agent from one person to another.

CASE

A case is an episode of disease. Each reportable disease has a case definition, created by the Ministry of Health and Long-Term Care, which outlines the criteria necessary to confirm that episode of disease.

CASE-FATALITY RATE

The proportion of persons with a particular condition (cases) who die from that condition in a given period of time. The denominator is the total number of cases in the time period; the numerator is the number of deaths among those cases and is determined for each disease based on RDIS category.

CARRIER

A person or animal without evident clinical disease who harbours an infectious agent and is able to transmit the agent to others.

COINFECTION

Having two infections at the same time. For example, a person infected with both human immunodeficiency virus (HIV) and tuberculosis (TB), has a coinfection. With coinfection the progression of both or either disease can potentially be accelerated as a result of infection with the other disease.

CONFIDENCE INTERVAL (CI)

In this report, 95% confidence intervals are used to demonstrate the annual variation in the mean number of cases for a particular disease, for a given month, during the period 1995 – 2004. The term confidence interval is abbreviated as CI.

CONTACT

A person who has been in association with an infected person so as to have had an opportunity to acquire the infection.

DIRECT TRANSMISSION

The immediate transfer of an infectious agent from a reservoir to a host by direct contact or droplet spread (short-ranged large droplets produced by sneezing, coughing or talking).

ENDEMIC

The constant presence of a disease in a given geographic area or within a given population. It may also refer to a disease that is usually present at a relatively high prevalence and incidence rate in comparison with other areas or populations.

In the area of HIV/AIDS surveillance, there is another definition of the term endemic that is often used. Endemic may be used to refer to a country where the principal way people become infected with HIV is through heterosexual contact.

EXPOSURE CATEGORY

In HIV/AIDS surveillance, exposure category refers to the most likely way a person became infected with the HIV virus.

The exposure categories used in this report are explained below:

MSM

Men who report having had sex with men; this includes men who report either homosexual or bisexual.

MSM/IDU

Men who have had sex with men and have injected drugs.

IDU

People who inject drugs, also called injection drug users.

Perinatal transmission

The transmission of HIV from an HIV-infected mother to her child either

- during pregnancy
- during labour
- at birth
- after birth through breastfeeding

Clotting factor/transfusion pre 1985

- Recipient of Blood/Blood Products before 1985
- Recipient of Clotting Factor before 1985

HIV-endemic

People who were born in a country in which the principal means of HIV transmission is heterosexual contact.

HET-partner

Heterosexual contact with a person at risk: a person who reports heterosexual contact with another person who is either HIV-infected or who is at an increased risk for HIV infection. A person at an increased risk for HIV infection would include someone who is an injection drug user, a bisexual man, a person born in a country in which the predominant means of HIV transmission is heterosexual contact, a person with hemophilia/coagulation disorder, or a person with suspected HIV infection or AIDS.

NIR-HET

If heterosexual contact is the only risk factor reported and nothing is known about the HIV-related risk factor(s) associated with the partner, the case would be classified as No Identified Risk-Heterosexual (NIR-HET).

Other

Used to classify a person whose mode of HIV transmission is known but who cannot be classified into any of the major exposure categories listed above (e.g. occupational exposure, other medical procedure, non-medical or non-occupational exposure, blood transfusion after 1985, clotting factor after 1985).

Unknown

Where the history of exposure to HIV through any of the other categories is unknown, or there is no reported history. This exposure category may include:

- people who are currently being followed up
- people whose exposure history is incomplete because they have died
- people whose exposure history is incomplete because they declined to be interviewed or were lost to follow-up
- people who cannot identify any mode of transmission

GROUPED MEAN

The mean for grouped data is

$$\text{Mean} = \frac{\sum xf}{\sum f}$$

where:

The midpoint of each class interval is denoted by x_1, x_2, \dots, x_n .

The frequencies for each interval are denoted by f_1, f_2, \dots, f_n .

xf is the product of the midpoint of the interval, x , multiplied by the frequency, f , of the same interval. This approximation is required because we do not know the exact age of each case. As a result, we must treat all of the ages as if they were midpoints for their interval.

For example in the case where the grouped mean is calculated for a variable with 7 intervals:

$$\text{Mean} = \frac{(xf_1 + xf_2 + xf_3 + xf_4 + xf_5 + xf_6 + xf_7)}{(f_1 + f_2 + f_3 + f_4 + f_5 + f_6 + f_7)}$$

GROUPED MEDIAN

The median is the value that divides a set of numbers exactly in half when they are placed in order from lowest to highest. The grouped median can be calculated as follows:

$$\text{Median} = L + I \frac{(N/2 - F)}{f}$$

where:

L = lower limit of the interval containing the median

I = width of the interval containing the median

N = total number of respondents

F = cumulative frequency corresponding to the lower limit

f = number of cases in the interval containing the median

INCIDENCE

Incidence is the number of new events of a specific disease during a specified period of time in a specified population.

INCIDENCE RATE

The incidence rate is the rate at which new events, or new cases, occur in a specified time in a defined population that is "at risk" of experiencing the condition or event.

$$\text{Incidence rate} = \frac{\text{Number of new events in a specified period}}{\text{Number of people at risk in this period}}$$

INDIRECT TRANSMISSION

The transmission of an infectious agent carried from a reservoir to a susceptible host by air particles or by living (vector) or non-living (vehicle) intermediaries.

LUNG TUBERCULOSIS

This term refers to tuberculosis that was reported as pulmonary, primary pulmonary, miliary, or other respiratory tuberculosis.

MEAN

The mean or average is calculated by adding the individual results of the item being measured and then dividing by the total number of results.

MEDIAN

The median is the value that divides a set of numbers exactly in half when they are placed in order from lowest to highest. In other words, half of the values occur before the median and half of the values occur after the median.

MDR-TB

Tuberculosis (TB) bacteria with resistance to the two front-line drugs, isoniazid and rifampin, with or without resistance to other drugs.

NACI

The Canadian National Advisory Committee on Immunization.

NOTIFIABLE DISEASE or REPORTABLE DISEASE

A reportable disease is a disease that is considered to be of such importance to public health that its occurrence is required to be reported to public health authorities. In Ontario, regulation 599/91 under the Health Protection and Promotion Act, defines the diseases that are designated as reportable. Under this legislation, these diseases must be reported to the local public health unit by physicians, laboratories, hospitals, principals of schools, and superintendents of institutions. A list of diseases that are reportable in Ontario is provided on page 189 of this report.

OUTBREAK

When the rate of infection or illness is above what is expected for a certain place and time, and this is localized to smaller areas.

- *Enteric Outbreaks:* Outbreaks that involve instances of acute gastroenteritis (e.g. nausea, vomiting, diarrhea, etc.) and/or laboratory confirmation of agents known to cause these signs and symptoms.
- *Respiratory Outbreaks:* Outbreaks that involve instances of respiratory tract signs and symptoms (e.g. cough, congestion, malaise, etc.)

and/or laboratory confirmation of agents known to cause these signs and symptoms.

- *Other Outbreaks:* Outbreaks that involve agents and/or signs and symptoms that cannot be classified as either enteric or respiratory.

PROPORTION

A proportion is a type of ratio in which the numerator is included in the denominator. A proportion is calculated by dividing the number of people with a common characteristic at a given time period by the total population that shares the same event in the same time period. This is usually multiplied by 100 and reported as a percentage.

RANGE

The range describes the spread of values. In this report it is used to describe the highest and lowest values (e.g. youngest and oldest ages).

RATE

A rate is an expression of the frequency with which an event occurs in a defined population in a specified period of time. A rate can be calculated by dividing the number of cases in a given time period by the population at risk in the same time period and then usually multiplying the result by a multiple of ten. In this report, 100,000 is used as this number. The rate can then be expressed as the number of people with the "disease" per 100,000 population.

RISK FACTOR

A risk factor is an aspect of someone's behaviour or lifestyle, a characteristic that a person was born with, or an event that he or she has been exposed to, that is associated with acquiring a disease.

RISK SETTING

The place or environment where the case acquired the infection. The risk settings reported by cases include:

| Risk Setting | Definition |
|--|---|
| Encounter following major event | Disease acquired following attendance of a large event such as a sporting event or concert. |
| Day care | These include day care centre and nursery school. |
| Home | The location where the case resides. |

| | |
|--|--|
| Hospital | This category includes: acute care hospital, psychiatric hospital, rehabilitation hospital and chronic care hospital. |
| Local camping | Camping within Canada. |
| Local vacation property | Cottage |
| Local park or recreational area | Any outdoor area or designated park or recreational facility |
| Medical office | Medical office |
| Rendezvous outside usual domicile | A sexual encounter that occurs at a public place or environment (e.g. club, bar or bathhouse) typically used as a meeting place that is not someone's home. |
| Residential facility | A residential facility can include long-term care facilities, group home or a retirement home. |
| Restaurant or food vendor | A business establishment where meals or refreshments are served. In this report, restaurant or food vendor may also include banquet hall, catered event, social event and wedding reception. |
| School | Elementary or secondary school, college or university |
| Shelter/rooming house | Shelter/rooming house |
| Travel | Visiting or recently living in another country where the given disease is endemic |
| Workplace | The place or environment where the case works. |

SPORADIC

A disease that occurs infrequently and irregularly. This term is also used to refer to non-outbreak associated cases.

TRENDS

Trends are changes in frequencies, proportions or rates of a disease, or an event observed over time. Trends may be irregular, flat or move in one direction. Trends can be expressed in many forms, including tables, graphs and pie charts.

VECTOR

An animate intermediary in the indirect transmission of an agent that carries the agent from a reservoir to a susceptible host. □

**Appendix Table 1: Number of cases and incidence rates* by disease.
Toronto, 1995 - 2005**

| Disease | 1995 | | 1996 | | 1997 | | 1998 | | 1999 | | 2000 | | 2001 | | 2002 | | 2003 | | 2004 | | 2005 | | | |
|---|------|-------|------|-------|------|-------|------|-------|------|-------|------|-------|------|-------|------|-------|------|-------|------|-------|------|-------|----|-----|
| | # | Rate | # | Rate | # | Rate | # | Rate | # | Rate | # | Rate | # | Rate | # | Rate | # | Rate | # | Rate | # | Rate | | |
| AIDS | NA | | NA | | NA | | NA | | NA | | NA | | NA | | NA | | NA | | NA | | NA | | NA | |
| HIV | 637 | 26.2 | 535 | 21.7 | 448 | 18.0 | 413 | 16.5 | 432 | 17.1 | 456 | 17.9 | 511 | 19.7 | 618 | 23.6 | 574 | 22.0 | 569 | 21.9 | 555 | 21.3 | | |
| Amebiasis | 398 | 16.4 | 363 | 14.7 | 459 | 18.4 | 381 | 15.2 | 355 | 14.1 | 488 | 19.2 | 400 | 15.4 | 380 | 14.5 | 426 | 16.3 | 327 | 12.6 | 376 | 14.4 | | |
| Botulism | 1 | <0.1 | 0 | 0.0 | 0 | 0.0 | 1 | <0.1 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 2 | <0.1 | 2 | <0.1 | 0 | 0.0 | | |
| Brucellosis | 1 | <0.1 | 1 | <0.1 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 2 | <0.1 | 2 | <0.1 | 2 | <0.1 | 2 | <0.1 | 3 | 0.1 |
| <i>Campylobacter</i> enteritis | 1804 | 74.2 | 1651 | 67.0 | 1589 | 63.8 | 1770 | 70.5 | 1312 | 52.0 | 1492 | 58.6 | 1560 | 60.2 | 1362 | 52.0 | 1125 | 43.1 | 976 | 37.5 | 997 | 38.3 | | |
| Chickenpox | 3433 | 141.2 | 2165 | 87.9 | 4049 | 162.6 | 3801 | 151.5 | 2509 | 99.4 | 3586 | 140.8 | 2689 | 103.7 | 2895 | 110.6 | 3403 | 130.3 | 5317 | 204.3 | 3668 | 140.9 | | |
| Chlamydia | 4278 | 176.0 | 4018 | 163.2 | 3923 | 157.5 | 4646 | 185.2 | 5157 | 204.2 | 5385 | 211.5 | 5732 | 221.1 | 6294 | 240.5 | 6290 | 240.8 | 6293 | 241.7 | 6497 | 249.6 | | |
| Cholera | 2 | <0.1 | 0 | 0.0 | 0 | 0.0 | 1 | <0.1 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
| Cryptosporidiosis | NR | | 29 | 1.2 | 43 | 1.7 | 18 | 0.7 | 34 | 1.3 | 44 | 1.7 | 45 | 1.7 | 37 | 1.4 | 35 | 1.3 | 49 | 1.9 | 52 | 2.0 | | |
| Cyclosporiasis | NR | | NR | | NR | | NR | | NR | | NR | | NR | | 28 | 1.1 | 14 | 0.5 | 30 | 1.2 | 48 | 1.8 | | |
| Cytomegalovirus infection, congenital | 1 | <0.1 | 3 | 0.1 | 2 | <0.1 | 3 | 0.1 | 3 | 0.1 | 1 | <0.1 | 0 | 0.0 | 0 | 0.0 | 3 | 0.1 | 0 | 0.0 | 3 | 0.1 | | |
| Encephalitis/ Meningitis: bacterial | 18 | 0.7 | 10 | 0.4 | 25 | 1.0 | 9 | 0.4 | 10 | 0.4 | 18 | 0.7 | 22 | 0.8 | 5 | 0.2 | 6 | 0.2 | 13 | 0.5 | 4 | 0.2 | | |
| Encephalitis/ Meningitis: viral | 31 | 1.3 | 27 | 1.1 | 20 | 0.8 | 50 | 2.0 | 43 | 1.7 | 40 | 1.6 | 53 | 2.0 | 85 | 3.2 | 75 | 2.9 | 47 | 1.8 | 55 | 2.1 | | |
| Encephalitis/ Meningitis: other | 19 | 0.8 | 9 | 0.4 | 1 | <0.1 | 5 | 0.2 | 3 | 0.1 | 2 | <0.1 | 5 | 0.2 | 4 | 0.2 | 5 | 0.2 | 7 | 0.3 | 6 | 0.2 | | |
| Encephalitis/ Meningitis: unclassified | 6 | 0.2 | 2 | <0.1 | 7 | 0.3 | 1 | <0.1 | 6 | 0.2 | 6 | 0.2 | 5 | 0.2 | 8 | 0.3 | 9 | 0.3 | 8 | 0.3 | 7 | 0.3 | | |
| Giardiasis | 670 | 27.6 | 637 | 25.9 | 509 | 20.4 | 511 | 20.4 | 489 | 19.4 | 532 | 20.9 | 592 | 22.8 | 609 | 23.3 | 531 | 20.3 | 523 | 20.1 | 547 | 21.0 | | |
| Gonorrhoea | 1846 | 75.9 | 1533 | 62.3 | 1199 | 48.1 | 1441 | 57.4 | 1399 | 55.4 | 1754 | 68.9 | 1760 | 67.9 | 1780 | 68.0 | 1847 | 70.7 | 1737 | 66.7 | 1659 | 63.7 | | |
| <i>Haemophilus influenzae</i> b disease, invasive | 2 | <0.1 | 1 | <0.1 | 1 | <0.1 | 0 | 0.0 | 0 | 0.0 | 5 | 0.2 | 3 | 0.1 | 0 | 0.0 | 3 | 0.1 | 4 | 0.2 | 0 | 0.0 | | |
| Hemorrhagic fevers | 1 | <0.1 | 0 | 0.0 | 1 | <0.1 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
| Hepatitis A | 203 | 8.3 | 267 | 10.8 | 194 | 7.8 | 108 | 4.3 | 90 | 3.6 | 56 | 2.2 | 74 | 2.9 | 64 | 2.4 | 35 | 1.3 | 48 | 1.8 | 48 | 1.8 | | |
| Hepatitis B cases | 113 | 4.6 | 82 | 3.3 | 47 | 1.9 | 26 | 1.0 | 24 | 1.0 | 26 | 1.0 | 32 | 1.2 | 49 | 1.9 | 51 | 2.0 | 38 | 1.5 | 34 | 1.3 | | |
| Hepatitis B carriers | 3096 | 127.3 | 2629 | 106.8 | 2082 | 83.6 | 1970 | 78.5 | 2092 | 82.8 | 2015 | 79.1 | 2227 | 85.9 | 2381 | 91.0 | 1954 | 74.8 | 2024 | 77.8 | 1469 | 56.4 | | |
| Hepatitis B unclassified reports | 456 | 18.8 | 401 | 16.3 | 212 | 8.5 | 278 | 11.1 | 307 | 12.2 | 429 | 16.8 | 458 | 17.7 | 370 | 14.1 | 349 | 13.4 | 570 | 21.9 | 852 | 32.7 | | |
| Hepatitis C | 2631 | 108.2 | 2647 | 107.5 | 2231 | 89.6 | 2008 | 80.0 | 1790 | 70.9 | 1553 | 61.0 | 1518 | 58.6 | 1445 | 55.2 | 1296 | 49.6 | 1336 | 51.3 | 1165 | 44.8 | | |
| Hepatitis D | 1 | <0.1 | 3 | 0.1 | 3 | 0.1 | 0 | 0.0 | 3 | 0.1 | 5 | 0.2 | 5 | 0.2 | 4 | 0.2 | 1 | <0.1 | 1 | <0.1 | 5 | 0.2 | | |
| Herpes, neonatal | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 1 | <0.1 | 3 | 0.1 | 0 | 0.0 | 1 | <0.1 | 2 | <0.1 | 0 | 0.0 | 5 | 0.2 | 1 | <0.1 | | |
| Influenza [†] | 94 | 3.9 | 249 | 10.1 | 493 | 19.8 | 345 | 13.7 | 475 | 18.8 | 107 | 4.2 | 296 | 11.4 | 204 | 7.8 | 616 | 23.6 | 941 | 36.1 | 517 | 19.9 | | |
| Legionellosis | 12 | 0.5 | 11 | 0.4 | 20 | 0.8 | 18 | 0.7 | 23 | 0.9 | 19 | 0.7 | 10 | 0.4 | 4 | 0.2 | 10 | 0.4 | 3 | 0.1 | 53 | 2.0 | | |
| Leprosy | 4 | 0.2 | 3 | 0.1 | 2 | <0.1 | 1 | <0.1 | 3 | 0.1 | 0 | 0.0 | 2 | <0.1 | 1 | <0.1 | 2 | <0.1 | 0 | 0.0 | 1 | <0.1 | | |
| Listeriosis | 12 | 0.5 | 5 | 0.2 | 7 | 0.3 | 14 | 0.6 | 5 | 0.2 | 11 | 0.4 | 9 | 0.3 | 14 | 0.5 | 8 | 0.3 | 14 | 0.5 | 10 | 0.4 | | |
| Lyme disease | 8 | 0.3 | 9 | 0.4 | 6 | 0.2 | 6 | 0.2 | 10 | 0.4 | 10 | 0.4 | 5 | 0.2 | 12 | 0.5 | 4 | 0.2 | 4 | 0.2 | 13 | 0.5 | | |
| Malaria | 123 | 5.1 | 213 | 8.6 | 239 | 9.6 | 84 | 3.3 | 75 | 3.0 | 97 | 3.8 | 86 | 3.3 | 82 | 3.1 | 93 | 3.6 | 93 | 3.6 | 90 | 3.5 | | |
| Measles | 286 | 11.8 | 25 | 1.0 | 5 | 0.2 | 3 | 0.1 | 1 | <0.1 | 6 | 0.2 | 3 | 0.1 | 0 | 0.0 | 12 | 0.5 | 2 | <0.1 | 1 | <0.1 | | |
| Meningococcal disease, invasive | 16 | 0.7 | 20 | 0.8 | 19 | 0.8 | 6 | 0.2 | 21 | 0.8 | 22 | 0.9 | 26 | 1.0 | 13 | 0.5 | 9 | 0.3 | 6 | 0.2 | 3 | 0.1 | | |
| Mumps | 34 | 1.4 | 16 | 0.6 | 21 | 0.8 | 3 | 0.1 | 4 | 0.2 | 9 | 0.4 | 1 | <0.1 | 3 | 0.1 | 4 | 0.2 | 2 | <0.1 | 7 | 0.3 | | |

*Rates per 100,000 population. NR = Not reportable. NA = Not available.

[†]Seasonal year from July to June (eg. 2005/06 includes cases from July 1, 2005 to June 30, 2006).

Continued

**Appendix Table 1: Number of cases and incidence rates* by disease.
Toronto, 1995 - 2005**

| Disease | 1995 | | 1996 | | 1997 | | 1998 | | 1999 | | 2000 | | 2001 | | 2002 | | 2003 | | 2004 | | 2005 | |
|--|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|
| | # | Rate | # | Rate | # | Rate | # | Rate | # | Rate | # | Rate | # | Rate | # | Rate | # | Rate | # | Rate | # | Rate |
| Ophthalmia neonatorum | 3 | 0.1 | 6 | 0.2 | 3 | 0.1 | 4 | 0.2 | 4 | 0.2 | 7 | 0.3 | 1 | <0.1 | 1 | <0.1 | 2 | <0.1 | 3 | 0.1 | 0 | 0.0 |
| Paratyphoid fever | 9 | 0.4 | 7 | 0.3 | 3 | 0.1 | 4 | 0.2 | 5 | 0.2 | 2 | <0.1 | 6 | 0.2 | 10 | 0.4 | 10 | 0.4 | 16 | 0.6 | 13 | 0.5 |
| Pertussis | 149 | 6.1 | 104 | 4.2 | 90 | 3.6 | 149 | 5.9 | 127 | 5.0 | 152 | 6.0 | 85 | 3.3 | 83 | 3.2 | 32 | 1.2 | 94 | 3.6 | 177 | 6.8 |
| Psittacosis/ Ornithosis | 0 | 0.0 | 3 | 0.1 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
| Q fever | 2 | <0.1 | 0 | 0.0 | 0 | 0.0 | 1 | <0.1 | 3 | 0.1 | 0 | 0.0 | 1 | <0.1 | 0 | 0.0 | 2 | <0.1 | 1 | <0.1 | 0 | 0.0 |
| Rubella | 13 | 0.5 | 22 | 0.9 | 4 | 0.2 | 9 | 0.4 | 0 | 0.0 | 5 | 0.2 | 12 | 0.5 | 1 | <0.1 | 4 | 0.2 | 3 | 0.1 | 4 | 0.2 |
| Rubella, congenital syndrome | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 1 | <0.1 | 0 | 0.0 | 1 | <0.1 | 1 | <0.1 | 2 | <0.1 | 0 | 0.0 |
| Salmonellosis | 883 | 36.3 | 830 | 33.7 | 855 | 34.3 | 985 | 39.3 | 644 | 25.5 | 658 | 25.8 | 671 | 25.9 | 637 | 24.3 | 536 | 20.5 | 482 | 18.5 | 686 | 26.4 |
| Severe acute respiratory syndrome (SARS) | NR | | NR | | NR | | NR | | NR | | NR | | NR | | NR | | 228 | 8.7 | 0 | 0.0 | 0 | 0.0 |
| Shigellosis | 175 | 7.2 | 146 | 5.9 | 154 | 6.2 | 160 | 6.4 | 103 | 4.1 | 120 | 4.7 | 90 | 3.5 | 350 | 13.4 | 98 | 3.8 | 100 | 3.8 | 100 | 3.8 |
| Streptococcal infections, Group A invasive | NR | | 40 | 1.6 | 72 | 2.9 | 65 | 2.6 | 54 | 2.1 | 76 | 3.0 | 72 | 2.8 | 105 | 4.0 | 70 | 2.7 | 52 | 2.0 | 72 | 2.8 |
| Streptococcal infections, Group B neonatal | NR | | 14 | 0.6 | 12 | 0.5 | 3 | 0.1 | 11 | 0.4 | 10 | 0.4 | 23 | 0.9 | 20 | 0.8 | 18 | 0.7 | 16 | 0.6 | 12 | 0.5 |
| <i>Streptococcus pneumoniae</i> , invasive | NR | | NR | | NR | | NR | | NR | | NR | | NR | | 276 | 10.5 | 235 | 9.0 | 263 | 10.1 | 216 | 8.3 |
| Syphilis, infectious | 66 | 2.7 | 61 | 2.5 | 36 | 1.4 | 19 | 0.8 | 30 | 1.2 | 32 | 1.3 | 29 | 1.1 | 193 | 7.4 | 330 | 12.6 | 384 | 14.8 | 250 | 9.6 |
| Syphilis, late latent | 169 | 7.0 | 126 | 5.1 | 118 | 4.7 | 103 | 4.1 | 117 | 4.6 | 152 | 6.0 | 122 | 4.7 | 164 | 6.3 | 131 | 5.0 | 149 | 5.7 | 484 | 18.6 |
| Syphilis, congenital | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 1 | <0.1 | 1 | <0.1 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
| Syphilis, other [‡] | 8 | 0.3 | 3 | 0.1 | 2 | <0.1 | 4 | 0.2 | 4 | 0.2 | 3 | 0.1 | 1 | <0.1 | 11 | 0.4 | 14 | 0.5 | 19 | 0.7 | 11 | 0.4 |
| Tetanus | 1 | <0.1 | 0 | 0.0 | 1 | <0.1 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
| Tuberculosis | 492 | 20.2 | 454 | 18.4 | 453 | 18.2 | 414 | 16.5 | 385 | 15.2 | 381 | 15.0 | 371 | 14.3 | 383 | 14.6 | 368 | 14.1 | 361 | 13.9 | 344 | 13.2 |
| Tularemia | 0 | 0.0 | 0 | 0.0 | 1 | <0.1 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
| Typhoid fever | 24 | 1.0 | 12 | 0.5 | 16 | 0.6 | 15 | 0.6 | 19 | 0.8 | 24 | 0.9 | 31 | 1.2 | 30 | 1.1 | 25 | 1.0 | 28 | 1.1 | 23 | 0.9 |
| Verotoxin-producing <i>E.coli</i> infection | 107 | 4.4 | 76 | 3.1 | 91 | 3.7 | 73 | 2.9 | 66 | 2.6 | 60 | 2.4 | 69 | 2.7 | 46 | 1.8 | 55 | 2.1 | 50 | 1.9 | 34 | 1.3 |
| West Nile Virus | NR | | NR | | NR | | NR | | NR | | NR | | NR | | 163 | 6.2 | 44 | 1.7 | 6 | 0.2 | 38 | 1.5 |
| Yersiniosis | 186 | 7.7 | 148 | 6.0 | 153 | 6.1 | 125 | 5.0 | 144 | 5.7 | 142 | 5.6 | 123 | 4.7 | 147 | 5.6 | 126 | 4.8 | 92 | 3.5 | 117 | 4.5 |

*Rates per 100,000 population. NR = Not reportable. NA = Not available.

[‡]Excludes infectious, late latent and congenital syphilis.

Appendix Table 2: Number of cases and incidence rates* by disease and sex†.
Toronto, 1995 - 2005

| Disease | Sex | 1995 | | 1996 | | 1997 | | 1998 | | 1999 | | 2000 | | 2001 | | 2002 | | 2003 | | 2004 | | 2005 | |
|---------------------------------------|--------|------|-------|------|-------|------|-------|------|-------|------|-------|------|-------|------|-------|------|-------|------|-------|------|-------|------|-------|
| | | # | Rate | # | Rate | # | Rate | # | Rate | # | Rate | # | Rate | # | Rate | # | Rate | # | Rate | # | Rate | # | Rate |
| AIDS | Female | NA | | NA | | NA | | NA | | NA | | NA | | NA | | NA | | NA | | NA | | NA | |
| | Male | NA | | NA | | NA | | NA | | NA | | NA | | NA | | NA | | NA | | NA | | NA | |
| | Total | NA | | NA | | NA | | NA | | NA | | NA | | NA | | NA | | NA | | NA | | NA | |
| HIV | Female | 71 | 5.7 | 68 | 5.4 | 69 | 5.4 | 74 | 5.7 | 55 | 4.2 | 87 | 6.7 | 117 | 8.8 | 137 | 10.2 | 116 | 8.7 | 135 | 10.1 | 102 | 7.6 |
| | Male | 564 | 47.7 | 462 | 38.7 | 379 | 31.3 | 336 | 27.5 | 375 | 30.5 | 366 | 29.5 | 391 | 30.9 | 479 | 37.5 | 457 | 35.9 | 434 | 34.2 | 450 | 35.5 |
| | Total | 637 | 26.2 | 535 | 21.7 | 448 | 18.0 | 413 | 16.5 | 432 | 17.1 | 456 | 17.9 | 511 | 19.7 | 618 | 23.6 | 574 | 22.0 | 569 | 21.9 | 555 | 21.3 |
| Amebiasis | Female | 120 | 9.6 | 105 | 8.3 | 115 | 9.0 | 100 | 7.8 | 92 | 7.1 | 117 | 9.0 | 99 | 7.5 | 109 | 8.1 | 110 | 8.2 | 93 | 7.0 | 95 | 7.1 |
| | Male | 277 | 23.4 | 256 | 21.4 | 342 | 28.3 | 281 | 23.0 | 263 | 21.4 | 371 | 29.9 | 301 | 23.8 | 271 | 21.2 | 316 | 24.8 | 234 | 18.4 | 281 | 22.2 |
| | Total | 398 | 16.4 | 363 | 14.7 | 459 | 18.4 | 381 | 15.2 | 355 | 14.1 | 488 | 19.2 | 400 | 15.4 | 380 | 14.5 | 426 | 16.3 | 327 | 12.6 | 376 | 14.4 |
| Botulism | Female | 1 | <0.1 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 2 | 0.1 | 1 | <0.1 | 0 | 0.0 |
| | Male | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 1 | <0.1 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 1 | <0.1 | 0 | 0.0 |
| | Total | 1 | <0.1 | 0 | 0.0 | 0 | 0.0 | 1 | <0.1 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 2 | <0.1 | 2 | <0.1 | 0 | 0.0 |
| Brucellosis | Female | 1 | <0.1 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 1 | <0.1 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
| | Male | 0 | 0.0 | 1 | <0.1 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 1 | <0.1 | 2 | 0.2 | 2 | 0.2 | 1 | <0.1 |
| | Total | 1 | <0.1 | 1 | <0.1 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 2 | <0.1 | 2 | <0.1 | 2 | <0.1 | 3 | 0.1 |
| Campylobacter enteritis | Female | 884 | 70.7 | 770 | 60.8 | 746 | 58.3 | 799 | 62.0 | 642 | 49.5 | 711 | 54.4 | 693 | 52.2 | 633 | 47.2 | 487 | 36.4 | 447 | 33.5 | 444 | 33.3 |
| | Male | 911 | 77.1 | 879 | 73.6 | 838 | 69.2 | 969 | 79.4 | 669 | 54.5 | 780 | 62.9 | 864 | 68.3 | 729 | 57.1 | 638 | 50.1 | 528 | 41.6 | 553 | 43.6 |
| | Total | 1804 | 74.2 | 1651 | 67.0 | 1589 | 63.8 | 1770 | 70.5 | 1312 | 52.0 | 1492 | 58.6 | 1560 | 60.2 | 1362 | 52.0 | 1125 | 43.1 | 976 | 37.5 | 997 | 38.3 |
| Chickenpox | Total | 3433 | 141.2 | 2165 | 87.9 | 4049 | 162.6 | 3801 | 151.5 | 2509 | 99.4 | 3586 | 140.8 | 2689 | 103.7 | 2895 | 110.6 | 3403 | 130.3 | 5317 | 204.3 | 3668 | 140.9 |
| Chlamydia | Female | 3186 | 255.0 | 2997 | 236.5 | 2824 | 220.6 | 3124 | 242.4 | 3355 | 258.7 | 3480 | 266.5 | 3640 | 274.1 | 3891 | 290.4 | 3831 | 286.3 | 3783 | 283.4 | 3804 | 285.0 |
| | Male | 1092 | 92.4 | 1020 | 85.4 | 1099 | 90.8 | 1520 | 124.6 | 1801 | 146.6 | 1904 | 153.5 | 2089 | 165.2 | 2403 | 188.1 | 2459 | 192.9 | 2508 | 197.7 | 2690 | 212.1 |
| | Total | 4278 | 176.0 | 4018 | 163.2 | 3923 | 157.5 | 4646 | 185.2 | 5157 | 204.2 | 5385 | 211.5 | 5732 | 221.1 | 6294 | 240.5 | 6290 | 240.8 | 6293 | 241.7 | 6497 | 249.6 |
| Cholera | Female | 1 | <0.1 | 0 | 0.0 | 0 | 0.0 | 1 | <0.1 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
| | Male | 1 | <0.1 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
| | Total | 2 | <0.1 | 0 | 0.0 | 0 | 0.0 | 1 | <0.1 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
| Cryptosporidiosis | Female | NR | | 10 | 0.8 | 9 | 0.7 | 12 | 0.9 | 17 | 1.3 | 3 | 0.2 | 19 | 1.4 | 8 | 0.6 | 17 | 1.3 | 10 | 0.7 | 14 | 1.0 |
| | Male | NR | | 19 | 1.6 | 34 | 2.8 | 6 | 0.5 | 17 | 1.4 | 41 | 3.3 | 26 | 2.1 | 29 | 2.3 | 18 | 1.4 | 39 | 3.1 | 38 | 3.0 |
| | Total | NR | | 29 | 1.2 | 43 | 1.7 | 18 | 0.7 | 34 | 1.3 | 44 | 1.7 | 45 | 1.7 | 37 | 1.4 | 35 | 1.3 | 49 | 1.9 | 52 | 2.0 |
| Cyclosporiasis | Female | NR | | NR | | NR | | NR | | NR | | NR | | NR | | 14 | 1.0 | 4 | 0.3 | 16 | 1.2 | 24 | 1.8 |
| | Male | NR | | NR | | NR | | NR | | NR | | NR | | NR | | 14 | 1.1 | 10 | 0.8 | 14 | 1.1 | 24 | 1.9 |
| | Total | NR | | NR | | NR | | NR | | NR | | NR | | NR | | 28 | 1.1 | 14 | 0.5 | 30 | 1.2 | 48 | 1.8 |
| Cytomegalovirus infection, congenital | Female | 1 | <0.1 | 1 | <0.1 | 2 | 0.2 | 2 | 0.2 | 3 | 0.2 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 1 | <0.1 |
| | Male | 0 | 0.0 | 2 | 0.2 | 0 | 0.0 | 1 | <0.1 | 0 | 0.0 | 1 | <0.1 | 0 | 0.0 | 0 | 0.0 | 3 | 0.2 | 0 | 0.0 | 2 | 0.2 |
| | Total | 1 | <0.1 | 3 | 0.1 | 2 | <0.1 | 3 | 0.1 | 3 | 0.1 | 1 | <0.1 | 0 | 0.0 | 0 | 0.0 | 3 | 0.1 | 0 | 0.0 | 3 | 0.1 |
| Encephalitis/ Meningitis: bacterial | Female | 5 | 0.4 | 5 | 0.4 | 17 | 1.3 | 6 | 0.5 | 8 | 0.6 | 8 | 0.6 | 7 | 0.5 | 2 | 0.1 | 1 | <0.1 | 9 | 0.7 | 2 | 0.1 |
| | Male | 13 | 1.1 | 5 | 0.4 | 8 | 0.7 | 3 | 0.2 | 2 | 0.2 | 10 | 0.8 | 15 | 1.2 | 3 | 0.2 | 5 | 0.4 | 4 | 0.3 | 2 | 0.2 |
| | Total | 18 | 0.7 | 10 | 0.4 | 25 | 1.0 | 9 | 0.4 | 10 | 0.4 | 18 | 0.7 | 22 | 0.8 | 5 | 0.2 | 6 | 0.2 | 13 | 0.5 | 4 | 0.2 |
| Encephalitis/ Meningitis: viral | Female | 14 | 1.1 | 19 | 1.5 | 10 | 0.8 | 18 | 1.4 | 18 | 1.4 | 20 | 1.5 | 22 | 1.7 | 39 | 2.9 | 36 | 2.7 | 13 | 1.0 | 24 | 1.8 |
| | Male | 17 | 1.4 | 8 | 0.7 | 10 | 0.8 | 32 | 2.6 | 25 | 2.0 | 20 | 1.6 | 31 | 2.5 | 46 | 3.6 | 39 | 3.1 | 34 | 2.7 | 31 | 2.4 |
| | Total | 31 | 1.3 | 27 | 1.1 | 20 | 0.8 | 50 | 2.0 | 43 | 1.7 | 40 | 1.6 | 53 | 2.0 | 85 | 3.2 | 75 | 2.9 | 47 | 1.8 | 55 | 2.1 |
| Encephalitis/ Meningitis: other | Female | 0 | 0.0 | 2 | 0.2 | 0 | 0.0 | 1 | <0.1 | 0 | 0.0 | 0 | 0.0 | 1 | <0.1 | 2 | 0.1 | 2 | 0.1 | 2 | 0.1 | 2 | 0.1 |
| | Male | 19 | 1.6 | 7 | 0.6 | 1 | <0.1 | 4 | 0.3 | 3 | 0.2 | 2 | 0.2 | 4 | 0.3 | 2 | 0.2 | 3 | 0.2 | 5 | 0.4 | 4 | 0.3 |
| | Total | 19 | 0.8 | 9 | 0.4 | 1 | <0.1 | 5 | 0.2 | 3 | 0.1 | 2 | <0.1 | 5 | 0.2 | 4 | 0.2 | 5 | 0.2 | 7 | 0.3 | 6 | 0.2 |

*Rates per 100,000 population. NR = Not reportable. NA = Not available.

†Due to missing sex data, the total number of cases reported by sex may not correspond with the total number of cases reported for a disease.

Continued

**Appendix Table 2: Number of cases and incidence rates* by disease and sex[†].
Toronto, 1995 - 2005**

| Disease | Sex | 1995 | | 1996 | | 1997 | | 1998 | | 1999 | | 2000 | | 2001 | | 2002 | | 2003 | | 2004 | | 2005 | |
|--|--------------|-------------|----------------|-------------|----------------|-------------|----------------|-------------|----------------|-------------|-------------|-------------|-------------|-------------|----------------|-------------|----------------|-------------|----------------|-------------|----------------|-------------|----------------|
| | | # | Rate | # | Rate | # | Rate | # | Rate | # | Rate | # | Rate | # | Rate | # | Rate | # | Rate | # | Rate | # | Rate |
| Encephalitis/ Meningitis: unclassified | Female | 4 | 0.3 | 1 | <0.1 | 2 | 0.2 | 0 | 0.0 | 2 | 0.2 | 4 | 0.3 | 2 | 0.2 | 3 | 0.2 | 6 | 0.4 | 3 | 0.2 | 2 | 0.1 |
| | Male | 2 | 0.2 | 1 | <0.1 | 5 | 0.4 | 1 | <0.1 | 4 | 0.3 | 2 | 0.2 | 3 | 0.2 | 5 | 0.4 | 3 | 0.2 | 5 | 0.4 | 5 | 0.4 |
| | Total | 6 | 0.2 | 2 | <0.1 | 7 | 0.3 | 1 | <0.1 | 6 | 0.2 | 6 | 0.2 | 5 | 0.2 | 8 | 0.3 | 9 | 0.3 | 8 | 0.3 | 7 | 0.3 |
| Giardiasis | Female | 279 | 22.3 | 246 | 19.4 | 188 | 14.7 | 190 | 14.7 | 177 | 13.6 | 195 | 14.9 | 225 | 16.9 | 204 | 15.2 | 187 | 14.0 | 192 | 14.4 | 188 | 14.1 |
| | Male | 391 | 33.1 | 391 | 32.7 | 321 | 26.5 | 321 | 26.3 | 312 | 25.4 | 337 | 27.2 | 367 | 29.0 | 405 | 31.7 | 344 | 27.0 | 331 | 26.1 | 359 | 28.3 |
| | Total | 670 | 27.6 | 637 | 25.9 | 509 | 20.4 | 511 | 20.4 | 489 | 19.4 | 532 | 20.9 | 592 | 22.8 | 609 | 23.3 | 531 | 20.3 | 523 | 20.1 | 547 | 21.0 |
| Gonorrhea | Female | 715 | 57.2 | 627 | 49.5 | 451 | 35.2 | 544 | 42.2 | 503 | 38.8 | 634 | 48.5 | 605 | 45.6 | 565 | 42.2 | 593 | 44.3 | 534 | 40.0 | 501 | 37.5 |
| | Male | 1131 | 95.7 | 906 | 75.8 | 748 | 61.8 | 896 | 73.4 | 896 | 72.9 | 1120 | 90.3 | 1155 | 91.3 | 1214 | 95.0 | 1254 | 98.4 | 1201 | 94.7 | 1156 | 91.1 |
| | Total | 1846 | 75.9 | 1533 | 62.3 | 1199 | 48.1 | 1441 | 57.4 | 1399 | 55.4 | 1754 | 68.9 | 1760 | 67.9 | 1780 | 68.0 | 1847 | 70.7 | 1737 | 66.7 | 1659 | 63.7 |
| <i>Haemophilus influenzae</i> b disease, invasive | Female | 2 | 0.2 | 1 | <0.1 | 1 | <0.1 | 0 | 0.0 | 0 | 0.0 | 2 | 0.2 | 1 | <0.1 | 0 | 0.0 | 1 | <0.1 | 1 | <0.1 | 0 | 0.0 |
| | Male | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 3 | 0.2 | 2 | 0.2 | 0 | 0.0 | 2 | 0.2 | 3 | 0.2 | 0 | 0.0 |
| | Total | 2 | <0.1 | 1 | <0.1 | 1 | <0.1 | 0 | 0.0 | 0 | 0.0 | 5 | 0.2 | 3 | 0.1 | 0 | 0.0 | 3 | 0.1 | 4 | 0.2 | 0 | 0.0 |
| Hemorrhagic fevers | Female | 1 | <0.1 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
| | Male | 0 | 0.0 | 0 | 0.0 | 1 | <0.1 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
| | Total | 1 | <0.1 | 0 | 0.0 | 1 | <0.1 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
| Hepatitis A | Female | 83 | 6.6 | 82 | 6.5 | 44 | 3.4 | 33 | 2.6 | 31 | 2.4 | 27 | 2.1 | 29 | 2.2 | 29 | 2.2 | 19 | 1.4 | 17 | 1.3 | 18 | 1.3 |
| | Male | 119 | 10.1 | 184 | 15.4 | 150 | 12.4 | 75 | 6.1 | 59 | 4.8 | 29 | 2.3 | 45 | 3.6 | 35 | 2.7 | 16 | 1.3 | 31 | 2.4 | 30 | 2.4 |
| | Total | 203 | 8.3 | 267 | 10.8 | 194 | 7.8 | 108 | 4.3 | 90 | 3.6 | 56 | 2.2 | 74 | 2.9 | 64 | 2.4 | 35 | 1.3 | 48 | 1.8 | 48 | 1.8 |
| Hepatitis B cases | Female | 38 | 3.0 | 24 | 1.9 | 19 | 1.5 | 11 | 0.9 | 8 | 0.6 | 6 | 0.5 | 13 | 1.0 | 13 | 1.0 | 19 | 1.4 | 15 | 1.1 | 8 | 0.6 |
| | Male | 75 | 6.3 | 58 | 4.9 | 28 | 2.3 | 15 | 1.2 | 16 | 1.3 | 20 | 1.6 | 19 | 1.5 | 36 | 2.8 | 32 | 2.5 | 23 | 1.8 | 26 | 2.0 |
| | Total | 113 | 4.6 | 82 | 3.3 | 47 | 1.9 | 26 | 1.0 | 24 | 1.0 | 26 | 1.0 | 32 | 1.2 | 49 | 1.9 | 51 | 2.0 | 38 | 1.5 | 34 | 1.3 |
| Hepatitis B carriers | Female | 1384 | 110.8 | 1152 | 90.9 | 961 | 75.1 | 887 | 68.8 | 979 | 75.5 | 927 | 71.0 | 1008 | 75.9 | 1044 | 77.9 | 920 | 68.8 | 950 | 71.2 | 688 | 51.5 |
| | Male | 1653 | 139.9 | 1435 | 120.1 | 1098 | 90.7 | 1064 | 87.2 | 1098 | 89.4 | 1072 | 86.4 | 1193 | 94.3 | 1322 | 103.5 | 1026 | 80.5 | 1069 | 84.3 | 774 | 61.0 |
| | Total | 3096 | 127.3 | 2629 | 106.8 | 2082 | 83.6 | 1970 | 78.5 | 2092 | 82.8 | 2015 | 79.1 | 2227 | 85.9 | 2381 | 91.0 | 1954 | 74.8 | 2024 | 77.8 | 1469 | 56.4 |
| Hepatitis B unclassified reports | Female | 187 | 15.0 | 181 | 14.3 | 98 | 7.7 | 119 | 9.2 | 144 | 11.1 | 183 | 14.0 | 192 | 14.5 | 143 | 10.7 | 143 | 10.7 | 237 | 17.8 | 372 | 27.9 |
| | Male | 260 | 22.0 | 216 | 18.1 | 109 | 9.0 | 154 | 12.6 | 162 | 13.2 | 231 | 18.6 | 259 | 20.5 | 222 | 17.4 | 202 | 15.9 | 331 | 26.1 | 476 | 37.5 |
| | Total | 456 | 18.8 | 401 | 16.3 | 212 | 8.5 | 278 | 11.1 | 307 | 12.2 | 429 | 16.8 | 458 | 17.7 | 370 | 14.1 | 349 | 13.4 | 570 | 21.9 | 852 | 32.7 |
| Hepatitis C | Female | 979 | 78.3 | 957 | 75.5 | 769 | 60.1 | 717 | 55.6 | 638 | 49.2 | 552 | 42.3 | 532 | 40.1 | 546 | 40.8 | 531 | 39.7 | 513 | 38.4 | 427 | 32.0 |
| | Male | 1637 | 138.5 | 1674 | 140.1 | 1445 | 119.4 | 1284 | 105.2 | 1145 | 93.2 | 978 | 78.8 | 968 | 76.6 | 897 | 70.2 | 761 | 59.7 | 819 | 64.6 | 735 | 57.9 |
| | Total | 2631 | 108.2 | 2647 | 107.5 | 2231 | 89.6 | 2008 | 80.0 | 1790 | 70.9 | 1553 | 61.0 | 1518 | 58.6 | 1445 | 55.2 | 1296 | 49.6 | 1336 | 51.3 | 1165 | 44.8 |
| Hepatitis D | Female | 0 | 0.0 | 0 | 0.0 | 1 | <0.1 | 0 | 0.0 | 0 | 0.0 | 2 | 0.2 | 0 | 0.0 | 2 | 0.1 | 0 | 0.0 | 1 | <0.1 | 2 | 0.1 |
| | Male | 1 | <0.1 | 3 | 0.3 | 2 | 0.2 | 0 | 0.0 | 3 | 0.2 | 3 | 0.2 | 5 | 0.4 | 2 | 0.2 | 1 | <0.1 | 0 | 0.0 | 3 | 0.2 |
| | Total | 1 | <0.1 | 3 | 0.1 | 3 | 0.1 | 0 | 0.0 | 3 | 0.1 | 5 | 0.2 | 5 | 0.2 | 4 | 0.2 | 1 | <0.1 | 1 | <0.1 | 5 | 0.2 |
| Herpes, neonatal | Female | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 1 | <0.1 | 2 | 0.2 | 0 | 0.0 | 0 | 0.0 | 1 | <0.1 | 0 | 0.0 | 4 | 0.3 | 0 | 0.0 |
| | Male | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 1 | <0.1 | 0 | 0.0 | 1 | <0.1 | 1 | <0.1 | 0 | 0.0 | 1 | <0.1 | 1 | <0.1 |
| | Total | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 1 | <0.1 | 3 | 0.1 | 0 | 0.0 | 1 | <0.1 | 2 | <0.1 | 0 | 0.0 | 5 | 0.2 | 1 | <0.1 |
| Influenza [‡] | Female | 42 | 3.4 | 125 | 9.9 | 255 | 19.9 | 169 | 13.1 | 237 | 18.3 | 52 | 4.0 | 163 | 12.3 | 90 | 6.7 | 331 | 24.7 | 520 | 39.0 | 248 | 18.6 |
| | Male | 51 | 4.3 | 124 | 10.4 | 238 | 19.7 | 175 | 14.3 | 237 | 19.3 | 55 | 4.4 | 133 | 10.5 | 114 | 8.9 | 285 | 22.4 | 421 | 33.2 | 268 | 21.1 |
| | Total | 94 | 3.9 | 249 | 10.1 | 493 | 19.8 | 345 | 13.7 | 475 | 18.8 | 107 | 4.2 | 296 | 11.4 | 204 | 7.8 | 616 | 23.6 | 941 | 36.1 | 517 | 19.9 |
| Legionellosis | Female | 3 | 0.2 | 2 | 0.2 | 6 | 0.5 | 10 | 0.8 | 8 | 0.6 | 5 | 0.4 | 3 | 0.2 | 2 | 0.1 | 5 | 0.4 | 2 | 0.1 | 30 | 2.2 |
| | Male | 9 | 0.8 | 9 | 0.8 | 14 | 1.2 | 8 | 0.7 | 15 | 1.2 | 14 | 1.1 | 7 | 0.6 | 2 | 0.2 | 5 | 0.4 | 1 | <0.1 | 23 | 1.8 |
| | Total | 12 | 0.5 | 11 | 0.4 | 20 | 0.8 | 18 | 0.7 | 23 | 0.9 | 19 | 0.7 | 10 | 0.4 | 4 | 0.2 | 10 | 0.4 | 3 | 0.1 | 53 | 2.0 |

*Rates per 100,000 population. NR = Not reportable. NA = Not available.

[†]Due to missing sex data, the total number of cases reported by sex may not correspond with the total number of cases reported for a disease.[‡]Seasonal year from July to June (eg. 2005/06 includes cases from July 1, 2005 to June 30, 2006).

Continued

**Appendix Table 2: Number of cases and incidence rates* by disease and sex[†].
Toronto, 1995 - 2005**

| Disease | Sex | 1995 | | 1996 | | 1997 | | 1998 | | 1999 | | 2000 | | 2001 | | 2002 | | 2003 | | 2004 | | 2005 | |
|---------------------------------|--------------|------------|----------------|------------|------------|------------|----------------|------------|----------------|------------|----------------|------------|----------------|-----------|----------------|-----------|----------------|-----------|----------------|-----------|----------------|------------|----------------|
| | | # | Rate | # | Rate | # | Rate | # | Rate | # | Rate | # | Rate | # | Rate | # | Rate | # | Rate | # | Rate | # | Rate |
| Leptosy | Female | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 1 | <0.1 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
| | Male | 4 | 0.3 | 3 | 0.3 | 2 | 0.2 | 1 | <0.1 | 2 | 0.2 | 0 | 0.0 | 2 | 0.2 | 1 | <0.1 | 2 | 0.2 | 0 | 0.0 | 1 | <0.1 |
| | Total | 4 | 0.2 | 3 | 0.1 | 2 | <0.1 | 1 | <0.1 | 3 | 0.1 | 0 | 0.0 | 2 | <0.1 | 1 | <0.1 | 2 | <0.1 | 0 | 0.0 | 1 | <0.1 |
| Listeriosis | Female | 5 | 0.4 | 1 | <0.1 | 3 | 0.2 | 7 | 0.5 | 4 | 0.3 | 6 | 0.5 | 7 | 0.5 | 10 | 0.7 | 3 | 0.2 | 10 | 0.7 | 7 | 0.5 |
| | Male | 7 | 0.6 | 4 | 0.3 | 4 | 0.3 | 7 | 0.6 | 1 | <0.1 | 5 | 0.4 | 2 | 0.2 | 4 | 0.3 | 5 | 0.4 | 4 | 0.3 | 3 | 0.2 |
| | Total | 12 | 0.5 | 5 | 0.2 | 7 | 0.3 | 14 | 0.6 | 5 | 0.2 | 11 | 0.4 | 9 | 0.3 | 14 | 0.5 | 8 | 0.3 | 14 | 0.5 | 10 | 0.4 |
| Lyme disease | Female | 7 | 0.6 | 5 | 0.4 | 4 | 0.3 | 4 | 0.3 | 4 | 0.3 | 7 | 0.5 | 2 | 0.2 | 7 | 0.5 | 2 | 0.1 | 2 | 0.1 | 5 | 0.4 |
| | Male | 1 | <0.1 | 4 | 0.3 | 2 | 0.2 | 2 | 0.2 | 6 | 0.5 | 2 | 0.2 | 3 | 0.2 | 5 | 0.4 | 2 | 0.2 | 2 | 0.2 | 8 | 0.6 |
| | Total | 8 | 0.3 | 9 | 0.4 | 6 | 0.2 | 6 | 0.2 | 10 | 0.4 | 10 | 0.4 | 5 | 0.2 | 12 | 0.5 | 4 | 0.2 | 4 | 0.2 | 13 | 0.5 |
| Malaria | Female | 54 | 4.3 | 86 | 6.8 | 96 | 7.5 | 34 | 2.6 | 21 | 1.6 | 26 | 2.0 | 23 | 1.7 | 21 | 1.6 | 25 | 1.9 | 31 | 2.3 | 26 | 1.9 |
| | Male | 69 | 5.8 | 122 | 10.2 | 142 | 11.7 | 50 | 4.1 | 54 | 4.4 | 71 | 5.7 | 63 | 5.0 | 61 | 4.8 | 68 | 5.3 | 62 | 4.9 | 64 | 5.0 |
| | Total | 123 | 5.1 | 213 | 8.6 | 239 | 9.6 | 84 | 3.3 | 75 | 3.0 | 97 | 3.8 | 86 | 3.3 | 82 | 3.1 | 93 | 3.6 | 93 | 3.6 | 90 | 3.5 |
| Measles | Female | 128 | 10.2 | 9 | 0.7 | 2 | 0.2 | 2 | 0.2 | 0 | 0.0 | 3 | 0.2 | 1 | <0.1 | 0 | 0.0 | 6 | 0.4 | 1 | <0.1 | 1 | <0.1 |
| | Male | 158 | 13.4 | 16 | 1.3 | 3 | 0.2 | 1 | <0.1 | 1 | <0.1 | 3 | 0.2 | 2 | 0.2 | 0 | 0.0 | 6 | 0.5 | 1 | <0.1 | 0 | 0.0 |
| | Total | 286 | 11.8 | 25 | 1.0 | 5 | 0.2 | 3 | 0.1 | 1 | <0.1 | 6 | 0.2 | 3 | 0.1 | 0 | 0.0 | 12 | 0.5 | 2 | <0.1 | 1 | <0.1 |
| Meningococcal disease, invasive | Female | 7 | 0.6 | 10 | 0.8 | 9 | 0.7 | 3 | 0.2 | 14 | 1.1 | 13 | 1.0 | 13 | 1.0 | 8 | 0.6 | 4 | 0.3 | 5 | 0.4 | 2 | 0.1 |
| | Male | 9 | 0.8 | 10 | 0.8 | 10 | 0.8 | 3 | 0.2 | 7 | 0.6 | 9 | 0.7 | 13 | 1.0 | 5 | 0.4 | 5 | 0.4 | 1 | <0.1 | 1 | <0.1 |
| | Total | 16 | 0.7 | 20 | 0.8 | 19 | 0.8 | 6 | 0.2 | 21 | 0.8 | 22 | 0.9 | 26 | 1.0 | 13 | 0.5 | 9 | 0.3 | 6 | 0.2 | 3 | 0.1 |
| Mumps | Female | 16 | 1.3 | 5 | 0.4 | 11 | 0.9 | 1 | <0.1 | 2 | 0.2 | 6 | 0.5 | 1 | <0.1 | 2 | 0.1 | 1 | <0.1 | 2 | 0.1 | 2 | 0.1 |
| | Male | 18 | 1.5 | 11 | 0.9 | 10 | 0.8 | 2 | 0.2 | 2 | 0.2 | 3 | 0.2 | 0 | 0.0 | 1 | <0.1 | 3 | 0.2 | 0 | 0.0 | 5 | 0.4 |
| | Total | 34 | 1.4 | 16 | 0.6 | 21 | 0.8 | 3 | 0.1 | 4 | 0.2 | 9 | 0.4 | 1 | <0.1 | 3 | 0.1 | 4 | 0.2 | 2 | <0.1 | 7 | 0.3 |
| Ophthalmia neonatorum | Female | 3 | 0.2 | 3 | 0.2 | 0 | 0.0 | 3 | 0.2 | 1 | <0.1 | 2 | 0.2 | 1 | <0.1 | 1 | <0.1 | 1 | <0.1 | 2 | 0.1 | 0 | 0.0 |
| | Male | 0 | 0.0 | 3 | 0.3 | 3 | 0.2 | 1 | <0.1 | 3 | 0.2 | 5 | 0.4 | 0 | 0.0 | 0 | 0.0 | 1 | <0.1 | 1 | <0.1 | 0 | 0.0 |
| | Total | 3 | 0.1 | 6 | 0.2 | 3 | 0.1 | 4 | 0.2 | 4 | 0.2 | 7 | 0.3 | 1 | <0.1 | 1 | <0.1 | 2 | <0.1 | 3 | 0.1 | 0 | 0.0 |
| Paratyphoid fever | Female | 4 | 0.3 | 1 | <0.1 | 0 | 0.0 | 2 | 0.2 | 4 | 0.3 | 0 | 0.0 | 1 | <0.1 | 5 | 0.4 | 5 | 0.4 | 8 | 0.6 | 8 | 0.6 |
| | Male | 5 | 0.4 | 6 | 0.5 | 3 | 0.2 | 2 | 0.2 | 1 | <0.1 | 2 | 0.2 | 5 | 0.4 | 5 | 0.4 | 5 | 0.4 | 8 | 0.6 | 5 | 0.4 |
| | Total | 9 | 0.4 | 7 | 0.3 | 3 | 0.1 | 4 | 0.2 | 5 | 0.2 | 2 | <0.1 | 6 | 0.2 | 10 | 0.4 | 10 | 0.4 | 16 | 0.6 | 13 | 0.5 |
| Pertussis | Female | 81 | 6.5 | 60 | 4.7 | 44 | 3.4 | 73 | 5.7 | 56 | 4.3 | 76 | 5.8 | 50 | 3.8 | 42 | 3.1 | 12 | 0.9 | 47 | 3.5 | 91 | 6.8 |
| | Male | 67 | 5.7 | 44 | 3.7 | 46 | 3.8 | 76 | 6.2 | 71 | 5.8 | 76 | 6.1 | 35 | 2.8 | 41 | 3.2 | 20 | 1.6 | 46 | 3.6 | 86 | 6.8 |
| | Total | 149 | 6.1 | 104 | 4.2 | 90 | 3.6 | 149 | 5.9 | 127 | 5.0 | 152 | 6.0 | 85 | 3.3 | 83 | 3.2 | 32 | 1.2 | 94 | 3.6 | 177 | 6.8 |
| Psittacosis/ Ornithosis | Female | 0 | 0.0 | 2 | 0.2 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
| | Male | 0 | 0.0 | 1 | <0.1 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
| | Total | 0 | 0.0 | 3 | 0.1 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
| Q fever | Female | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 1 | <0.1 | 0 | 0.0 | 1 | <0.1 | 0 | 0.0 | 1 | <0.1 | 0 | 0.0 | 0 | 0.0 |
| | Male | 2 | 0.2 | 0 | 0.0 | 0 | 0.0 | 1 | <0.1 | 2 | 0.2 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 1 | <0.1 | 1 | <0.1 | 0 | 0.0 |
| | Total | 2 | <0.1 | 0 | 0.0 | 0 | 0.0 | 1 | <0.1 | 3 | 0.1 | 0 | 0.0 | 1 | <0.1 | 0 | 0.0 | 2 | <0.1 | 1 | <0.1 | 0 | 0.0 |
| Rubella | Female | 7 | 0.6 | 9 | 0.7 | 3 | 0.2 | 6 | 0.5 | 0 | 0.0 | 2 | 0.2 | 6 | 0.5 | 0 | 0.0 | 2 | 0.1 | 1 | <0.1 | 4 | 0.3 |
| | Male | 6 | 0.5 | 13 | 1.1 | 1 | <0.1 | 3 | 0.2 | 0 | 0.0 | 3 | 0.2 | 6 | 0.5 | 1 | <0.1 | 2 | 0.2 | 2 | 0.2 | 0 | 0.0 |
| | Total | 13 | 0.5 | 22 | 0.9 | 4 | 0.2 | 9 | 0.4 | 0 | 0.0 | 5 | 0.2 | 12 | 0.5 | 1 | <0.1 | 4 | 0.2 | 3 | 0.1 | 4 | 0.2 |
| Rubella, congenital syndrome | Female | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 1 | <0.1 | 0 | 0.0 | 1 | <0.1 | 1 | <0.1 | 1 | <0.1 | 0 | 0.0 |
| | Male | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 1 | <0.1 | 0 | 0.0 |
| | Total | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 1 | <0.1 | 0 | 0.0 | 1 | <0.1 | 1 | <0.1 | 2 | <0.1 | 0 | 0.0 |

*Rates per 100,000 population. NR = Not reportable. NA = Not available.

[†]Due to missing sex data, the total number of cases reported by sex may not correspond with the total number of cases reported for a disease.

Continued

**Appendix Table 2: Number of cases and incidence rates* by disease and sex[†].
Toronto, 1995 - 2005**

| Disease | Sex | 1995 | | 1996 | | 1997 | | 1998 | | 1999 | | 2000 | | 2001 | | 2002 | | 2003 | | 2004 | | 2005 | |
|--|--------------|------------|----------------|------------|-------------|------------|----------------|------------|----------------|------------|----------------|------------|-------------|------------|----------------|------------|-------------|------------|-------------|------------|-------------|------------|-------------|
| | | # | Rate | # | Rate | # | Rate | # | Rate | # | Rate | # | Rate | # | Rate | # | Rate | # | Rate | # | Rate | # | Rate |
| Salmonellosis | Female | 467 | 37.4 | 428 | 33.8 | 429 | 33.5 | 540 | 41.9 | 308 | 23.8 | 355 | 27.2 | 316 | 23.8 | 318 | 23.7 | 272 | 20.3 | 229 | 17.2 | 339 | 25.4 |
| | Male | 409 | 34.6 | 397 | 33.2 | 424 | 35.0 | 443 | 36.3 | 332 | 27.0 | 303 | 24.4 | 355 | 28.1 | 319 | 25.0 | 264 | 20.7 | 252 | 19.9 | 347 | 27.4 |
| | Total | 883 | 36.3 | 830 | 33.7 | 855 | 34.3 | 985 | 39.3 | 644 | 25.5 | 658 | 25.8 | 671 | 25.9 | 637 | 24.3 | 536 | 20.5 | 482 | 18.5 | 686 | 26.4 |
| Severe acute respiratory syndrome (SARS) | Female | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | 147 | 11.0 | 0 | 0.0 | 0 | 0.0 | |
| | Male | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | 81 | 6.4 | 0 | 0.0 | 0 | 0.0 | |
| | Total | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | 228 | 8.7 | 0 | 0.0 | 0 | 0.0 | |
| Shigellosis | Female | 72 | 5.8 | 74 | 5.8 | 77 | 6.0 | 92 | 7.1 | 48 | 3.7 | 56 | 4.3 | 30 | 2.3 | 183 | 13.7 | 32 | 2.4 | 42 | 3.1 | 48 | 3.6 |
| | Male | 102 | 8.6 | 71 | 5.9 | 76 | 6.3 | 68 | 5.6 | 55 | 4.5 | 64 | 5.2 | 60 | 4.7 | 166 | 13.0 | 66 | 5.2 | 58 | 4.6 | 52 | 4.1 |
| | Total | 175 | 7.2 | 146 | 5.9 | 154 | 6.2 | 160 | 6.4 | 103 | 4.1 | 120 | 4.7 | 90 | 3.5 | 350 | 13.4 | 98 | 3.8 | 100 | 3.8 | 100 | 3.8 |
| Streptococcal infections, Group A invasive | Female | NR | NR | 17 | 1.3 | 34 | 2.7 | 34 | 2.6 | 30 | 2.3 | 35 | 2.7 | 31 | 2.3 | 45 | 3.4 | 39 | 2.9 | 28 | 2.1 | 31 | 2.3 |
| | Male | NR | NR | 23 | 1.9 | 37 | 3.1 | 31 | 2.5 | 24 | 2.0 | 40 | 3.2 | 41 | 3.2 | 59 | 4.6 | 31 | 2.4 | 24 | 1.9 | 41 | 3.2 |
| | Total | NR | NR | 40 | 1.6 | 72 | 2.9 | 65 | 2.6 | 54 | 2.1 | 76 | 3.0 | 72 | 2.8 | 105 | 4.0 | 70 | 2.7 | 52 | 2.0 | 72 | 2.8 |
| Streptococcal infections, Group B neonatal | Female | NR | NR | 9 | 0.7 | 5 | 0.4 | 3 | 0.2 | 8 | 0.6 | 3 | 0.2 | 11 | 0.8 | 12 | 0.9 | 10 | 0.7 | 7 | 0.5 | 4 | 0.3 |
| | Male | NR | NR | 5 | 0.4 | 7 | 0.6 | 0 | 0.0 | 3 | 0.2 | 7 | 0.6 | 11 | 0.9 | 8 | 0.6 | 8 | 0.6 | 9 | 0.7 | 8 | 0.6 |
| | Total | NR | NR | 14 | 0.6 | 12 | 0.5 | 3 | 0.1 | 11 | 0.4 | 10 | 0.4 | 23 | 0.9 | 20 | 0.8 | 18 | 0.7 | 16 | 0.6 | 12 | 0.5 |
| <i>Streptococcus pneumoniae</i> , invasive | Female | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | 124 | 9.3 | 110 | 8.2 | 98 | 7.3 | 85 | 6.4 |
| | Male | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | 151 | 11.8 | 125 | 9.8 | 164 | 12.9 | 131 | 10.3 |
| | Total | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | 276 | 10.5 | 235 | 9.0 | 263 | 10.1 | 216 | 8.3 |
| Syphilis, infectious | Female | 24 | 1.9 | 26 | 2.1 | 16 | 1.2 | 9 | 0.7 | 8 | 0.6 | 11 | 0.8 | 9 | 0.7 | 7 | 0.5 | 17 | 1.3 | 7 | 0.5 | 10 | 0.7 |
| | Male | 42 | 3.6 | 35 | 2.9 | 20 | 1.7 | 10 | 0.8 | 22 | 1.8 | 21 | 1.7 | 20 | 1.6 | 186 | 14.6 | 313 | 24.6 | 377 | 29.7 | 240 | 18.9 |
| | Total | 66 | 2.7 | 61 | 2.5 | 36 | 1.4 | 19 | 0.8 | 30 | 1.2 | 32 | 1.3 | 29 | 1.1 | 193 | 7.4 | 330 | 12.6 | 384 | 14.8 | 250 | 9.6 |
| Syphilis, late latent | Female | 75 | 6.0 | 63 | 5.0 | 57 | 4.5 | 50 | 3.9 | 54 | 4.2 | 77 | 5.9 | 59 | 4.4 | 75 | 5.6 | 45 | 3.4 | 47 | 3.5 | 218 | 16.3 |
| | Male | 94 | 8.0 | 63 | 5.3 | 61 | 5.0 | 53 | 4.3 | 62 | 5.0 | 75 | 6.0 | 62 | 4.9 | 88 | 6.9 | 86 | 6.7 | 102 | 8.0 | 266 | 21.0 |
| | Total | 169 | 7.0 | 126 | 5.1 | 118 | 4.7 | 103 | 4.1 | 117 | 4.6 | 152 | 6.0 | 122 | 4.7 | 164 | 6.3 | 131 | 5.0 | 149 | 5.7 | 484 | 18.6 |
| Syphilis, congenital | Female | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 1 | <0.1 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
| | Male | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 1 | <0.1 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
| | Total | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 1 | <0.1 | 1 | <0.1 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
| Syphilis, other [§] | Female | 3 | 0.2 | 1 | <0.1 | 1 | <0.1 | 2 | 0.2 | 2 | 0.2 | 0 | 0.0 | 0 | 0.0 | 2 | 0.1 | 5 | 0.4 | 1 | <0.1 | 1 | <0.1 |
| | Male | 5 | 0.4 | 2 | 0.2 | 1 | <0.1 | 2 | 0.2 | 2 | 0.2 | 3 | 0.2 | 1 | <0.1 | 9 | 0.7 | 9 | 0.7 | 18 | 1.4 | 10 | 0.8 |
| | Total | 8 | 0.3 | 3 | 0.1 | 2 | <0.1 | 4 | 0.2 | 4 | 0.2 | 3 | 0.1 | 1 | <0.1 | 11 | 0.4 | 14 | 0.5 | 19 | 0.7 | 11 | 0.4 |
| Tetanus | Female | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
| | Male | 1 | <0.1 | 0 | 0.0 | 1 | <0.1 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
| | Total | 1 | <0.1 | 0 | 0.0 | 1 | <0.1 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
| Tuberculosis | Female | 226 | 18.1 | 213 | 16.8 | 225 | 17.6 | 196 | 15.2 | 190 | 14.7 | 172 | 13.2 | 151 | 11.4 | 188 | 14.0 | 172 | 12.9 | 169 | 12.7 | 164 | 12.3 |
| | Male | 266 | 22.5 | 241 | 20.2 | 228 | 18.8 | 218 | 17.9 | 195 | 15.9 | 209 | 16.8 | 220 | 17.4 | 195 | 15.3 | 196 | 15.4 | 192 | 15.1 | 180 | 14.2 |
| | Total | 492 | 20.2 | 454 | 18.4 | 453 | 18.2 | 414 | 16.5 | 385 | 15.2 | 381 | 15.0 | 371 | 14.3 | 383 | 14.6 | 368 | 14.1 | 361 | 13.9 | 344 | 13.2 |
| Tularemia | Female | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
| | Male | 0 | 0.0 | 0 | 0.0 | 1 | <0.1 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
| | Total | 0 | 0.0 | 0 | 0.0 | 1 | <0.1 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
| Typhoid fever | Female | 11 | 0.9 | 5 | 0.4 | 6 | 0.5 | 6 | 0.5 | 8 | 0.6 | 15 | 1.1 | 13 | 1.0 | 15 | 1.1 | 14 | 1.0 | 16 | 1.2 | 13 | 1.0 |
| | Male | 13 | 1.1 | 7 | 0.6 | 10 | 0.8 | 9 | 0.7 | 11 | 0.9 | 9 | 0.7 | 18 | 1.4 | 15 | 1.2 | 11 | 0.9 | 12 | 0.9 | 10 | 0.8 |
| | Total | 24 | 1.0 | 12 | 0.5 | 16 | 0.6 | 15 | 0.6 | 19 | 0.8 | 24 | 0.9 | 31 | 1.2 | 30 | 1.1 | 25 | 1.0 | 28 | 1.1 | 23 | 0.9 |

*Rates per 100,000 population. NR = Not reportable. NA = Not available.

[†]Due to missing sex data, the total number of cases reported by sex may not correspond with the total number of cases reported for a disease.

[§]Excludes infectious, late latent and congenital syphilis.

Continued

**Appendix Table 2: Number of cases and incidence rates* by disease and sex[†].
Toronto, 1995 - 2005**

| Disease | Sex | 1995 | | 1996 | | 1997 | | 1998 | | 1999 | | 2000 | | 2001 | | 2002 | | 2003 | | 2004 | | 2005 | |
|---|--------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|-----------|------------|------------|------------|
| | | # | Rate | # | Rate | # | Rate | # | Rate | # | Rate | # | Rate | # | Rate | # | Rate | # | Rate | # | Rate | # | Rate |
| Verotoxin-producing <i>E. coli</i> infection | Female | 49 | 3.9 | 34 | 2.7 | 50 | 3.9 | 39 | 3.0 | 37 | 2.9 | 29 | 2.2 | 40 | 3.0 | 26 | 1.9 | 25 | 1.9 | 29 | 2.2 | 19 | 1.4 |
| | Male | 58 | 4.9 | 42 | 3.5 | 41 | 3.4 | 34 | 2.8 | 29 | 2.4 | 31 | 2.5 | 29 | 2.3 | 20 | 1.6 | 30 | 2.4 | 21 | 1.7 | 15 | 1.2 |
| | Total | 107 | 4.4 | 76 | 3.1 | 91 | 3.7 | 73 | 2.9 | 66 | 2.6 | 60 | 2.4 | 69 | 2.7 | 46 | 1.8 | 55 | 2.1 | 50 | 1.9 | 34 | 1.3 |
| West Nile Virus | Female | NR | | NR | | NR | | NR | | NR | | NR | | NR | | 89 | 6.6 | 24 | 1.8 | 4 | 0.3 | 22 | 1.6 |
| | Male | NR | | NR | | NR | | NR | | NR | | NR | | NR | | 74 | 5.8 | 20 | 1.6 | 2 | 0.2 | 16 | 1.3 |
| | Total | NR | | NR | | NR | | NR | | NR | | NR | | NR | | 163 | 6.2 | 44 | 1.7 | 6 | 0.2 | 38 | 1.5 |
| Yersiniosis | Female | 84 | 6.7 | 70 | 5.5 | 63 | 4.9 | 43 | 3.3 | 69 | 5.3 | 62 | 4.7 | 50 | 3.8 | 71 | 5.3 | 58 | 4.3 | 40 | 3.0 | 43 | 3.2 |
| | Male | 102 | 8.6 | 78 | 6.5 | 90 | 7.4 | 82 | 6.7 | 75 | 6.1 | 80 | 6.4 | 73 | 5.8 | 76 | 5.9 | 68 | 5.3 | 52 | 4.1 | 74 | 5.8 |
| | Total | 186 | 7.7 | 148 | 6.0 | 153 | 6.1 | 125 | 5.0 | 144 | 5.7 | 142 | 5.6 | 123 | 4.7 | 147 | 5.6 | 126 | 4.8 | 92 | 3.5 | 117 | 4.5 |

*Rates per 100,000 population. NR = Not reportable. NA = Not available.

[†]Due to missing sex data, the total number of cases reported by sex may not correspond with the total number of cases reported for a disease.

**Appendix Table 3: Number of cases by disease, sex* and age group.
Toronto, 2005**

| Disease | Sex | Age group (years) | | | | | | | | | | | | | | | | | | | |
|---------------------------------------|--------------|-------------------|-----------|------------|-------------|------------|-------------|-------------|-------------|------------|------------|------------|------------|-----------|-----------|-----------|-----------|-----------|-----------|-----------|----------|
| | | Total | <1 | 01-04 | 05-09 | 10-14 | 15-19 | 20-24 | 25-29 | 30-34 | 35-39 | 40-44 | 45-49 | 50-54 | 55-59 | 60-64 | 65-69 | 70-74 | 75-79 | 80-84 | 85+ |
| AIDS | Female | NA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| | Male | NA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| | Total | NA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| HIV | Female | 102 | 0 | 0 | 0 | 1 | 1 | 4 | 27 | 29 | 17 | 8 | 5 | 6 | 0 | 2 | 1 | 0 | 1 | 0 | 0 |
| | Male | 450 | 0 | 0 | 0 | 0 | 3 | 43 | 53 | 81 | 109 | 81 | 39 | 12 | 13 | 9 | 5 | 0 | 2 | 0 | 0 |
| | Total | 555 | 0 | 0 | 0 | 1 | 4 | 47 | 80 | 110 | 126 | 90 | 45 | 18 | 13 | 11 | 6 | 0 | 3 | 0 | 0 |
| Amebiasis | Female | 95 | 0 | 0 | 2 | 3 | 5 | 5 | 11 | 10 | 13 | 16 | 9 | 8 | 7 | 2 | 1 | 1 | 2 | 0 | 0 |
| | Male | 281 | 0 | 4 | 5 | 8 | 6 | 14 | 22 | 32 | 56 | 50 | 28 | 23 | 18 | 1 | 8 | 3 | 2 | 0 | 1 |
| | Total | 376 | 0 | 4 | 7 | 11 | 11 | 19 | 33 | 42 | 69 | 66 | 37 | 31 | 25 | 3 | 9 | 4 | 4 | 0 | 1 |
| Botulism | Female | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| | Male | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| | Total | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Brucellosis | Female | 2 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| | Male | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| | Total | 3 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Campylobacter enteritis | Female | 444 | 4 | 41 | 19 | 16 | 21 | 45 | 51 | 46 | 34 | 23 | 27 | 25 | 18 | 19 | 12 | 15 | 13 | 11 | 4 |
| | Male | 553 | 5 | 48 | 32 | 25 | 26 | 38 | 58 | 48 | 53 | 47 | 35 | 40 | 35 | 19 | 15 | 11 | 11 | 2 | 5 |
| | Total | 997 | 9 | 89 | 51 | 41 | 47 | 83 | 109 | 94 | 87 | 70 | 62 | 65 | 53 | 38 | 27 | 26 | 24 | 13 | 9 |
| Chickenpox [†] | Total | 3668 | 42 | 773 | 2086 | 559 | 75 | 27 | 29 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 71 | |
| Chlamydia | Female | 3804 | 1 | 0 | 0 | 22 | 1030 | 1353 | 657 | 345 | 185 | 117 | 48 | 34 | 4 | 6 | 2 | 0 | 0 | 0 | 0 |
| | Male | 2690 | 1 | 0 | 0 | 0 | 283 | 825 | 570 | 383 | 279 | 173 | 96 | 35 | 36 | 6 | 1 | 1 | 0 | 1 | 0 |
| | Total | 6497 | 2 | 0 | 0 | 22 | 1315 | 2179 | 1227 | 728 | 464 | 290 | 144 | 69 | 40 | 12 | 3 | 1 | 0 | 1 | 0 |
| Cholera | Female | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| | Male | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| | Total | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cryptosporidiosis | Female | 14 | 1 | 5 | 7 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| | Male | 38 | 1 | 1 | 5 | 1 | 0 | 1 | 3 | 11 | 4 | 6 | 1 | 2 | 0 | 1 | 1 | 0 | 0 | 0 | 0 |
| | Total | 52 | 2 | 6 | 12 | 1 | 0 | 1 | 3 | 11 | 4 | 6 | 1 | 2 | 0 | 1 | 1 | 0 | 0 | 1 | 0 |
| Cyclosporiasis | Female | 24 | 0 | 1 | 0 | 0 | 10 | 1 | 2 | 0 | 1 | 1 | 1 | 2 | 2 | 2 | 0 | 0 | 1 | 0 | 0 |
| | Male | 24 | 0 | 0 | 0 | 0 | 5 | 3 | 0 | 2 | 2 | 1 | 3 | 1 | 1 | 1 | 1 | 2 | 2 | 0 | 0 |
| | Total | 48 | 0 | 1 | 0 | 0 | 15 | 4 | 2 | 2 | 3 | 2 | 4 | 3 | 3 | 3 | 1 | 2 | 3 | 0 | 0 |
| Cytomegalovirus infection, congenital | Female | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| | Male | 2 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| | Total | 3 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Encephalitis/ Meningitis: bacterial | Female | 2 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| | Male | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| | Total | 4 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Encephalitis/ Meningitis: viral | Female | 24 | 9 | 1 | 1 | 2 | 0 | 2 | 6 | 0 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| | Male | 31 | 9 | 3 | 3 | 3 | 3 | 1 | 2 | 2 | 0 | 3 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 |
| | Total | 55 | 18 | 4 | 4 | 5 | 3 | 3 | 8 | 2 | 1 | 4 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 1 |
| Encephalitis/ Meningitis: other | Female | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| | Male | 4 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| | Total | 6 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |

*Due to missing sex data, the total number of cases reported by sex may not correspond with the total number of cases reported for a disease.

†Reports of chickenpox are received in aggregate numbers based on the following defined age categories: <1, 1-4, 5-9, 10-14, 15-19, 20-24, 25-29, 30-39, 40-49, 50-59, 60+.

Continued

**Appendix Table 3: Number of cases by disease, sex* and age group.
Toronto, 2005**

| Disease | Sex | Age group (years) | | | | | | | | | | | | | | | | | | | | |
|--|--------------|-------------------|-----------|------------|-----------|-----------|------------|------------|------------|------------|------------|------------|------------|------------|-----------|-----------|-----------|-----------|-----------|-----------|-----------|----------|
| | | Total | <1 | 01-04 | 05-09 | 10-14 | 15-19 | 20-24 | 25-29 | 30-34 | 35-39 | 40-44 | 45-49 | 50-54 | 55-59 | 60-64 | 65-69 | 70-74 | 75-79 | 80-84 | 85+ | Unk. |
| Encephalitis/ Meningitis: unclassified | Female | 2 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| | Male | 5 | 0 | 0 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| | Total | 7 | 0 | 0 | 1 | 1 | 1 | 2 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Giardiasis | Female | 188 | 2 | 23 | 28 | 10 | 8 | 17 | 13 | 15 | 18 | 15 | 9 | 10 | 5 | 7 | 1 | 2 | 3 | 2 | 0 | 0 |
| | Male | 359 | 1 | 41 | 35 | 13 | 11 | 23 | 40 | 36 | 41 | 42 | 26 | 15 | 17 | 6 | 5 | 3 | 3 | 1 | 0 | 0 |
| | Total | 547 | 3 | 64 | 63 | 23 | 19 | 40 | 53 | 51 | 59 | 57 | 35 | 25 | 22 | 13 | 6 | 5 | 6 | 3 | 0 | 0 |
| Gonorrhea | Female | 501 | 0 | 0 | 0 | 8 | 162 | 179 | 77 | 38 | 20 | 7 | 4 | 3 | 1 | 0 | 1 | 0 | 1 | 0 | 0 | 0 |
| | Male | 1156 | 0 | 0 | 0 | 0 | 77 | 252 | 227 | 185 | 170 | 131 | 55 | 34 | 14 | 7 | 3 | 1 | 0 | 0 | 0 | 0 |
| | Total | 1659 | 0 | 0 | 0 | 8 | 239 | 431 | 305 | 224 | 190 | 138 | 59 | 37 | 15 | 7 | 4 | 1 | 1 | 0 | 0 | 0 |
| <i>Haemophilus influenzae</i> b disease, invasive | Female | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| | Male | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| | Total | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hemorrhagic fevers | Female | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| | Male | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| | Total | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hepatitis A | Female | 18 | 0 | 0 | 5 | 2 | 4 | 3 | 1 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| | Male | 30 | 0 | 3 | 4 | 5 | 1 | 1 | 3 | 2 | 1 | 2 | 3 | 1 | 2 | 1 | 0 | 0 | 1 | 0 | 0 | 0 |
| | Total | 48 | 0 | 3 | 9 | 7 | 5 | 4 | 4 | 3 | 1 | 2 | 4 | 1 | 2 | 1 | 1 | 0 | 1 | 0 | 0 | 0 |
| Hepatitis B cases | Female | 8 | 0 | 0 | 0 | 0 | 0 | 4 | 0 | 0 | 2 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| | Male | 26 | 0 | 0 | 0 | 0 | 0 | 2 | 3 | 6 | 4 | 3 | 1 | 1 | 3 | 2 | 0 | 0 | 1 | 0 | 0 | 0 |
| | Total | 34 | 0 | 0 | 0 | 0 | 0 | 6 | 3 | 6 | 6 | 3 | 1 | 1 | 5 | 2 | 0 | 0 | 1 | 0 | 0 | 0 |
| Hepatitis B carriers | Female | 688 | 0 | 1 | 4 | 4 | 30 | 98 | 113 | 125 | 86 | 76 | 46 | 30 | 17 | 22 | 14 | 8 | 7 | 4 | 3 | 0 |
| | Male | 774 | 0 | 1 | 1 | 8 | 30 | 59 | 98 | 138 | 129 | 107 | 65 | 53 | 35 | 23 | 8 | 10 | 7 | 2 | 0 | 0 |
| | Total | 1469 | 0 | 2 | 5 | 12 | 60 | 159 | 213 | 264 | 215 | 184 | 111 | 83 | 53 | 45 | 22 | 18 | 14 | 6 | 3 | 0 |
| Hepatitis B unclassified reports | Female | 372 | 1 | 1 | 2 | 5 | 24 | 58 | 65 | 64 | 35 | 39 | 23 | 16 | 11 | 10 | 6 | 5 | 3 | 3 | 1 | 0 |
| | Male | 476 | 0 | 3 | 2 | 5 | 22 | 58 | 54 | 79 | 68 | 57 | 52 | 38 | 15 | 9 | 5 | 4 | 4 | 1 | 0 | 0 |
| | Total | 852 | 1 | 4 | 4 | 10 | 46 | 117 | 119 | 143 | 106 | 96 | 75 | 54 | 26 | 19 | 11 | 9 | 7 | 4 | 1 | 0 |
| Hepatitis C | Female | 427 | 7 | 0 | 0 | 1 | 5 | 16 | 26 | 38 | 55 | 59 | 61 | 36 | 32 | 23 | 18 | 16 | 20 | 11 | 3 | 0 |
| | Male | 735 | 5 | 0 | 2 | 1 | 5 | 25 | 42 | 54 | 103 | 141 | 110 | 113 | 51 | 15 | 22 | 14 | 16 | 11 | 5 | 0 |
| | Total | 1165 | 12 | 0 | 2 | 2 | 11 | 41 | 68 | 92 | 158 | 200 | 171 | 149 | 83 | 38 | 40 | 30 | 38 | 22 | 8 | 0 |
| Hepatitis D | Female | 2 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| | Male | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| | Total | 5 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 2 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Herpes, neonatal | Female | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| | Male | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| | Total | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Influenza [†] | Female | 248 | 22 | 50 | 40 | 14 | 7 | 8 | 3 | 8 | 1 | 8 | 3 | 4 | 4 | 4 | 5 | 5 | 10 | 14 | 38 | 0 |
| | Male | 268 | 51 | 75 | 41 | 16 | 7 | 4 | 2 | 2 | 3 | 2 | 1 | 3 | 7 | 3 | 2 | 1 | 9 | 15 | 24 | 0 |
| | Total | 517 | 73 | 126 | 81 | 30 | 14 | 12 | 5 | 10 | 4 | 10 | 4 | 7 | 11 | 7 | 7 | 6 | 19 | 29 | 62 | 0 |
| Legionellosis | Female | 30 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 1 | 1 | 4 | 5 | 17 | 0 |
| | Male | 23 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 1 | 1 | 4 | 3 | 0 | 0 | 1 | 4 | 3 | 4 | 0 |
| | Total | 53 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 2 | 1 | 4 | 3 | 1 | 1 | 2 | 8 | 8 | 21 | 0 |

*Due to missing sex data, the total number of cases reported by sex may not correspond with the total number of cases reported for a disease.

[†]Seasonal year from July to June (eg. 2005/06 includes cases from July 1, 2005 to June 30, 2006).

Continued

**Appendix Table 3: Number of cases by disease, sex* and age group.
Toronto, 2005**

| Disease | Sex | Age group (years) | | | | | | | | | | | | | | | | | | | |
|---------------------------------|--------------|-------------------|-----------|-----------|-----------|-----------|----------|----------|----------|-----------|-----------|-----------|-----------|----------|----------|----------|----------|----------|----------|----------|----------|
| | | Total | <1 | 01-04 | 05-09 | 10-14 | 15-19 | 20-24 | 25-29 | 30-34 | 35-39 | 40-44 | 45-49 | 50-54 | 55-59 | 60-64 | 65-69 | 70-74 | 75-79 | 80-84 | 85+ |
| Leprosy | Female | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| | Male | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| | Total | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Listeriosis | Female | 7 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 1 | 1 | 0 | 2 | 0 |
| | Male | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 0 | 0 | 0 |
| | Total | 10 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 2 | 3 | 0 | 2 | 0 |
| Lyme disease | Female | 5 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| | Male | 8 | 0 | 0 | 1 | 1 | 0 | 1 | 0 | 1 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| | Total | 13 | 0 | 0 | 1 | 2 | 0 | 1 | 0 | 2 | 2 | 1 | 0 | 2 | 0 | 0 | 0 | 1 | 1 | 0 | 0 |
| Malaria | Female | 26 | 0 | 1 | 3 | 2 | 1 | 1 | 4 | 1 | 2 | 5 | 4 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 |
| | Male | 64 | 0 | 1 | 1 | 1 | 2 | 4 | 1 | 11 | 10 | 5 | 12 | 6 | 6 | 1 | 3 | 0 | 0 | 0 | 0 |
| | Total | 90 | 0 | 2 | 4 | 3 | 3 | 5 | 5 | 12 | 12 | 10 | 16 | 6 | 6 | 1 | 5 | 0 | 0 | 0 | 0 |
| Measles | Female | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| | Male | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| | Total | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Meningococcal disease, invasive | Female | 2 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| | Male | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| | Total | 3 | 0 | 0 | 0 | 0 | 2 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Mumps | Female | 2 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| | Male | 5 | 0 | 0 | 1 | 1 | 0 | 1 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| | Total | 7 | 0 | 0 | 2 | 1 | 0 | 1 | 0 | 2 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Ophthalmia neonatorum | Female | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| | Male | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| | Total | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Paratyphoid fever | Female | 8 | 0 | 1 | 1 | 0 | 0 | 0 | 2 | 1 | 2 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| | Male | 5 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| | Total | 13 | 0 | 1 | 1 | 0 | 0 | 1 | 4 | 1 | 3 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Pertussis | Female | 91 | 24 | 39 | 4 | 7 | 2 | 2 | 0 | 1 | 4 | 0 | 5 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 0 |
| | Male | 86 | 24 | 28 | 8 | 17 | 2 | 0 | 1 | 2 | 2 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| | Total | 177 | 48 | 67 | 12 | 24 | 4 | 2 | 1 | 3 | 6 | 1 | 5 | 1 | 0 | 0 | 0 | 1 | 1 | 1 | 0 |
| Psittacosis/ Ornithosis | Female | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| | Male | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| | Total | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Q fever | Female | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| | Male | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| | Total | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Rubella | Female | 4 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| | Male | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| | Total | 4 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Rubella, congenital syndrome | Female | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| | Male | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| | Total | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |

*Due to missing sex data, the total number of cases reported by sex may not correspond with the total number of cases reported for a disease.

Continued

**Appendix Table 3: Number of cases by disease, sex* and age group.
Toronto, 2005**

| Disease | Sex | Age group (years) | | | | | | | | | | | | | | | | | | | | Unk. |
|--|--------------|-------------------|-----------|-----------|-----------|-----------|-----------|-----------|-----------|-----------|-----------|-----------|-----------|-----------|-----------|-----------|-----------|-----------|-----------|-----------|-----------|----------|
| | | Total | <1 | 01-04 | 05-09 | 10-14 | 15-19 | 20-24 | 25-29 | 30-34 | 35-39 | 40-44 | 45-49 | 50-54 | 55-59 | 60-64 | 65-69 | 70-74 | 75-79 | 80-84 | 85+ | |
| Salmonellosis | Female | 339 | 11 | 36 | 26 | 19 | 18 | 35 | 36 | 33 | 17 | 21 | 15 | 17 | 8 | 11 | 9 | 12 | 7 | 6 | 2 | 0 |
| | Male | 347 | 15 | 42 | 32 | 20 | 15 | 25 | 36 | 36 | 23 | 23 | 17 | 15 | 13 | 5 | 12 | 6 | 4 | 5 | 3 | 0 |
| | Total | 686 | 26 | 78 | 58 | 39 | 33 | 60 | 72 | 69 | 40 | 44 | 32 | 32 | 21 | 16 | 21 | 18 | 11 | 11 | 5 | 0 |
| Severe acute respiratory syndrome (SARS) | Female | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| | Male | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| | Total | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Shigellosis | Female | 48 | 0 | 7 | 7 | 6 | 0 | 2 | 2 | 6 | 5 | 3 | 3 | 2 | 3 | 0 | 0 | 1 | 1 | 0 | 0 | 0 |
| | Male | 52 | 0 | 9 | 7 | 2 | 1 | 4 | 3 | 4 | 6 | 7 | 7 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| | Total | 100 | 0 | 16 | 14 | 8 | 1 | 6 | 5 | 10 | 11 | 10 | 10 | 2 | 4 | 0 | 0 | 1 | 2 | 0 | 0 | 0 |
| Streptococcal infections, Group A invasive | Female | 31 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 3 | 5 | 1 | 0 | 2 | 2 | 0 | 1 | 5 | 3 | 2 | 3 | 0 |
| | Male | 41 | 1 | 0 | 3 | 0 | 0 | 0 | 0 | 1 | 4 | 5 | 3 | 2 | 1 | 5 | 3 | 3 | 5 | 1 | 4 | 0 |
| | Total | 72 | 1 | 0 | 3 | 1 | 1 | 1 | 1 | 4 | 9 | 6 | 3 | 4 | 3 | 5 | 4 | 8 | 8 | 3 | 7 | 0 |
| Streptococcal infections, Group B neonatal | Female | 4 | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| | Male | 8 | 8 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| | Total | 12 | 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| <i>Streptococcus pneumoniae</i> , invasive | Female | 85 | 1 | 6 | 3 | 3 | 0 | 1 | 3 | 3 | 5 | 3 | 4 | 2 | 8 | 6 | 5 | 7 | 7 | 6 | 12 | 0 |
| | Male | 131 | 4 | 7 | 0 | 0 | 0 | 0 | 4 | 7 | 5 | 17 | 14 | 11 | 9 | 6 | 10 | 15 | 11 | 5 | 6 | 0 |
| | Total | 216 | 5 | 13 | 3 | 3 | 0 | 1 | 7 | 10 | 10 | 20 | 18 | 13 | 17 | 12 | 15 | 22 | 18 | 11 | 18 | 0 |
| Syphilis, infectious | Female | 10 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 2 | 1 | 1 | 0 | 1 | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| | Male | 240 | 0 | 0 | 0 | 0 | 3 | 26 | 28 | 28 | 60 | 50 | 19 | 14 | 6 | 5 | 0 | 1 | 0 | 0 | 0 | 0 |
| | Total | 250 | 0 | 0 | 0 | 0 | 3 | 27 | 28 | 30 | 61 | 51 | 19 | 15 | 10 | 5 | 0 | 1 | 0 | 0 | 0 | 0 |
| Syphilis, late latent | Female | 218 | 0 | 0 | 0 | 0 | 0 | 7 | 15 | 22 | 18 | 22 | 23 | 20 | 18 | 24 | 20 | 8 | 10 | 8 | 3 | 0 |
| | Male | 266 | 0 | 0 | 0 | 0 | 2 | 11 | 10 | 19 | 35 | 48 | 41 | 25 | 25 | 13 | 12 | 8 | 8 | 5 | 4 | 0 |
| | Total | 484 | 0 | 0 | 0 | 0 | 2 | 18 | 25 | 41 | 53 | 70 | 64 | 45 | 43 | 37 | 32 | 16 | 18 | 13 | 7 | 0 |
| Syphilis, congenital | Female | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| | Male | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| | Total | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Syphilis, other [§] | Female | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| | Male | 10 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 2 | 3 | 0 | 1 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 |
| | Total | 11 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 2 | 3 | 0 | 2 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 |
| Tetanus | Female | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| | Male | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| | Total | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Tuberculosis | Female | 164 | 0 | 3 | 2 | 6 | 11 | 17 | 13 | 23 | 16 | 16 | 8 | 7 | 3 | 8 | 3 | 9 | 5 | 7 | 7 | 0 |
| | Male | 180 | 0 | 4 | 1 | 5 | 2 | 19 | 12 | 21 | 14 | 20 | 22 | 11 | 10 | 7 | 7 | 9 | 6 | 5 | 5 | 0 |
| | Total | 344 | 0 | 7 | 3 | 11 | 13 | 36 | 25 | 44 | 30 | 36 | 30 | 18 | 13 | 15 | 10 | 18 | 11 | 12 | 12 | 0 |
| Tularemia | Female | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| | Male | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| | Total | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Typhoid fever | Female | 13 | 0 | 4 | 1 | 1 | 1 | 1 | 2 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| | Male | 10 | 0 | 0 | 2 | 1 | 2 | 0 | 1 | 1 | 1 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| | Total | 23 | 0 | 4 | 3 | 2 | 3 | 1 | 3 | 1 | 1 | 1 | 0 | 2 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |

* Due to missing sex data, the total number of cases reported by sex may not correspond with the total number of cases reported for a disease.

[§]Excludes infectious, late latent and congenital syphilis.

Continued

**Appendix Table 3: Number of cases by disease, sex* and age group.
Toronto, 2005**

| Disease | Sex | Age group (years) | | | | | | | | | | | | | | | | | | | | |
|--|--------------|-------------------|-----------|-----------|-----------|-----------|----------|----------|----------|----------|----------|----------|----------|----------|----------|----------|----------|----------|----------|----------|----------|----------|
| | | Total | <1 | 01-04 | 05-09 | 10-14 | 15-19 | 20-24 | 25-29 | 30-34 | 35-39 | 40-44 | 45-49 | 50-54 | 55-59 | 60-64 | 65-69 | 70-74 | 75-79 | 80-84 | 85+ | Unk. |
| Verotoxin-producing <i>E. coli</i> infections | Female | 19 | 0 | 3 | 4 | 3 | 1 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 1 | 0 | 1 | 2 | 1 | 0 | 0 |
| | Male | 15 | 0 | 1 | 3 | 2 | 2 | 2 | 1 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 |
| | Total | 34 | 0 | 4 | 7 | 5 | 3 | 3 | 1 | 0 | 2 | 0 | 0 | 1 | 1 | 1 | 0 | 2 | 2 | 2 | 0 | 0 |
| West Nile Virus | Female | 22 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 2 | 0 | 3 | 4 | 1 | 1 | 4 | 0 | 2 | 1 | 0 | 2 | 0 |
| | Male | 16 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 1 | 0 | 0 | 2 | 1 | 2 | 2 | 1 | 1 | 1 | 1 | 1 | 2 |
| | Total | 38 | 0 | 0 | 0 | 0 | 0 | 2 | 2 | 3 | 0 | 3 | 6 | 2 | 3 | 6 | 1 | 3 | 2 | 1 | 4 | 0 |
| Yersiniosis | Female | 43 | 7 | 11 | 3 | 2 | 2 | 5 | 2 | 4 | 1 | 1 | 2 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 1 | 0 |
| | Male | 74 | 6 | 20 | 13 | 8 | 4 | 2 | 6 | 2 | 3 | 2 | 3 | 2 | 1 | 2 | 0 | 0 | 0 | 0 | 0 | 0 |
| | Total | 117 | 13 | 31 | 16 | 10 | 6 | 7 | 8 | 6 | 4 | 3 | 5 | 2 | 2 | 2 | 1 | 0 | 0 | 0 | 1 | 0 |

*Due to missing sex data, the total number of cases reported by sex may not correspond with the total number of cases reported for a disease.

**Appendix Table 4: 5-year and 10-year means and incidence rates* by disease and sex[†].
Toronto, 1995 - 2004**

| Disease | Sex | 5-year mean 1995-1999 | | 5-year mean 2000-2004 | | 10-year mean 1995-2004 | |
|---------------------------------------|--------------|--------------------------|----------------|--------------------------|----------------|---------------------------|----------------|
| | | # | Rate | # | Rate | # | Rate |
| AIDS | Female | NA | - | NA | - | NA | - |
| | Male | NA | - | NA | - | NA | - |
| | Total | NA | - | NA | - | NA | - |
| HIV | Female | 67 | 5.3 | 118 | 8.9 | 93 | 7.1 |
| | Male | 423 | 35.1 | 425 | 33.6 | 424 | 34.3 |
| | Total | 493 | 19.8 | 546 | 21.0 | 519 | 20.5 |
| Amebiasis | Female | 106 | 8.3 | 106 | 7.9 | 106 | 8.1 |
| | Male | 284 | 23.5 | 299 | 23.6 | 291 | 23.6 |
| | Total | 391 | 15.8 | 404 | 15.6 | 398 | 15.7 |
| Botulism | Female | <1 | <0.1 | <1 | <0.1 | <1 | <0.1 |
| | Male | <1 | <0.1 | <1 | <0.1 | <1 | <0.1 |
| | Total | <1 | <0.1 | <1 | <0.1 | <1 | <0.1 |
| Brucellosis | Female | <1 | <0.1 | <1 | <0.1 | <1 | <0.1 |
| | Male | <1 | <0.1 | 1 | <0.1 | <1 | <0.1 |
| | Total | <1 | <0.1 | 1 | <0.1 | <1 | <0.1 |
| <i>Campylobacter</i> enteritis | Female | 768 | 60.2 | 594 | 44.7 | 681 | 52.3 |
| | Male | 853 | 70.7 | 708 | 55.9 | 781 | 63.1 |
| | Total | 1625 | 65.4 | 1303 | 50.2 | 1464 | 57.7 |
| Chickenpox | Total | 3191 | 128.5 | 3578 | 137.9 | 3385 | 133.3 |
| Chlamydia | Female | 3097 | 242.6 | 3725 | 280.2 | 3411 | 261.8 |
| | Male | 1306 | 108.2 | 2273 | 179.6 | 1790 | 144.8 |
| | Total | 4404 | 177.3 | 5999 | 231.2 | 5202 | 204.9 |
| Cholera | Female | <1 | <0.1 | 0 | 0.0 | <1 | <0.1 |
| | Male | <1 | <0.1 | 0 | 0.0 | <1 | <0.1 |
| | Total | <1 | <0.1 | 0 | 0.0 | <1 | <0.1 |
| Cryptosporidiosis | Female | NR | - | 11 | 0.9 | NR | - |
| | Male | NR | - | 31 | 2.4 | NR | - |
| | Total | NR | - | 42 | 1.6 | NR | - |
| Cyclosporiasis | Female | NR | - | NR | - | NR | - |
| | Male | NR | - | NR | - | NR | - |
| | Total | NR | - | NR | - | NR | - |
| Cytomegalovirus infection, congenital | Female | 2 | 0.1 | 0 | 0.0 | <1 | <0.1 |
| | Male | <1 | <0.1 | <1 | <0.1 | <1 | <0.1 |
| | Total | 2 | <0.1 | <1 | <0.1 | 2 | <0.1 |
| Encephalitis/Meningitis: bacterial | Female | 8 | 0.6 | 5 | 0.4 | 7 | 0.5 |
| | Male | 6 | 0.5 | 7 | 0.6 | 7 | 0.6 |
| | Total | 14 | 0.6 | 13 | 0.5 | 14 | 0.5 |
| Encephalitis/Meningitis: viral | Female | 16 | 1.2 | 26 | 2.0 | 21 | 1.6 |
| | Male | 18 | 1.5 | 34 | 2.7 | 26 | 2.1 |
| | Total | 34 | 1.4 | 60 | 2.3 | 47 | 1.9 |
| Encephalitis/Meningitis: other | Female | <1 | <0.1 | 1 | 0.1 | 1 | <0.1 |
| | Male | 7 | 0.6 | 3 | 0.3 | 5 | 0.4 |
| | Total | 7 | 0.3 | 5 | 0.2 | 6 | 0.2 |

* Rates per 100,000 population. NR = Not reportable. NA = Not available.

[†] Due to missing sex data, the total number of cases reported by sex may not correspond with the total number of cases reported for a disease.

Continued

**Appendix Table 4: 5-year and 10-year means and incidence rates* by disease and sex[†].
Toronto, 1995 - 2004**

| Disease | Sex | 5-year mean 1995-1999 | | 5-year mean 2000-2004 | | 10-year mean 1995-2004 | |
|--|--------------|--------------------------|----------------|--------------------------|----------------|---------------------------|----------------|
| | | # | Rate | # | Rate | # | Rate |
| Encephalitis/Meningitis: unclassified | Female | 2 | 0.1 | 4 | 0.3 | 3 | 0.2 |
| | Male | 3 | 0.2 | 4 | 0.3 | 3 | 0.3 |
| | Total | 4 | 0.2 | 7 | 0.3 | 6 | 0.2 |
| Giardiasis | Female | 216 | 16.9 | 201 | 15.1 | 208 | 16.0 |
| | Male | 347 | 28.8 | 357 | 28.2 | 352 | 28.5 |
| | Total | 563 | 22.7 | 557 | 21.5 | 560 | 22.1 |
| Gonorrhea | Female | 568 | 44.5 | 586 | 44.1 | 577 | 44.3 |
| | Male | 915 | 75.8 | 1189 | 94.0 | 1052 | 85.1 |
| | Total | 1484 | 59.7 | 1776 | 68.4 | 1630 | 64.2 |
| <i>Haemophilus influenzae</i> b disease, invasive | Female | <1 | <0.1 | 1 | <0.1 | <1 | <0.1 |
| | Male | 0 | 0.0 | 2 | 0.2 | 1 | <0.1 |
| | Total | <1 | <0.1 | 3 | 0.1 | 2 | <0.1 |
| Hemorrhagic fevers | Female | <1 | <0.1 | 0 | 0.0 | <1 | <0.1 |
| | Male | <1 | <0.1 | 0 | 0.0 | <1 | <0.1 |
| | Total | <1 | <0.1 | 0 | 0.0 | <1 | <0.1 |
| Hepatitis A | Female | 55 | 4.3 | 24 | 1.8 | 39 | 3.0 |
| | Male | 117 | 9.7 | 31 | 2.5 | 74 | 6.0 |
| | Total | 172 | 6.9 | 55 | 2.1 | 114 | 4.5 |
| Hepatitis B cases | Female | 20 | 1.6 | 13 | 1.0 | 17 | 1.3 |
| | Male | 38 | 3.2 | 26 | 2.1 | 32 | 2.6 |
| | Total | 58 | 2.4 | 39 | 1.5 | 49 | 1.9 |
| Hepatitis B carriers | Female | 1073 | 84.0 | 970 | 73.0 | 1021 | 78.4 |
| | Male | 1270 | 105.2 | 1136 | 89.8 | 1203 | 97.3 |
| | Total | 2374 | 95.6 | 2120 | 81.7 | 2247 | 88.5 |
| Hepatitis B unclassified reports | Female | 146 | 11.4 | 180 | 13.5 | 163 | 12.5 |
| | Male | 180 | 14.9 | 249 | 19.7 | 215 | 17.4 |
| | Total | 331 | 13.3 | 435 | 16.8 | 383 | 15.1 |
| Hepatitis C | Female | 812 | 63.6 | 535 | 40.2 | 673 | 51.7 |
| | Male | 1437 | 119.0 | 885 | 69.9 | 1161 | 93.9 |
| | Total | 2261 | 91.0 | 1430 | 55.1 | 1846 | 72.7 |
| Hepatitis D | Female | <1 | <0.1 | 1 | <0.1 | <1 | <0.1 |
| | Male | 2 | 0.1 | 2 | 0.2 | 2 | 0.2 |
| | Total | 2 | <0.1 | 3 | 0.1 | 3 | 0.1 |
| Herpes, neonatal | Female | <1 | <0.1 | 1 | <0.1 | <1 | <0.1 |
| | Male | <1 | <0.1 | <1 | <0.1 | <1 | <0.1 |
| | Total | <1 | <0.1 | 2 | <0.1 | 1 | <0.1 |
| Influenza [‡] | Female | 166 | 13.0 | 231 | 17.4 | 198 | 15.2 |
| | Male | 165 | 13.7 | 202 | 15.9 | 183 | 14.8 |
| | Total | 331 | 13.3 | 433 | 16.7 | 382 | 15.0 |
| Legionellosis | Female | 6 | 0.5 | 3 | 0.3 | 5 | 0.4 |
| | Male | 11 | 0.9 | 6 | 0.5 | 8 | 0.7 |
| | Total | 17 | 0.7 | 9 | 0.4 | 13 | 0.5 |

* Rates per 100,000 population. NR = Not reportable. NA = Not available.

[†] Due to missing sex data, the total number of cases reported by sex may not correspond with the total number of cases reported for a disease.

[‡] Seasonal year from July to June (eg. 2005/06 includes cases from July 1, 2005 to June 30, 2006).

Continued

**Appendix Table 4: 5-year and 10-year means and incidence rates* by disease and sex[†].
Toronto, 1995 - 2004**

| Disease | Sex | 5-year mean 1995-1999 | | 5-year mean 2000-2004 | | 10-year mean 1995-2004 | |
|---------------------------------|--------------|--------------------------|----------------|--------------------------|----------------|---------------------------|----------------|
| | | # | Rate | # | Rate | # | Rate |
| Leptosy | Female | <1 | <0.1 | 0 | 0.0 | <1 | <0.1 |
| | Male | 2 | 0.2 | 1 | <0.1 | 2 | 0.1 |
| | Total | 3 | 0.1 | 1 | <0.1 | 2 | <0.1 |
| Listeriosis | Female | 4 | 0.3 | 7 | 0.5 | 6 | 0.4 |
| | Male | 5 | 0.4 | 4 | 0.3 | 4 | 0.3 |
| | Total | 9 | 0.3 | 11 | 0.4 | 10 | 0.4 |
| Lyme disease | Female | 5 | 0.4 | 4 | 0.3 | 4 | 0.3 |
| | Male | 3 | 0.2 | 3 | 0.2 | 3 | 0.2 |
| | Total | 8 | 0.3 | 7 | 0.3 | 7 | 0.3 |
| Malaria | Female | 58 | 4.6 | 25 | 1.9 | 42 | 3.2 |
| | Male | 87 | 7.2 | 65 | 5.1 | 76 | 6.2 |
| | Total | 147 | 5.9 | 90 | 3.5 | 119 | 4.7 |
| Measles | Female | 28 | 2.2 | 2 | 0.2 | 15 | 1.2 |
| | Male | 36 | 3.0 | 2 | 0.2 | 19 | 1.5 |
| | Total | 64 | 2.6 | 5 | 0.2 | 34 | 1.4 |
| Meningococcal disease, invasive | Female | 9 | 0.7 | 9 | 0.6 | 9 | 0.7 |
| | Male | 8 | 0.6 | 7 | 0.5 | 7 | 0.6 |
| | Total | 16 | 0.7 | 15 | 0.6 | 16 | 0.6 |
| Mumps | Female | 7 | 0.5 | 2 | 0.2 | 5 | 0.4 |
| | Male | 9 | 0.7 | 1 | 0.1 | 5 | 0.4 |
| | Total | 16 | 0.6 | 4 | 0.1 | 10 | 0.4 |
| Ophthalmia neonatorum | Female | 2 | 0.2 | 1 | 0.1 | 2 | 0.1 |
| | Male | 2 | 0.2 | 1 | 0.1 | 2 | 0.1 |
| | Total | 4 | 0.2 | 3 | 0.1 | 3 | 0.1 |
| Paratyphoid fever | Female | 2 | 0.2 | 4 | 0.3 | 3 | 0.2 |
| | Male | 3 | 0.3 | 5 | 0.4 | 4 | 0.3 |
| | Total | 6 | 0.2 | 9 | 0.3 | 7 | 0.3 |
| Pertussis | Female | 63 | 4.9 | 45 | 3.4 | 54 | 4.2 |
| | Male | 61 | 5.0 | 44 | 3.4 | 52 | 4.2 |
| | Total | 124 | 5.0 | 89 | 3.4 | 107 | 4.2 |
| Psittacosis/Ornithosis | Female | <1 | <0.1 | 0 | 0.0 | <1 | <0.1 |
| | Male | <1 | <0.1 | 0 | 0.0 | <1 | <0.1 |
| | Total | <1 | <0.1 | 0 | 0.0 | <1 | <0.1 |
| Q fever | Female | <1 | <0.1 | <1 | <0.1 | <1 | <0.1 |
| | Male | 1 | <0.1 | <1 | <0.1 | <1 | <0.1 |
| | Total | 1 | <0.1 | <1 | <0.1 | 1 | <0.1 |
| Rubella | Female | 5 | 0.4 | 2 | 0.2 | 4 | 0.3 |
| | Male | 5 | 0.4 | 3 | 0.2 | 4 | 0.3 |
| | Total | 10 | 0.4 | 5 | 0.2 | 7 | 0.3 |
| Rubella, congenital syndrome | Female | 0 | 0.0 | <1 | <0.1 | <1 | <0.1 |
| | Male | 0 | 0.0 | <1 | <0.1 | <1 | <0.1 |
| | Total | 0 | 0.0 | 1 | <0.1 | <1 | <0.1 |

* Rates per 100,000 population. NR = Not reportable. NA = Not available.

[†] Due to missing sex data, the total number of cases reported by sex may not correspond with the total number of cases reported for a disease.

Continued

**Appendix Table 4: 5-year and 10-year means and incidence rates* by disease and sex[†].
Toronto, 1995 - 2004**

| Disease | Sex | 5-year mean 1995-1999 | | 5-year mean 2000-2004 | | 10-year mean 1995-2004 | |
|--|--------------|--------------------------|----------------|--------------------------|-------------|---------------------------|----------------|
| | | # | Rate | # | Rate | # | Rate |
| Salmonellosis | Female | 434 | 34.0 | 298 | 22.4 | 366 | 28.1 |
| | Male | 401 | 33.2 | 299 | 23.6 | 350 | 28.3 |
| | Total | 839 | 33.8 | 597 | 23.0 | 718 | 28.3 |
| Severe acute respiratory syndrome (SARS) | Female | NR | - | NR | - | NR | - |
| | Male | NR | - | NR | - | NR | - |
| | Total | NR | - | NR | - | NR | - |
| Shigellosis | Female | 73 | 5.7 | 69 | 5.2 | 71 | 5.4 |
| | Male | 74 | 6.2 | 83 | 6.5 | 79 | 6.4 |
| | Total | 148 | 5.9 | 152 | 5.8 | 150 | 5.9 |
| Streptococcal infections, Group A invasive | Female | NR | - | 36 | 2.7 | NR | - |
| | Male | NR | - | 39 | 3.1 | NR | - |
| | Total | NR | - | 75 | 2.9 | NR | - |
| Streptococcal infections, Group B neonatal | Female | NR | - | 9 | 0.6 | NR | - |
| | Male | NR | - | 9 | 0.7 | NR | - |
| | Total | NR | - | 17 | 0.7 | NR | - |
| <i>Streptococcus pneumoniae</i> , invasive | Female | NR | - | NR | - | NR | - |
| | Male | NR | - | NR | - | NR | - |
| | Total | NR | - | NR | - | NR | - |
| Syphilis, infectious | Female | 17 | 1.3 | 10 | 0.8 | 13 | 1.0 |
| | Male | 26 | 2.1 | 183 | 14.5 | 105 | 8.5 |
| | Total | 42 | 1.7 | 194 | 7.5 | 118 | 4.6 |
| Syphilis, late latent | Female | 60 | 4.7 | 61 | 4.6 | 60 | 4.6 |
| | Male | 67 | 5.5 | 83 | 6.5 | 75 | 6.0 |
| | Total | 127 | 5.1 | 144 | 5.5 | 135 | 5.3 |
| Syphilis, congenital | Female | <1 | <0.1 | 0 | 0.0 | <1 | <0.1 |
| | Male | <1 | <0.1 | 0 | 0.0 | <1 | <0.1 |
| | Total | <1 | <0.1 | 0 | 0.0 | <1 | <0.1 |
| Syphilis, other [§] | Female | 2 | 0.1 | 2 | 0.1 | 2 | 0.1 |
| | Male | 2 | 0.2 | 8 | 0.6 | 5 | 0.4 |
| | Total | 4 | 0.2 | 10 | 0.4 | 7 | 0.3 |
| Tetanus | Female | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
| | Male | <1 | <0.1 | 0 | 0.0 | <1 | <0.1 |
| | Total | <1 | <0.1 | 0 | 0.0 | <1 | <0.1 |
| Tuberculosis | Female | 210 | 16.4 | 170 | 12.8 | 190 | 14.6 |
| | Male | 230 | 19.0 | 202 | 16.0 | 216 | 17.5 |
| | Total | 440 | 17.7 | 373 | 14.4 | 406 | 16.0 |
| Tularemia | Female | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
| | Male | <1 | <0.1 | 0 | 0.0 | <1 | <0.1 |
| | Total | <1 | <0.1 | 0 | 0.0 | <1 | <0.1 |
| Typhoid fever | Female | 7 | 0.6 | 15 | 1.1 | 11 | 0.8 |
| | Male | 10 | 0.8 | 13 | 1.0 | 12 | 0.9 |
| | Total | 17 | 0.7 | 28 | 1.1 | 22 | 0.9 |

* Rates per 100,000 population. NR = Not reportable. NA = Not available.

[†] Due to missing sex data, the total number of cases reported by sex may not correspond with the total number of cases reported for a disease.

[§] Excludes infectious, late latent and congenital syphilis.

Continued

**Appendix Table 4: 5-year and 10-year means and incidence rates* by disease and sex[†].
Toronto, 1995 - 2004**

| Disease | Sex | 5-year mean 1995-1999 | | 5-year mean 2000-2004 | | 10-year mean 1995-2004 | |
|---|--------------|--------------------------|------------|--------------------------|------------|---------------------------|------------|
| | | # | Rate | # | Rate | # | Rate |
| Verotoxin-producing <i>E.coli</i> infection | Female | 42 | 3.3 | 30 | 2.2 | 36 | 2.7 |
| | Male | 41 | 3.4 | 26 | 2.1 | 34 | 2.7 |
| | Total | 83 | 3.3 | 56 | 2.2 | 69 | 2.7 |
| West Nile Virus | Female | NR | - | NR | - | NR | - |
| | Male | NR | - | NR | - | NR | - |
| | Total | NR | - | NR | - | NR | - |
| Yersiniosis | Female | 66 | 5.2 | 56 | 4.2 | 61 | 4.7 |
| | Male | 85 | 7.1 | 70 | 5.5 | 78 | 6.3 |
| | Total | 151 | 6.1 | 126 | 4.9 | 139 | 5.5 |

* Rates per 100,000 population. NR = Not reportable. NA = Not available.

[†] Due to missing sex data, the total number of cases reported by sex may not correspond with the total number of cases reported for a disease.

